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ABSTRACT 
Background: Patients with diabetes mellitus often take prescription medications 
throughout their lives to maintain glycemic control and/or treat co-morbid conditions such 
as dyslipidemia. The effect of glycemic control and reductions in lipid levels in the 
prevention of diabetes-related complications has been demonstrated. However, one 
important factor affecting the pharmacological management of glycemic control and 
dyslipidemia is adherence and persistence (i.e., continuous use) with treatment. 
Objective: The objective of this research was to 1) use measurements of medication 
availability, gaps in therapy, and surplus medication to assess adherence with 
sulfonylurea medications, evaluate the relationship between these measures, and 
examine patient- and medication-related characteristics that may influence adherence 
with sulfonylureas; 2) evaluate adherence with lipid-lowering medications in patients with 
diabetes mellitus and examine the effect of patient- and medication-related 
characteristics on adherence; 3) assess persistence with lipid-lowering medications and 
evaluate patient- and medication-related characteristics that may influence 
discontinuation of lipid-lowering treatment in patients with diabetes mellitus. 
Data Source/Methods: Analyses were performed using pharmacy claims data. The 
data source provided all prescription claims {288,171 dispensations) between April 27, 
1997 and May 16, 1999 for 4,503 patients with diabetes. The cohort for the first study 
was comprised of patients prescribed sulfonylurea medications while new users of 
lipid-lowering medications comprised the study population for the other two studies. 
Adherence was measured by continuous and dichotomous measurements of medication 
availability, gaps in therapy, and surplus medication while persistence was defined as 
continuation of therapy with a sufficient quantity of medication to cover the observation 
period. Regression models were used to analyze the effect of patient-related and 
medication-related characteristics and adherence and persistence with medications. 
Results: Sulfonylurea medication was available to patients for an average of 89% of 
days during a 12-month period. This continuous measure of medication availability 
correlated with measures of gaps in therapy and surplus medication which showed that 
on average, patients had 15% of days in which medication was not available and 5% of 
days with surplus medication during the 12-month study period. Interestingly, rates of 
adherence were similar whether nine or 12 months of prescription claims were 
examined, suggesting that an additional three months of data did not add any 
information to the assessment of medication adherence. None of the patient- or 
medication-related characteristics in the multivariate regression model significantly 
influenced adherence with sulfonylureas (F5,987=0.59; p=0.7065). 
Approximately 66% of patients filled enough lipid-lowering medication prescriptions to 
cover at least 80% or more days in a nine-month observation period. Adherence differed 
by the class of lipid-lowering medication prescribed at the index date: patients prescribed 
statin and non-statin medications had an average Continuous multiple-interval measure 
of Medication Availability (CMA) of 84.1 % ± 22.3% and 70.0% ± 31 .7%, respectively 
(p=0.2627). Adherent patients ~80%) were less likely to be prescribed insulin therapy 
(OR=0.304, 95% Cl=0.114, 0.815, p=0.0180) and more likely to be prescribed statin 
medications (0R=4.709, 95% Cl=0.996, 22.268, p=0.0506) compared with non-adherent 
patients. No other study factors significantly influenced adherence with lipid-lowering 
therapy. 
Of the 165 patients prescribed statin medications, 74% persisted with treatment over six 
months, 59% over 12 months, and 46% over 18 months of observation. At six months, 
60% of patients persisted with non-statin treatment while only 26% of patients were 
persistent over 12 and 18 months of observation. Approximately 26% of patients who 
discontinued treatment did so after the initial dispensing. One in 10 patients switched to 
another lipid-lowering medication: the majority of switches were to another medication 
within the same class. Compared with patients prescribed statins, patients prescribed 
non-statin medications were more than twice as likely to discontinue treatment 
(HR=2.240; 95% Cl= 1.260, 3.982; p=0.0060). Age, gender, type of health plan, number 
of concomitantly prescribed medications and antidiabetic medication regimen, were not 
found to be a significant influence on discontinuation of lipid-lowering therapy. 
Conclusions: Patients with diabetes obtained less medication than prescribed over six-, 
nine-, 12- and 18-month periods of observation. Measures of medication availability, 
gaps in therapy, surplus medication and persistence provide an overall picture of 
medication adherence. The findings of this research provide insight into sub-optimal 
adherence and persistence with antidiabetic and lipid-lowering medications among 
patients with diabetes mellitus. These observations highlight the need for health care 
providers to establish a partnership with patients to improve adherence and persistence 
with medications. 
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PREFACE 
This dissertation is organized using the manuscript format. Part 1 consists of three 
research studies that form the main body of the dissertation. Part 2 contains 
appendices that provide details required by the University of Rhode Island but are not 
usually presented in publications. 
PART1 
Study 1 
Using Prescription Claim Records to Assess Measures of Medication Adherence 
(Medication Availability, Gaps, and Surplus) with Sulfonylureas in Patients with 
Diabetes Mellitus 
Study 2 
Using Prescription Claim Records to Evaluate Adherence with Lipid-lowering 
Medications in Patients with Diabetes Mellitus 
Study 3 
Using Prescription Claim Records to Evaluate Persistence with Lipid-lowering 
Medications in Patients with Diabetes Mellitus 
PART2 
Appendix A. Background and Review of the Problem 
Appendix B. Details of Methodology 
Appendix C. Confidentiality of Data 
Appendix D. Overview of Major Findings 
Appendix E. Interventions to Improve Adherence with Prescribed Medication 
Regimens for Patients with Diabetes Mellitus 
BIBLIOGRAPHY 
vi 
TABLE OF CONTENTS 
PART1 
Abstract ....................... ....... ......... ........ ... .... ..... ... .. .... .......... ................................... ii 
Acknowledgements ...... ... ........... .............................. ..... .... ... ...... ... ... ..... .... .. ...... ..... v 
Preface ...... .... ... ..... ..... .. ........ ........ ... ........ .... .................... ..... .. .. ... .. ... ... .... ..... .... .... . vi 
Table of Contents ....... ... ........ .. ... ... ...... .. .. ....... .... .. .... ..... ............. ... .. ....... ..... .... .. .... vii 
List of Tables ... .................. .................................................. ... .... ... ........................ x 
List of Figures ................ .... ..... .... ....... ...... ...... .... ........ .. ....... ..................... .... .... .. ... xiii 
Manuscripts 
Study 1 
Using Prescription Claim Records to Assess Measures of Medication 
Adherence (Medication Availability, Gaps, and Surplus) with Sulfonylureas in 
Patients with Diabetes Mellitus 
Abstract ... ....... ......... .................. ... .. .. ................................ ... ... ....... . 
Introduction ..... .... ......... .. ....... ...... ....... ...... ......... ... ...... ....... .............. 4 
Methods ........... ................. .. ......... .. .. ... ...... ..... .. .... ......................... .. 9 
Results ... ... ... ............ ........ .. ......... ... ....... ......... ............. ...... ... .......... 15 
Discussion .. ........ .......... .......... .. .... ................... ......... ............ .. .... ... . 21 
Conclusion ....... ............... ....... ... ..... .... .... .... ............................. .... .... 27 
Tables ......... ...... ............................ .... ........... .............. .•........ ..... ... ... 29 
Figures ...................... ..... ........ ...... .... ... .... ... .. ....................... ..... .. .... 39 
References ............... .. ... ...... .... .... .. ............ ......... .................. .......... 47 
vii 
Study 2 
Using Prescription Claim Records to Evaluate Adherence with Lipid-lowering 
Medications in Patients with Diabetes Mellitus 
Abstract .. ...................................... .. ................................................ 53 
lntroduction ....... ....... ......... ..... ... .. ... .. .... ..... ..... ..... ...... ....... ....... ... ... .. 55 
Methods .......... ... .. .... ..... .. ..... .. ........ .. ..... ... ...... ... .. .... ...... ... ...... .... ..... 58 
Results .... .............. ......................... ... .... ..... .. ..... ............................. 67 
Discussion .... ....... ........ .. ...... .... ...... ... ....... ... ......... .. .. .. .. ..... ...... .... .... 71 
Conclusion ......... ...... ............... ... .......... .. ..... ... .......... ... ....... ...... ....... 76 
Tables ........... ..... ... ........ ....... .......... .... ....... ..... ...... ...... ... .. ....... ..... .... 78 
Figures ......... ... ........... ... .... ..... ....... .. ... .... ..... .. .... .................. ........... 95 
References ...... ... .. ... .......... ..... ..... ... ...... .. ... ... ....... .............. ...... ....... 98 
Study 3 
Using Prescription Claim Records to Evaluate Persistence with Lipid-lowering 
Medications in Patients with Diabetes Mellitus 
Abstract ....................... ..................... ... ..... .... ....... ........ .................. . 1 06 
Introduction .. ..... ....... .... .. ... ....... ... ..... ... ..... ....... .. ..... ........... .. ........ .. .. 109 
Methods .............. ......... ... ....... .................... ... ...... ............. ............ ... 113 
Results ......................... .. .............................. .... ........... ..... ........ ... ... 121 
Discussion .................................................. ........... ... ........ ...... ..... ... 124 
Conclusion ............... ....... ..... ..... .. .... ............ ............. ........ ...... ......... 129 
Tables .. .. .... ...... .... .. ............. ...... .... .... ... ..................................... ..... . 131 
Figures ....... .. .. ......... ....... ..... ................ ..... ............................. .. ....... 144 
vii i 
References ......... .. ... .. ........ ............ .... .... .... ............................ ....... .. 154 
PART2 
Appendix A. Background and Review of the Problem .......... .. ... ..... ............. ..... .... .. 160 
References ....... ..... .......... ... ...... ...... ............... ...... ..... ... ....... .... ... ..... 165 
Appendix B. Details of Methodology ..... ..... ..... ................................... ............... ... .. 168 
Tables ............. ..... ... ... ..... .. ...... .... ...... ........ .... .... ... ...... .... .. .... ......... .. 170 
References ..................... .. ......... ......... .......................................... .. 182 
Appendix C. Confidentiality of Data ..... .... ... ...... .... ..... ......... .. ..... ... .... ... ... ..... .. ......... 183 
Appendix D. Overview of Major Findings .............................................. ........ ..... .. .. 184 
Appendix E. Interventions to Improve Adherence with Prescribed Medication 
Regimens for Patients with Diabetes Mellitus ........ ........... ... ... .... ..... .. . 190 
References .......... .......... ........... ......... ......... ......... .................. ..... ..... .. . 194 
BIBLIOGRAPHY ... ........ ......................... ... ..... .......... ....... .. ... .... ...... .... ...... ............. 197 
ix 
LIST OF TABLES 
Table 1-1 Measures of adherence ........ ..... ....... ........ .. ... ....... ..... ..... .......... .... .. 29 
Table 1-2 Characteristics of the study population (N = 988) .... .. .................. .... 30 
Table 1-3 Illustration of single- and multiple-interval measures of adherence 
with sulfonylurea medication .......... ..................... ............ .... ... .. ...... . 31 
Table 1-4 Measures of adherence with sulfonylureas in patients with 
diabetes (N = 988) ... ........... .. ... ...... ................................................. 32 
Table 1-5a Bivariate correlation of continuous measures of medication 
availability, gaps, and surplus ........ ........ ........ .. ........ .... .. ..... .... .... ... . 33 
Table 1-5b Bivariate correlation of continuous and dichotomous measures 
of medication availability ............. .............. ..... ..... .... ... ..... ......... .. ..... 33 
Table 1-5c Bivariate correlation of continuous and dichotomous measures 
of gaps in therapy .. ................................. ......... ...... .. .. .... ..... ........... . 34 
Table 1-5d Bivariate correlation of continuous and dichotomous measures 
of surplus medication ............. ..... ........ ... ........... ......... ..... ..... .. ..... .. .. 34 
Table 1-6 Measures of adherence with sulfonylureas in patients with 
diabetes grouped by time period of observation .............. ... .. .. ....... .. 35 
Table 1-7 Beta estimates of predictive factors of adherence with 
sulfonylurea medications in patients with diabetes .......................... 36 
Table 1A-1 Bivariate correlation of CMA and all 6 predictive variables .............. 37 
Table 1A-2 Collinearity Diagnostics ..... .... ............ ... ....... ............ .......... ...... ...... . 38 
Table 2-1 Pharmacological management of lipid abnormalities in adult 
patients with diabetes ...... .... .................................. .... .... ................. 78 
Table 2-2 Lipid-lowering medications ... ..... ...... .. ................................ .......... .... 79 
Table 2-3 Characteristics of the study population ........... ..... .......... ........ ......... 80 
Table 2-4 Frequency of lipid-lowering prescription claims during a 
nine-month observation period ........................................................ 81 
Table 2-5 Mean CMA (%) by lipid-lowering medication prescribed at the 
index date .................. ........ ...................... ................... ... ................. 82 
Table 2-6 General characteristics of adherent (?.80%) and non-adherent 
patients .. ......... ........ ........... ... ................... ....... .......... .. ..... ... ... ..... .. .. 83 
x 
Table 2-7 Bivariate logistic regression models for adherence (?.80%) ..... .. ..... . 84 
Table 2-8 Multivariate logistic regression models for adherence (?.80%) ........ 85 
Table 2-9 Final logistic regression model of adherence (?.80%) ... ........ ...... ..... 86 
Table 2-10 General characteristics of adherent (?.90%) and non-adherent 
patients ....................... ...... .... ..... ....... .... ..... ... ...... .. ..... ............... .... .. 87 
Table 2-11 Bivariate logistic regression models for adherence (?.90%) ............. 88 
Table 2-12 Multivariate logistic regression models for adherence (?.90%) ..... ... 89 
Table 2A-1a Parametric form analysis for continuous independent variables 
(?.80% adherence) .... .... ............. ..................................................... 90 
Table 2A-1 b Parametric form analysis for continuous independent variables 
(?.90% adherence) ...... ........................... .................... ......... ...... ... ... 90 
Table 2A-2 Collinearity Diagnostics ... ...... .. ... ....... .... .... ......... ...... .. ......... ............ 91 
Table 2A-3a Log Likelihood (LL) ratio test: logistic regression model of 
adherence (?.80%) .... .... .. ............. ... .... ........ ............... ............. ....... . 92 
Table 2A-3b Log Likelihood (LL) ratio test: logistic regression model of 
adherence (?.90%) .................... ...................................................... 92 
Table 2A-4a Test for confounding variables in the logistic regression model of 
adherence (?.80%) .............. .... ..... ....... ... ..... .... ..... .... .. ......... .. .. ..... ... 93 
Table 2A-4b Test for confounding variables in the logistic regression model of 
adherence (?.90%) ..... ......... ...... .... ... .... ....... ..... ... ....... ............. ..... ... 94 
Table 3-1 Relationship between lipid parameter changes and compliance 
in the Helsinki Heart Study (n = 1963 males treated with 600mg 
gemfibrozil BID) ........ ... ..... ............ ... ............................ ........... ....... . 131 
Table 3-2 Lipid-lowering medications ..... .... ................... ... ..... ... ...... ................ . 132 
Table 3-3 Characteristics of the study population ....... ..... ..... ...... ......... .. .... .... . 133 
Table 3-4 Characteristics of the study population by class of index 
lipid-lowering medication .... ...... ... ....... .... .... .... ... ....... ... ... ... ....... .. ... .. 134 
Table 3-5 Characteristics of the study population by the pattern of 
persistence with lipid-lowering therapy ....... ... .... .......................... .... 135 
Table 3-6 Frequency of re-initiation of lipid-lowering therapy during the 
18-month follow-up period (N = 28) ............ ... .... ........ .................. ... . 136 
xi 
J Table 3-7 Frequency of switching of lipid-lowering therapy during the 
18-month follow-up period (N = 19) ... ......................... ......... ......... ... 137 
Table 3-8 Cox regression model: time to discontinuation with lipid-lowering 
therapy in patients with diabetes ..... ............ ..... .. ......... ...... ... ... ... .... . 138 
Table 3-9 Final Cox regression model: time to discontinuation with 
lipid-lowering therapy in patients with diabetes ........................... .... 139 
Table 3A-1 Collinearity diagnostics ...... ..... ...... .. ....... .......... .. ..... .•....... ............... 140 
Table 3A-2 Test for confounding variables ....... ................. ................. ............ ... 141 
Table 3A-3 Likelihood Ratio (LR) statistic: modeling of time to 
discontinuation .... ... ..... ........... .... ...... ....... ..... ........ ... .. ......... .... ... ..... . 142 
Table 3A-4 Likelihood Ratio (LR) statistics for choosing the best model of 
time to discontinuation with lipid-lowering therapy .... ... ..... .... .... ... .... 143 
Table B-1 Variables available in the CVS pharmacy dataset... .... ...... .. ........ ... . 170 
Table B-2 Variable specifications for Study 1 ... ......... ... ........ ....................... ... . 171 
Table B-3 Variable specifications for Study 2 ... ... ..... .... ........... ..... ......... .......... 175 
Table B-4 Variable specifications for Study 3 ... .......... .... ..... .. .... ...... .... ......... ... 178 
Table B-5 SAS procedures and their respective analytical measure ...... ........ . 181 
xii 
LIST OF FIGURES 
Figure 1-1 Eligibility criteria of study population .................. .. .. ...... .............. .... 39 
Figure 1A-1 Frequency distribution of the measurement: CMA .............. ............ 40 
Figure 1A-2 Frequency distribution of the measurement: CMG .... .. .................. .. 41 
Figure 1A-3 Frequency distribution of the measurement: CMOS ........................ 42 
Figure 1 A-4 Two-dimensional plot of residuals against the dependent 
variable, CMA .............................................................. ........ .... .... ... 43 
Figure 1 A-5 Two-dimensional plot of studentized residuals against the 
dependent variable, CMA ................. ...... .. ........... ....... ...... ..... ..... ... . 44 
Figure 1 A-6 Two-dimensional plot of studentized residuals against age ............ . 45 
Figure 1 A-7 Two-dimensional plot of studentized residuals against number of 
concomitantly prescribed medications ............................................ 46 
Figure 2-1 Eligibility criteria of study population ............................................... 95 
Figure 2A-1 Frequency distribution of the measurement: adherence (80%) ....... 96 
Figure 2A-2 Frequency distribution of the measurement: adherence (90%) ....... 97 
Figure 3-1 Eligibility criteria of study population ................ ............................ ... 144 
Figure 3-2 Kaplan-Meier time-to-event curves of persistence with lipid-lowering 
medications in patients with diabetes, stratified by class of 
index lipid-lowering medication .... .... ...... ......................................... 145 
Figure 3-3 Kaplan-Meier time-to-event curves of persistence with lipid-lowering 
medications in patients with diabetes (excluding patients with one 
lipid-lowering medication prescription), stratified by class of index 
lipid-lowering medication ...... ..... ......... ..... .... ....... ...... ....................... 146 
Figure 3A-1 Frequency distribution of the measurement: time to 
discontinuation .............................................................. ... ........... ... . 147 
Figure 3A-2 Test of Proportional Hazard Assumption: Gender ........................... 148 
Figure 3A-3 Test of Proportional Hazard Assumption: Class of Index 
Lipid-Lowering Medication ..... .. ... ... ................. ........................ ....... 149 
Figure 3A-4 Test of Proportional Hazard Assumption: Healthplan ...................... 150 
Figure 3A-5 Test of Proportional Hazard Assumption: Antidiabetic Medication 
Regimen ............. ......... .... .................. .... .... ......... ... .............. ... ...... .. 151 
xiii 
Figure 3A-6 Martingale residual plot of final Cox regression model .... .. .............. 152 
Figure 3A-7 Deviance residual plot of final Cox regression model ...... .... ..... ... .... 153 
xiv 
Study 1 
Using Prescription Claim Records to Assess Measures of Medication 
Adherence (Medication Availability, Gaps, and Surplus) with Sulfonylureas in 
Patients with Diabetes 
ABSTRACT 
Background: Medication adherence with antidiabetic medications is key in the 
multi-faceted management of diabetes to achieve glycemic control. Estimates of 
adherence with sulfonylureas in patients with diabetes mellitus vary from 31 % to 83% 
depending on the study. Although there is no standard way to evaluate medication 
adherence, adherence is generally based on a continuous measure of medication 
availability that is often dichotomized using either an 80% or 90% level. Few studies 
analyze gaps in therapy and surplus medication. 
Objective: The objective of this study was to measure adherence with sulfonylureas 
based on continuous and dichotomous measures of medication availability, gaps, and 
surplus and evaluate the relationship between these measures. In addition, 
patient-related and medication-related characteristics that may influence adherence 
with sulfonylureas in patients with diabetes mellitus were examined. 
Methods: This was a retrospective analysis of six- , nine-, and 12-months of 
prescription claim records in patients with diabetes dispensed sulfonylureas. 
Medication adherence was assessed by three continuous multiple-interval 
proportions: the total number of days in which medication was available to the patient 
(CMA}, gaps in therapy (CMG}, and surplus medication (CMOS} which were 
dichotomized based on clinically relevant levels. Medication availability of 
sulfonylureas during the 12-month period of observation was modeled as a function of 
clusters of patient- and medication-related characteristics. 
Results: A total of 988 patients with diabetes (58% males; mean age, 59.2 ± 10.9 
years) had at least two prescription claims for sulfonylurea medications from 
December 1, 1997 through December 31, 1998. Overall , sulfonylurea medication was 
available for an average of 89% of days during a 12-month period. This continuous 
measure of medication availability correlated with measures of gaps in therapy and 
surplus medication which showed that on average, patients had 15% of days in which 
medication was not available and 5% of days with surplus medication during the 
12-month observation period. Measures of medication availability were significantly 
correlated with gaps in therapy (r= -0.95) and surplus medication (r=0.41) (p<0.0001). 
Continuous and dichotomous measures of adherence with sulfonylureas were 
significantly correlated with the strongest relationships observed between CMA and 
an 80% level of adherence (r=0.82} and CMG and a 20% level of gaps in therapy 
(r=0.84) (p<0.0001 ). Interestingly, rates of adherence were similar whether nine or 12 
months of prescription claims were examined, suggesting that an additional three 
months of data did not add any information to the assessment of medication 
adherence. None of the patient-related (age, gender and type of health plan) or 
medication-related (number of concomitantly prescribed medications and number of 
sulfonylurea pills per day) characteristics in the multivariate regression model 
significantly influenced adherence with sulfonylureas in our patient population 
(Fs.•01=0.59; p=0.7065). 
Conclusions: Patients with diabetes obtained less sulfonylurea medication than 
prescribed over six- , nine-, and 12-month periods of observation as evidenced by low 
measures of medication availability and surplus and a high proportion of gaps in 
therapy. All these measures can be used alone but as illustrated by the findings of 
this study, the combination of all three measures of adherence concurrently provides 
an overall picture of medication adherence. Understanding the integral components, 
2 
I such as age and medication-related characteristics, associated with adherence is a 
crucial component of designing effective diabetes management plans. Further 
research is needed to evaluate the appropriate level of adherence associated with 
glycemic control in patients with diabetes. 
Key Words: sulfonylurea, diabetes, adherence, CMA, CMG, CMOS, medication gap, 
medication availability, medication surplus 
3 
I INTRODUCTION 
Since Hippocrates, physicians have been plagued by concerns over patients' 
adherence to medication regimens.1·3 In general, the scope of nonadherence ranges 
across all age groups and medical disciplines and can be influenced by many factors 
including tolerability of the medication, complexity of the medication regimen , cost 
and convenience of the therapy, and characteristics of the patient, medical system 
and physician.' .4 Adherence with prescribed medications is an important component 
of disease management especially for patients with chronic diseases who must often 
obtain prescription refills throughout their lives.5 
Adherence· has been defined as the extent to which a patient freely chooses 
to follow physicians' orders (i.e., by taking medications or modification of lifestyle 
changes such as diet and exercise) with medical advice.6 The term adherence 
captures the increasing complexity of medical care by characterizing patients taking a 
more active and voluntary role in defining and pursuing goals for their own medical 
treatment.3 Adherence consists of the initial fill of the prescribed medication, 
consumption of the medication, and acquisition of refills. 
In spite of pharmacotherapeutic advances, a major barrier to management of 
diabetes is the extent to which individuals adhere to their prescribed treatment 
regimens. 7 Patients with diabetes mellitus are at particular risk for non-adherence 
with antidiabetic treatment regimens,8 which may have a deleterious effect on 
glycemic control. Estimates of adherence with sulfonylureas vary widely from a low of 
31 % to 83%,1·•·11 depending on the methodology employed. 
There are several ways to evaluate adherence in a patient population. Indirect 
Adherence and compliance are used interchangeably in the literature. Although the 
term compliance has negative connotations, it is still in use and will be referred to in 
this study if utilized in the cited published material. 
4 
methods include patient interviews or questionnaires, pill counts, review of 
prescription records and claims, and electronic monitoring devices, while direct 
methods of adherence include pharmacologic markers and direct observation of the 
patient taking the medication. 12·14 The method chosen to measure medication 
adherence can significantly affect the results. 15 For example, the rate of adherence 
with sulfonylureas was 83% when prescription records were examined" while rates of 
79% and 97% were observed using Medication Event Monitoring System (MEMS) 
data and pill count, respectively.16 While no single method of adherence is 
appropriate for all settings or outcomes, database records of dispensed prescriptions 
may represent one of the most accurate methods of assessing medication utilization 
in a patient population. 17• 18 
Several investigations have compared use of medications measured in 
pharmacy records with other sources of medication use. Pharmacy data and 
self-administered questionnaires showed good agreement for antihypertensives, 
lipid-lowering medications, oral antidiabetic medications, and oral contraceptives 
(kappa values between 0.6-0.8).19 Pharmacy records were a reliable source of 
medication exposure as estimated in a home-based inventory.20 Refill compliance 
was significantly correlated (Pearson correlation coefficient of 0.31, p<0.05) with 
MEMS data, specifically with tablet compliance (measured as the percentage of 
tablets used).21 Grymonpre and colleagues found no difference in mean adherence 
rates, by medication, as estimated by pharmacy claims data or self report.22 
Studies have found that measures of medication adherence (i.e., measures of 
medication availability and gaps in therapy) based on pharmacy claims were a 
reliable source of medication exposure. Correlations between medication adherence, 
using measures of medication availability or gaps, and measures of drug exposure 
(e.g., phenytoin and digoxin drug levels) and medication effects (e.g., blood pressure) 
5 
were statistically significant, with Pearson correlation coefficients between 0.30 and 
0.42.12 
Thus, pharmacy claims provide a reliable tool to measure adherence with 
long-term medications. Although prescription refill data does not verify administration 
of the therapy regimen, it does signify availability of medication. This method of 
assessing adherence is based on the assumption that if the medication is not 
available for use, patients clearly cannot adhere with the medication regimen. 
Various measures have been developed to assess adherence with 
medications using pharmacy claims although a gold standard does not exist. The 
best measure likely depends on the intended use of the data. For example, in order to 
formulate patient diabetes education programs, a finding of low medication 
adherence measured by gaps in therapy may suggest that a refill reminder program 
is needed. 
Measurements of medication adherence are usually classified three ways: 1) 
single-interval versus multiple-interval; 2) continuous versus categorical; and 3) 
measures that assess availability of medication, gaps in therapy or 
surplus/oversupply (i.e., stockpiling) of medication. Categorizations of the total 
number of days supply have been used as a surrogate measure of adherence.7 For 
all of these classifications, the time period of observation is a principal component. 
Most often, adherence with medications is assessed on multiple-intervals, as 
the degree of adherence is not a single event but an accumulation of many 
pill-takings or neglects. Generally, a continuous measure of adherence is calculated 
by dividing the sum of the days supply between the first and last fill by the number of 
days from first to last fill of medication (i.e., the number of days in which medication is 
available for use). This measurement, termed Medication Possession Ratio (MPR) or 
Continuous multiple-interval measure of Medication Availability (CMA) (hereafter, 
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measures of medication availability will refer to CMA}, provides an overall 
assessment of the amount of medication available for use during a specified time 
period under observation. The conclusions based on an analysis of CMA is 
dependent upon the choice of denominator as the time period used in the 
denominator can be either the length of therapy which is individualized or calendar 
time (e.g., 365 days for a 12-month assessment) which is the same for every person 
in the study population. When length of therapy is used as the denominator, the 
continuous measure of adherence is affected by gaps and oversupplies of 
medication. In contrast, using calendar time, adherence is affected both by 
medication gaps and oversupply as well as discontinuations of treatment.23 
This continuous measurement is frequently converted to a dichotomous 
variable (e.g., adherent or non-adherent 9• 24' 25 or acceptable or fair/poor26) based on 
a choice of various levels (e.g., 80%, 90%, or 95%). However, an explanation of the 
rationale for choosing a particular level is often not provided. While the convention 
has been to define good adherence as carrying out either 80% or 90% of the 
recommended behaviors, there is no standard on which to base this level of 
adherence with many medications.27• 29 In a few cases, medication-specific or 
condition-specific levels for taking medication have been defined. Consumption of at 
least 80% of prescribed antihypertensive medication was sufficient to maintain control 
of blood pressure.29• 30 Higher adherence rates (~90%) with antiretroviral therapy have 
been associated with virologic success rates.31 ·34 Such levels are difficult to determine 
as they must take into account the likelihood, clinical consequences, and time course 
of treatment failure.35 
Supplementing analyses of medication availability with an analysis of gaps 
and surplus medication indicates whether the patient is actually taking the medication 
as prescribed.36-40 Gaps in therapy or stockpiling of medication may be due to 
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reasons of patient conven ience (e.g., a patient-initiated medication holiday) or dosage 
adjustments. For example, patients may reduce their dosage thus extending the 
period of medication-taking beyond the estimated depletion date (i.e. , the fill date of a 
prescription claim plus the days supply}. In this situation, the patient is taking 
medication throughout the time period without any actual gaps in medication use. 
Thus, not all gaps represent non-adherence with medication. 
Finally, researchers have measured medication adherence using different 
time periods of observation ranging from months to several years. When reporting 
adherence with sulfonylureas as a continuous measure, the mean proportion of time 
with available medication varies greatly: 77% over a 4-month period,41 49% to 80% 
over a one-year period,10.42. 43 and 42% to 83% over a two-year period.10• 11 • 43 While 
variations in study design, patient population characteristics, and the definition and 
actual calculation of the continuous measure of medication availability may account 
for the wide range of rates, the length of observed time is an important component in 
any assessment of medication adherence. 
While many published reports have studied the accordance between methods 
of medication adherence, 16• 21 • 22· 44 to the best of our knowledge, no study has 
examined the relationship between the various types of measures of medication 
adherence using pharmacy claims data. Recognizing the potential limitations of 
evaluating medication adherence by a single measure, this study was designed to 
measure adherence with sulfonylureas based on continuous and dichotomous 
measures of medication availability, gaps, and oversupply and evaluate the 
relationship between these measures using six, nine, and 12 months of pharmacy 
claims data. In addition, this study examined factors that may influence adherence 
with sulfonylureas in patients with diabetes mellitus. 
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METHODS 
Study Design 
This study was a retrospective analysis of adherence with sulfonylurea 
medications utilizing pharmacy claim prescription records in a cohort of patients with 
diabetes. 
Dataset 
Data examined in the analysis were obtained from 198 Consumer Value 
Stores (CVS) pharmacies located in Pennsylvania that provided prescription 
medications for 4503 patients with diabetes identified by specific therapeutic classes 
(insulins, oral antidiabetic medications-sulfonylureas and other oral antidiabetic 
medications) between April 27, 1997 and May 16, 1999. Patients were either enrolled 
in a nurse-based diabetes management plan or local/state/federal programs or paid 
for their prescriptions with cash payments. 
This prescription claims data extract includes records of dispensed outpatient 
pharmacy prescription records for all prescriptions. The following information was 
obtained from the CVS dataset for this analysis: patient characteristic variables such 
as birth date, gender, and health plan agency as well as prescription-related variables 
including quantity of medication dispensed, days supply of medication dispensed, and 
date the prescription was dispensed. No personally identifying information was 
provided. 
Sulfonylurea Medications Available in Dataset 
Each sulfonylurea medication in the database was categorized into 1 of 3 
categories: (1) first-generation sulfonylurea medications: acetohexamide (Dymelor~. 
chlorpropamide (Diabinase~. tolazamide (Tolinase®), tolbutamide (Orinase~ ; (2) 
second-generation sulfonylurea medications: glipizide (Glucotrol®, Glucotrol XL~ and 
9 
glyburide (DiaBeta®, Glynase®, Micronase®) ; and (3) third-generation sulfonylurea 
medication: glimepiride {Amaryl®). 
Study Population 
The study population was drawn from 2770 persons who had prescription fills 
for sulfonylurea medications in the database. Patients whose records were eligible for 
inclusion were persons ~18 years of age who (1) filled a prescription for a 
sulfonylurea medication during the index window of December 1, 1997 to December 
31 , 1997 (n=1411 ); (2) were dispensed at least two fills of a sulfonylurea medication 
(n=1372); and (3) had continuous dispensations of prescriptions at the pharmacy 
(n=1296). A continuous dispensation of prescriptions was confirmed by the 
dispensation of any medication six months prior to the index date and in the twelfth 
month alter the index date (i.e., the date of the sulfonylurea prescription claim during 
the index window). Patients dispensed multiple dosages of the same sulfonylurea 
were excluded from the analyses (n=23). 
Data Analysis 
Prescription claims for all patients who satisfied the inclusion/exclusion criteria 
were examined for the 12-month period from December 1997 through December 
1998. This period was selected to allow for a sufficient amount of data (i.e., a 
"washouf' period prior to the index date and at the end of the observation period to 
eliminate time periods of potentially incomplete data). Subsequent analyses 
examined claims for a six- and nine-month time period; since the inclusion criterion of 
at least two refills was not met, 8 {0.8%) and 3 (0.3%) patients were excluded from 
the six- and nine-month analyses, respectively. 
The most commonly prescribed sulfonylureas were the second-generation 
sulfonylureas. Due to the small proportion of patients prescribed first- or 
third-generation sulfonylurea medications (9%), comparisons of this group of patients 
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with patients prescribed second-generation sulfonylureas (91 %} lacked statistical 
power. Thus, categorization of sulfonylurea medication was not evaluated in the 
analysis. 
Dataset Preparation 
Prior to analysis, the dataset was checked for outliers for the variable days 
supply as it was an integral component of all calculations of medication adherence. 
Days supply, presumed to be incorrectly recorded for two patients, was imputed 
based on the days supply recorded for other sulfonylurea dispensations in the 
database. Patients with incomplete records (i.e., missing transaction dates) for 
sulfonylurea medications were excluded from the analysis (n = 285). 
Measures of Adherence 
Measures of adherence selected for evaluation in this study included 
continuous and dichotomous measures of medication availability, deficits and 
oversupply based on research published by Fairman and Motheral23 and Steiner and 
Prochazka.18 Table 1-1 describes the measures of adherence evaluated in this study 
along with the formulae used in the calculations. Continuous measures of medication 
availability, gaps in therapy, and surplus medication were expressed as a percentage. 
The days supply for the last prescription fill was not included in our calculation of 
CMA as there was no way to determine whether the patient continued to take the 
medication after the last prescription fill. 
To assess CMA as a dichotomous measure, CMA was categorized into levels 
of 80% and 90% adherence as these levels are commonly reported in the literature 
and clinical judgment that adherence with sulfonylureas is essential to maintain 
glycemic control. That is, patients who were dispensed enough sulfonylurea 
medication to cover at least 80% (or 90%) of days of therapy were classified as 
adherent. Since this calculated ratio may exceed 100% if a patient obtains refills 
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before their supply has been exhausted, patients with a CMA >100% were classified 
as over-adherent. 
Continuous multiple-interval measures of gaps in therapy or surplus 
sulfonylurea medication included CMG and CMOS, respectively. To evaluate these 
measures using dichotomous categorizations, levels of 10% and 20% (i.e ., equivalent 
to three and six days per month} were selected based on a previous report of gaps 
and oversupply with sulfonylurea medications 18• 36 and clinical judgment about the 
impact of missed doses or surplus sulfonylurea medication in this patient population. 
Predictive Variables of Interest 
The relationship of medication adherence and patient-related and medication 
complexity characteristics has been published ex1ensively even though the findings 
are inconsistent. 11 • 13• 36• 45""7 Several of these factors, such as age, gender, health plan 
agency, number of prescription medications, and use of insulin, were examined in the 
present study. Dosing instructions were unavailable in this database to calculate daily 
dose, another potential predictive factor, therefore a surrogate measure, the number 
of sulfonylurea pills· per day, was examined. These factors were constructed from the 
prescription profile of each patient and classified as patient-related characteristics 
(age, gender, health plan agency) or medication-related characteristics (number of 
sulfonylurea pills per day, use of insulin, and number of concomitantly prescribed 
medications). 
Age, a continuous variable, was based on the transaction date for the 
sulfonylurea prescription filled during the index window. The patients' health plan, 
used to acquire sulfonylurea medication during the index window, was categorized as 
Terminology used in this study to encompass all formulat ions of sulfonylurea 
medications (e.g., capsules, tablets) 
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either a nurse-based diabetes management plan or other (e.g., local/state/federal 
programs or cash payments). 
Use of insulin was based on whether a patient was prescribed insulin during 
the observation period (yes or no). The number of sulfonylurea pills prescribed per 
day was calculated by dividing the quantity of medication dispensed by the days 
supply and dichotomized as 1, > 1. The number of concomitantly prescribed 
medications included all medications (except antidiabetic medications and supplies) 
dispensed during the observation period and was analyzed as a continuous variable. 
Univariate Analysis 
Descriptive statistics were used to determine patient- and medication-related 
characteristics. The data was presented as mean ± SD (range) for continuous 
variables and frequencies (percentage) for categorical variables. Continuous and 
dichotomous measures of medication adherence were evaluated overall and by the 
time period of observation (i.e., six-, nine-, and 12-months). The frequency distribution 
of the medication adherence measurements CMA, CMG, and CMOS are presented in 
Figures 1A-1 to 1A-3. Correlation coefficients were computed to determine the 
relationship between the measures of medication availability, gaps in therapy, and 
surplus medication. 
Multivariate Analysis 
To analyze the effect of various factors that may influence adherence with 
sulfonylurea medications over 12 months, multiple regression models were built using 
CMA as the continuous dependent variable. This measure of medication availability 
was chosen as the dependent variable as it provides an overall view of adherence 
and is affected by gaps and surplus medication from fill to refill. Regression 
diagnostics included assessing the frequency distribution of the dependent variable, 
collinearity of study variables, the influence of outliers, and analyzing residuals.48 
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As recommended by Hatcher and Stepanski,49 the possible correlations 
between the study variables were assessed using the PROC CORR procedure.so 
These correlations provided an assessment of the bivariate relationship between the 
dependent variable and the predictor variables. Correlation coefficients are shown in 
Table 1A-1 and will be described in the Results section. 
The presence of collinearity between the independent variables was examined 
using the methodology of Kleinbaum and colleagues48 by the PROC REG 
procedure.so Independent variables with a condition index greater than 30 (moderate 
to severe collinearity) and proportion of variations greater than 0.5 were further 
examined for collinearity with other independent variables. When there was 
collinearity between two variables, the variable showing the strongest association 
with adherence with sulfonylureas was kept in the model. None of the six predictive 
factors had a proportion pattern that exhibited collinearity with another variable (Table 
1A-2). 
Simple descriptive statistics were computed for the dependent variable, CMA, 
and continuous independent variables to assess the influence of potential outliers. 
The five lowest and five highest values for these variables and frequency histograms 
were examined to detect potential data entry errors and outliers. Several outlying 
observations were detected for CMA and the number of concomitantly prescribed 
medications that upon further examination did not appear to be data errors but correct 
values for these variables. Thus, all observations remained in the dataset for 
analysis. 
Two clusters, patient-related and medication-related characteristics, were 
entered into the multiple linear regression model of adherence with sulfonylureas in a 
hierarchical approach.11 • 49• 51 This approach provided an estimate of the relative 
contribution of each cluster in the explanation of the variance in the dependent 
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variable, CMA. The beta weights (standardized regression estimates) and standard 
error are presented for each variable along with the F-value and adjusted R2 for the 
entire model. Multiple regression analysis was performed with the PROC REG 
procedure.50 
To assess the appropriateness of the fitted multiple linear regression model, a 
set of standardized and studentized residual plots were analyzed to check the validity 
of the regression assumptions (Figures 1A-4 and 1A-5). Figures 1A-6 and 1A-7 show 
plots of studentized residuals against the continuous independent variables, age and 
number of concomitantly prescribed medications, respectively. These tables show a 
random scatter of the data points above and below the line e = O with almost all the 
data points being within the band defined as e = ±2s as expected when the 
assumptions are satisfied. 
The a priori alpha level of significance was set at p<0.05. All data analyses were 
conducted using SAS release 8.2.50 
RESULTS 
Description of the Study Population 
A total of 2770 patients received prescriptions for sulfonylurea medications. Of 
these patients, 1644 were excluded because there were no prescription claims for a 
sulfonylurea medication between December 1, 1997 and December 31 , 1997 or had 
incomplete transaction dates for all sulfonylurea prescription claims during the 
observation period; 39 did not have at least two prescription claims for sulfonylureas 
during the observation period; 76 patients did not have continuous dispensations of 
prescriptions at the pharmacy (i.e., a prescription claim for any medication in the six 
months prior to and 12 months after the index date); and 23 patients were prescribed 
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more than one sulfonylurea dosage (Figure 1-1). A total of 988 patients were included 
in the study analyses: 571 (58%) males and 417 (42%) females with an average age 
of 59.2 ± 10.9 years (range, 22 - 88 years) (Table 1-2). Over half (54%) were enrolled 
in a nurse-based diabetes management plan. 
The most commonly prescribed sulfonylureas were the second-generation 
sulfonylureas: glyburide (57%) and glipizide (35%), 7% of patients were prescribed 
glimepiride and 2% prescribed a first-generation sulfonylurea. More than half (59%) of 
the patients were prescribed a dose of more than one sulfonylurea pill per day. The 
majority of patients (97%) did not receive a concomitant prescription for insulin during 
the observation period. During the observation period, patients were prescribed an 
average of 8 ± 7 medications (range, O - 44) other than antidiabetic medications and 
supplies. 
Evaluation of Single-Interval and Multiple-Interval Measures of Adherence with 
Sulfonylureas 
The data illustrated in Table 1-3 is representative of the array of single-interval 
and multiple-interval measures of medication adherence calculated in this study. 
Single-interval measures of medication availability (CSA). gaps (CSG), and 
oversupply (CSOS) provide an accurate representation of adherence with 
sulfonylureas from fill to refill. These measures allow an individual assessment of 
medication adherence and highlights particular times of non-adherence with 
medication, for example, patient-initiated medication holidays or dose reductions or 
overdoses. In contrast, multiple-interval measures of medication availability (CMA), 
gaps (CMG), and oversupply (CMOS) provide a broad assessment of medication 
adherence over an extended period of time. 
The data demonstrates single- and multiple-interval measures of adherence 
with sulfonylureas presented for an individual patient. Over a period of 354 days, this 
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patient received 45 days of medication from fill to fill (i.e., interval) that resulted in a 
total of 225 days supply of sulfonylurea medication. There were three intervals in 
which medication was not available for a total of 169 days whereas in the other two 
intervals, there were 40 days of surplus medication. Based on examination of single-
interval measures of adherence, this patient had a range of 23% to 214% of days in 
which medication was available, 6% to 77% of days with gaps in therapy, and 55% to 
114% of days with surplus medication. These single-interval measures show a wide 
range of adherence during the 354 days of therapy compared to the multiple-interval 
measures that demonstrate a single assessment of adherence during this time 
period. 
Upon closer examination, there was one interval in which a 150 day gap in 
therapy was observed. The length of this gap should prompt a discussion between 
the patient and health care provider to 1) determine the cause and 2) mutually agree 
on a plan to improve adherence. In comparison, a multiple-interval analysis of gaps 
would show that gaps in therapy were occurring but would not demonstrate the length 
or the number of gaps. 
In describing the results of this study, the focus will be on the multiple-interval 
measures of adherence are they are more descriptive when evaluating overall 
adherence in patient populations. 
Evaluation of Continuous and Dichotomous Measures of Adherence with 
Sulfonylureas 
Overall, patients had an average period of observation (i.e., date from first 
sulfonylurea dispensation to last fill in the observation period) of 315 ± 52 days 
(range, 32 to 364 days). Based on CMA, medication was available for an average of 
89% ± 18% (range, 10% to 150%) of days during the 12-month observation period 
(Table 1-4). When CMA was dichotomized, 78% and 66% of patients had sufficient 
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medication to cover at least 80% and 90% of days in the observation period, 
respectively. 
An analysis of gaps in therapy supports the findings of medication availability. 
Medication was not available for an average of 15% ± 16% of days (range, 0 to 90%) 
during 12 months. Thus, patients had an average of 47 (i.e., 15% X 315 days) days 
with gaps in therapy with nine (1 %) patients prescribed sulfonylureas during the 
12-month observation period having no gaps in therapy, 23 (2%) had one gap and 
the majority (956 (97%)) of patients had more than one gap. Some of the gaps were 
brief: 71 % of the gaps lasted for seven days or less while 17% of the gaps lasted 
more than two weeks. An analysis of dichotomous measures of gaps in therapy 
showed that 46% of patients had ?.10% of days during the 12-month observation 
period not covered by medication. That is, these patients had gaps in sulfonylurea 
therapy for three or more days per month. Almost 1 in 4 patients had gaps in therapy 
for six or more days per month. 
During the observation period, the mean proportion of days of surplus 
medication (CMOS) was 5% ± 7% days (range, O to 80%) among patients prescribed 
sulfonylurea medications. Overall , 146 (15%) of patients in the study population had 
no surplus supply of sulfonylurea medication during the 12-month observation period 
while the majority of patients (85%) had surplus of sulfonylurea medication. Overall , 
22% of medication oversupplies covered more than seven days. Dichotomous 
measures demonstrated that 15% of patients had ?.10% of days with surplus 
medication while 5% had ?.20% of days during the observation period with excess 
sulfonylurea medication. Another way to assess surplus medication was by examining 
the proportion of patients with CMA >100%. During the 12-month observation period, 
20% of patients had a CMA >100% indicating acquisition of more sulfonylurea 
medication than prescribed (i.e., stockpiling). 
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Evaluation of the Relationship between Measures of Adherence with Sulfony/ureas 
As shown in Tables 1-5a to 1-5d, correlations for all continuous and 
dichotomous measures were statistically significant (p<0.0001 ). Measures of 
medication availability were significantly correlated with measures of gaps in therapy 
(r= -0.95) and surplus medication (r= 0.41) (Table 1-5a}. Similarly, measures of gaps 
in therapy were significantly correlated with measures of surplus medication (r=-0.20). 
While the continuous measure of medication availability, CMA, was correlated 
with both dichotomous categorizations, the strongest relationship was observed 
between CMA and adherence dichotomized with the 80% level (r= 0.82) (Table 1-5b) 
The continuous measure of gaps in therapy was strongly associated with the 20% 
level of dichotomization (r = 0.84) while the correlation between dichotomous 
categorizations and the continuous measure of surplus medication (CMOS) were 
similar (r s:0.79} (Tables 1-5c and 1-5d). 
Evaluation of Measures of Adherence with Sulfonylureas Grouped by Time of 
Observation 
To evaluate the effect of observed time on the measures of adherence, 
subsequent analyses examined prescription claims for six and nine months. Table 
1-6 shows a comparison of the adherence measures obtained from these two time 
periods alongside the measures from the 12-month observation period. Since 
calculation of measures of adherence require at least two prescription claims during 
the period of observation, eight and three subjects had only one prescription claim for 
sulfonylurea medication and were excluded from the six and nine month analyses, 
respectively. 
As might be expected, as the length of follow-up time increased, measures of 
available medication decreased while measures of gaps in therapy and oversupplies 
of medication increased. Interestingly, findings from nine and 12 months of 
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observation were similar suggesting that an additional three months of claims data 
was not adding any information to the overall picture of adherence in our patient 
population. 
Based on CMA, the average proportion of days with available sulfonylurea 
medication was statistically lower over six-, nine-, and 12-months of observation: 
92%, 90%, and 89%, respectively (p = 0.0137). Similar, small decreases were 
observed when medication availability was assessed using the dichotomous 
measures of 80% and 90% levels of adherence. A statistically significant difference 
was observed in the three periods of observation when patients were classified as 
over-adherent (CMA > 100%) (p=0.0057). 
Continuous measures of medication gaps were lowest with six months of 
observation as compared to examinations of nine and 12 months of prescription 
claims. An average of 13% of days with gaps in therapy was observed during six 
months of observation while 15% of days had gaps when the observation time 
increased to nine and 12 months (p=0.0195). Similar findings were observed for 
dichotomous measures of medication gaps. In contrast, continuous and dichotomous 
measures of surplus medication did not seem to be affected by the amount of time 
under observation. 
Predictive Factors of Adherence with Sulfonylureas using a Continuous Measure of 
Medication Availability (CMA) 
Predictive factors were analyzed by both bivariate correlation and multiple 
linear regression. Due to the disproportionate number of patients in the 
categorizations of concomitantly prescribed insulin, the variable insulin use was not 
included in the regression modeling. As shown in Table 1A-1, correlations for all 
variables were non-significant (p?,0.2441 ). The strongest relationship was observed 
between CMA and age (r = 0.03709). 
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Table 1-7 presents the results of the hierarchical multiple regression model. 
The overall model containing the patient-related characteristics (e.g., age, gender, 
and health plan agency) cluster did not predict adherence with sulfonylurea 
medications (F3• 987 = 0.86; p=0.4632). The variance explained by this cluster was 
0.04%. The addition of medication-related characteristics in the model increased the 
adjusted R2 to 0.21 %. However, none of the patient- or medication-related 
characteristics in the full model significantly influenced adherence with sulfonylureas 
in our patient population (Fs, 987 = 0.59; p=O. 7065). 
Beta weights (standardized multiple regression coefficients) of the full model 
were reviewed to assess the relative importance of the variables in the prediction of 
CMA. In the final model, none of the study factors significantly influenced adherence 
(i.e., availability of sulfonylurea medication) in this patient population. Although not a 
significant predictor of medication availability in this patient population, increasing age 
by one-year increments led to an increase in the rate of adherence of approximately 
4.1 % (p=0.2072). An increase in the number of concomitantly prescribed medications 
had an inverse relationship with CMA (p=0.5985). Higher rates of adherence were 
also observed for males, patients enrolled in a nurse-based diabetes management 
plan, and patients prescribed one sulfonylurea pill per day (p~0 .3152) . 
DISCUSSION 
It is well known that adherence with prescription medication is complex. 
Despite its complexity, adherence is a challenging area of investigation from the 
variety of measures of medication adherence to the numerous methods used for 
evaluation. No standard way of measuring or reporting medication adherence has 
been established. 
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In the present study, we were able to evaluate adherence with sulfonylureas 
and establ ish the relationship between measures of adherence based on their ability 
to quantify medication availability, gaps, and surplus medication. Since the period of 
observation is an integral component of adherence measures, adherence with 
sulfonylurea medications using six and nine months of prescription claims was 
compared with the primary 12-month period of observation. 
Adherence with Sulfonylureas 
During the 12-month observation period, patients had an average 89% of days 
covered with available medication. Thus, most patients obtained less medication than 
prescribed. Analyses of gaps and surplus medication were in accord with this finding . 
Patients had an average of 15% of study days in which medication was not available 
while there was surplus medication for 5% of days. That is, patients had an average 
of 47 days without medication and 16 days with surplus sulfonylurea medication over 
a 12-month period. Although information on why gaps and surplus medication 
occurred was not available, these findings have clinical relevance as non-adherence 
with sulfonylureas or over dosages may have a deleterious effect on glycemic control 
and cause adverse effects. 
Our findings were similar to those reported by Morningstar and colleagues.36 
To the best of our knowledge, this is the only published report that examined gaps 
and oversupply of sulfonylureas along with medication availability. Prescription claims 
in 3,358 patients in a senior prescription medication insurance program under 
Medicare in Nova Scotia were evaluated for a three-year period of observation. 
Although these rates were not stratified by prescription medication, this study found 
that patients prescribed first- or second-generation sulfonylureas or biguanides had 
an average of 86% of days with available medication, 16% of days not covered by 
medication, and an average of 3% of days with surplus medication. 
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Relationship between Measures of Adherence with Sulfonytureas 
As illustrated in Table 1-3, examination of multiple-interval measures provide 
an assessment of adherence over an extended period of time while single-interval 
measures allow a detailed assessment of adherence from medication fill to fill (i.e., 
interval). By examining single-interval measures of adherence, we observed a gap of 
150 days without medication during one interval. While only a small proportion of 
medication refills are dispensed exactly on the date of depletion ,52 gaps in therapy 
may be caused by dosage adjustments, patient-initiated medication holidays, related 
to a cost barrier or simply forgetfulness whereas over-adherence with sulfonylureas 
may lead to serious adverse effects such as hypoglycemia. Identification of lengthy 
periods of gaps in therapy or stockpiling medication should encourage dialogue 
between the patient and health care provider to ascertain the cause and reach 
agreement on a strategy to improve medication adherence. Thus, single-interval 
measures are meaningful to assess medication adherence on an individual basis 
while multiple-interval measures are advantageous for assessing medication 
adherence in a patient population over a specified period of time. 
Often, researchers choose to describe medication adherence with 
dichotomous measures even though there is no standard of an "acceptable" level of 
medication adherence. One study reported that HbA1c was 0.19% lower for each 10% 
increase in adherence with oral antidiabetic medications (p < 0.0001) in a population 
of 829 patients enrolled in a university-based internal medicine clinic.53 Dichotomous 
levels of 80% and 90% adherence were selected for this study based on existing 
literature and on clinical judgment about the impact of missed doses or surplus 
sulfonylurea medication to the patient with diabetes. While these measures give a 
broad view of medication adherence, further research is needed to establish the level 
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( of adherence with antidiabetic medications associated with maintenance of optimal 
glycemic levels in patients with diabetes. 
Relying solely on a single measure of medication adherence, such as CMA, 
provides the health care provider one-dimension of information regarding appropriate 
and adequate use of a medication within a population.15 As illustrated in this study, by 
combining assessments of medication availability with analyses of gaps in therapy 
and surplus medication, the scope of the problems of non-adherence with 
sulfonylurea medications is more defined. All of these dimensions are equally 
important in evaluations of medication adherence. 
While we observed a statistically significant difference in CMA using six-, 
nine-, and 12-months of observation, we were unable to evaluate whether this 
difference (3%) is clinically meaningful. Further study is needed in the area of 
adherence and its effect on clinical outcomes such as glycemic control in patients 
with diabetes. 
As we have shown, consideration of the time period of observation is an 
important component in evaluating medication adherence. Early in therapy, dosages 
may be adjusted and it may be difficult to measure gaps or surpluses accurately. 
Christensen observed that over compliance (i.e., compliance rates >100%) 
diminished with longer observation periods.54 While we were unable to identify 
patients as new users of sulfonylurea therapy, our results similarly showed the 
proportion of patients with CMA >100% significantly decreased from 25% with 
six-months of observation to 20% with 12-months of observation. 
When using prescription refill patterns as a measure of adherence, the 
measured adherence approaches actual adherence as the follow-up period is 
lengthened.55 When using sufficiently long follow-up periods (e.g., one year), the 
amount of medication dispensed can be assumed to equal the amount of medication 
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consumed. Results of a pharmacy claims study of adherence with antipsychotic 
medications at six and 12 months demonstrated the importance of longer adherence 
assessments.56 A study evaluating prescription refill patterns of 570 hypertensive 
patients over a two-year period showed that examination of four dispensing dates 
(with three months' days supply) was enough to obtain an accurate picture of 
adherence; additional information gathered during a second year of observation was 
of minor importance. These observations were confirmed by findings from another 
study of adherence with 20 commonly prescribed medications.57 
Our findings confirmed that as the length of follow-up time increased from six 
months to 12 months, the proportion of available medication to cover the number of 
observation days slightly decreased whereas the proportion of gaps in therapy 
increased. While this is not an unexpected finding , it is probably due to an attenuation 
effect since the calculation of continuous adherence measures is affected by 
observation time from first dispensation of prescription to the last fill (i.e. , the 
denominator in the formulae). Interestingly, we observed similar adherence rates from 
examination of nine months and 12 months of pharmacy claims. Thus, nine months of 
data was adequate to assess adherence with sulfonylureas in this patient population. 
Factors that may Influence Adherence with Sulfonylureas 
The present study did not find any patient- or medication-related 
characteristics that significantly influenced medication availability with sulfonylureas. 
Pharmacy claims data lack clinical information that may influence patients' use of 
medication, such as physical and cognitive ability, health beliefs, and adverse effects 
experienced by the patient. Thus, our multiple linear regression model may be biased 
due to incompleteness of the model. 
We were unable to evaluate the categorization of sulfonylurea medication as a 
study factor due to the low proportion of patients prescribed first- or third-generation 
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( sulfonylureas in this patient population. Several factors may explain the low 
proportions. First, although all sulfonylureas have similar efficacy, second-generation 
sulfonylureas are more potent and have few adverse events when taken as 
prescribed when compared to first-generation sulfonylureas.58• 59 Second, data on 
glimepiride, a third-generation sulfonylurea, may be limited in this dataset as it was 
first marketed in the U.S. in 1997- the first year of data collected for this dataset. 
This study utilized pharmacy-based measures of adherence. This 
pharmacy-based methodology has a distinct-advantage of permitting 
population-based research21 and has been applied in studies of large populations.so-s3 
One important advantage of a retrospective review of prescription refill records is 
avoidance of the Hawthorne effect (i.e., improvement in adherence when the patient 
is under observation).13 Additional strengths of this approach are that it is not 
susceptible to reporting bias or tampering.64 Obtaining pharmacy claims is an 
unobtrusive method of data collection, allowing a naturalistic estimate of adherence.65 
The strengths of the present study include the length of the assessment 
period (12 months) and the use of a variety of measures of adherence based on 
pharmacy refill records. In addition, the fact that over half of the patients were 
enrolled in a diabetes management plan may have minimized any effect of financial 
burden on refill rates and increased the likelihood that the pharmacy records were 
complete. 
We should point out several limitations of this study. The accuracy of 
medication adherence calculations from pharmacy claims relies on an accurate days 
supply variable. Although, for most medications, days supply is relatively accurate, 
there are circumstances in which an erroneous error may exist.66 During our 
preliminary data clean up, there were two occurrences in which the days supply 
variable did not match the days supply recorded for other sulfonylurea prescription 
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claims for that patient. Thus, these values were imputed to coincide with data from 
the other claims during the observation period. While we may have inappropriately 
corrected data or missed other data entry errors, we are fairly confident that our data 
are accurate. 
Without access to the dosage instructions printed on the prescription label, it 
was not possible to determine the actual daily dose (e.g., QD, BID) of sulfonylureas in 
the present study. Our choice of a surrogate for daily dose, number of pills per day, 
may have overestimated the effect of this variable on adherence with sulfonylureas. 
Nonetheless, our findings are consistent with those of previous studies that observed 
lower rates of adherence with an increase in dosing frequency.9• 1'- 36 
Since the database included patients with diabetes who were dispensed 
sulfonylureas through CVS pharmacies in Pennsylvania, the results from this study 
may not be generalizable to the wider population of patients with diabetes. 
CONCLUSION 
By assessing adherence with a variety of measurement tools, this study 
demonstrated that patients with diabetes obtained less sulfonylurea medication than 
prescribed over six-, nine-, and 12-month periods of observation. One measure of 
adherence, such as CMA, presents a misleading picture of medication adherence. 
Inclusion of an analysis of gaps and surplus medication provides an overall picture of 
medication adherence in a patient population . The observations of this study illustrate 
that a nine-month examination of prescription claims was adequate to assess the 
rates of adherence. Continuous and dichotomous measures of medication availability, 
gaps in therapy and surplus medication were significantly correlated. However, since 
there is no standard of measuring medication adherence, further research is needed 
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to evaluate the appropriate level of adherence associated with glycemic control in 
patients with diabetes. 
It is important for health care providers to be able to appreciate the complexity 
of a diabetic's treatment regimen and understand the psychological , physiological , 
environmental , and regimen-specific factors that affect patient's adherence to 
treatment regimens. For example, a finding of gaps in therapy may suggest that a 
refill reminder program needs to be incorporated into a patients' diabetes 
management plan. Evaluation of medication adherence based on a combination of 
measures will increase knowledge of the extent of adherence with sulfonylureas in 
this patient population and guide future diabetes management plans. 
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TABLES 
Table 1-1 . Measures of adherence 
Measure Definition 
Medication Availabilitv 
CSA Continuous, Single-interval 
measure of medication 
Availability 
CMA Continuous, Multiple-interval 
measure of medication 
Availability 
Medication Unavailable for Use 
CSG Continuous, Single-interval 
measure of medication Gaps 
CMG Continuous, Multiple-interval 
measure of medication Gaps 
Oversupply of Medication Available for Use 
CSOS Continuous, Single-interval 
measure of medication 
Oversupply 
CMOS Continuous Multiple-interval 
measure of Over-Supply 
Formula 
Days supply obtained during an 
interval divided by the total 
number of days in that interval 
Sum of the days supply between 
the first and last fill divided by 
total number of days from first to 
last fill 
Number of days that medication 
was unavailable for use (i.e., 
gap)* in an interval divided by the 
total number of days in that 
interval 
Total number of days with a gap 
in medication* divided by total 
number of days from first to last 
fill 
Number of days that 
oversupply/surplust medication 
was available for use in an 
interval divided by the total 
number of days in that interval 
Total number of da{s that 
oversupply/surplus medication 
was available for use divided by 
total number of days from first to 
last fill 
* A gap is the number of days between the assumed depletion date of one fill (claim's 
fill date plus days supply) and the fill date of the next refill. When no gap occurs, gap 
=0. 
t A surplus is the(+) number of days between the assumed depletion date of one fill 
(claim's fill date plus days supply) and the fill date of the next refill. 
Measures adapted from Steiner and Prochazka Journal of Clinical Epidemiology 
(1997) and Fairman and Motheral Journal of Managed Care Pharmacy (2000) 
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Table 1-2. Characteristics of the study population (N = 988) 
Characteristic 
Age (years) 
Gender 
Male 
Female 
Health Plan* 
Nurse-based diabetes management plan 
Other 
Sulfonylurea Medication Regiment 
1•1 generation sulfonylureas 
acetohexamide 
chlorpropamide 
tolazamide 
tolbutamide 
:;tJd generation sulfonylureas 
glipizide 
glyburide 
:1" generation sulfonylureas 
glimepiride 
Number of Pills per Day 
1 
>1 
Use of Insulin* 
Yes 
No 
Frequency (%) or 
mean± SD (range) 
59.2 ± 10.9 (22-88) 
571 (57.8) 
417 (42.2) 
536 (54.2) 
452 (45.8) 
18( 1.8) 
1 ( 0.1) 
11 ( 1.1) 
3 ( 0.3) 
3 ( 0.3) 
904 (91.3) 
341 (34.5) 
561 (56.8) 
68 ( 6.9) 
68 ( 6.9) 
410 (41 .5) 
578 (58.5) 
30 ( 3.0) 
958 (97.0) 
Number of Medications§ 8 ± 7 (0-44) 
* Health plan used to dispense sulfonylurea medication during the index window. 
Other includes local/state/federal health care programs, cash payments, etc. 
t Sulfonylurea medication classified during the index window. 
* Use of insulin during observation period. 
§ Number of medications (other than antidiabetic medications or supplies) prescribed 
during observation period. 
Abbreviations: SD = 1 standard deviation 
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Table 1-3. Illustration of single- and multiple-interval measures of adherence with sulfonylurea medication 
Prescription Day of fill Days of Days in Days with Days with CSA CSG csos 
Interval Supply Interval treatment treatment 
Obtained gap in surplus in 
interval interval 
1 12/26/97 45 
2 01/24/98 45 29 0 16 1.56 0 0.55 
3 03/26/98 45 61 16 0 0.74 0.26 0 
4 05/13/98 45 48 3 0 0.94 0.06 0 
5 06/03/98 45 21 0 24 2.14 0 1.14 
6 12/15/98 45• 195 150 0 0.23 0.77 0 
Total 225 354 169 40 
Medication Availability 
CMA(o/o) 63.6 
Medication Deficits 
CMG(%) 47.7 
Medication Oversupply 
CMOS(%) 11.3 
• Days supply was not used in the calculation of CMA as the next fill date is unknown. 
Abbreviations: CMA = continuous measure of medication availability; CMG = continuous measure of medication gap; 
CMOS = cumulative multiple-interval measure of over-supply; CSA= single interval measure of medication availability; 
CSG = continuous single interval measure of medication gap; CSOS = continuous single-interval measure of medication 
oversupply. 
Table 1-4. Measures of adherence with sulfonylureas in patients with diabetes 
N =988 
Adherence Measure (%) 
Medication Availability 
CMA* 
>80%t 
~90%t 
>100% 
Medication Gap 
CMG* 
?.10% 
?.20% 
Medication Surplus 
Frequency(%) or mean± SD (range) 
89.3 ± 18.4 (10.0-150.4) 
775 (78.4) 
647 (65.5) 
194 (19.6) 
15.0 ± 16.2 (0 - 90.0) 
454 (46.0) 
240 (24.3) 
CMOS* 5.1 ± 7.4 (0 - 79.9) 
?_10% 146 (14.8) 
>20% 45 ( 4.6) 
• Calculated using period of observation (i.e. , the number of days between first and 
last 
fill during the observation period) as the denominator 
t Adherent with at least 80% (90%) days of therapy 
Abbreviations: CMA= continuous multiple-interval measure of medication availability; 
CMG =continuous multiple-interval measure of gap; CMOS= cumulative multiple-
interval measure of oversupply; SD = standard deviation 
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Table 1-5a. Bivariate correlation of continuous measures of medication availability. gaps. and surplus 
Correlation coefficient CMA CMG CMOS 
CMA 1.000 
CMG -0.95198* 
CMOS 0.41317* 
* p <0.0001 
1.000 
-0.20144* 1.000 
Abbreviations: CMA= continuous multiple-interval measure of medication availability; 
CMG = continuous multiple-interval measure of gap; CMOS= cumulative multiple-interval measure 
of oversupply. 
Table 1-5b. Bivariate correlation of continuous and dichotomous measures of medication availability 
Correlation coefficient CMA CMA >80% CMA >90% 
CMA 1.000 
CMA :::_80% 0.82110* 
CMA >90% 0.76040* 
* p <0.0001 
1.000 
0.72213* 1.000 
Abbreviations: CMA= continuous multiple-interval measure of medication availability. 
Table 1-5c. Bivariate correlation of continuous and dichotomous measures of gaps in therapy 
Correlation coefficient CMG CMG >10% CMG >20% 
CMG 1.000 
CMG ~10% 0.69026• 1.000 
CMG >20% 0.83781 • 0.61432• 1.000 
• p <0.0001 
Abbreviations: CMG = continuous multiple-interval measure of gap. 
Table 1-5d. Bivariate correlation of continuous and dichotomous measures of surplus medication 
Correlation coefficient CMOS CMOS >10% CMOS >20% ~ 
CMOS 1.000 
CMOS ~10% 0. 78836• 1.000 
CMOS >20% 0.75255• 0.52460• 1.000 
• p <0.0001 
Abbreviations: CMOS= cumulative multiple-interval measure of oversupply. 
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Table 1-6. Measures of adherence with sulfonylureas in patients with diabetes grouped by time period of observation• 
6 months 9 months 12 months 
Measure(%) n = 980* n = 985* n = 988 
Medication Availability 
CMAt 
>80%* 
~90%* 
>100% 
Medication Gap 
CMGt 
:::_10% 
:::_20% 
Medication Surplus 
91.7§± 18.7 (21 .6 - 159.1) 
792 (80.8) 
681 (69.5) 
243•• (24.8) 
13.1§ ± 15.4 (0- 78.4) 
380** (38.8) 
209 (21.3) 
90.0§ ± 18.5 (12.2-155.8) 
785 (79.7) 
638 (64.8) 
209 .. (21 .2) 
14.5§ ± 15.8 (0- 87.8) 
435 .. (44.2) 
231 (23.5) 
89.3§ ± 18.4 (10.0-150.4) 
775 (78.4) 
647 (65.5) 
194•• (19.6) 
15.0§ ± 16.2 (0- 90.0) 
454•• (46.0) 
240 (24.3) 
CMost 4.8 ± 9.o (O - 81.5) 5.1 ± 8.4 (O - 83.9) 5.1 ± 7.4 (O- 79.9) 
:::_10% 135 (13.8) 153 (15.5) 146 (14.8) 
:::_20% 61 ( 6.2) 52 ( 5.3) 45 ( 4.6) 
Data are presented as frequency(%} or mean± SD (range) 
• Time period of observation examined 6, 9, or 12 months of pharmacy claims data. 8 patients excluded 
with only 1 sulfonylurea fill during 6-month period and 3 patients excluded with only 1 sulfonylurea fill during 9-month period. 
t Calculated using period of observation (i.e., the number of days between first and last fill) as the denominator 
*Adherent with at least 80% (90%) days of therapy 
§ p < 0.05 
•• p < 0.01 
Abbreviations: CMA= continuous multiple-interval measure of medication availability; CMG = continuous multiple-interval 
measure of gap; CMOS= cumulative multiple-interval measure of oversupply; SD = standard deviation. 
Table 1-7. Beta estimates of predictive factors of adherence* with sulfonylurea 
medications in patients with diabetes 
Variable Beta estimate (SE) Beta estimate (SE) 
Intercept 0 (3.29078) 0 (3.43503) 
Patient-related characteristics 
Age (years) 0.03924 (0.05377) 0.04092 (0.05465) 
Gender {1 =female) -0.00931 {1.18887) -0.00713 (1 .20259) 
Health plan (1 =other) -0.03424 (1.18093) -0.03227 (1.18775) 
Medication-related characteristics 
No. of pills per day (1 = >1) 
Number of concomitantly 
prescribed medications 
Model F-value (p-value) 
Adjusted R2 
0.86 (0.4632) 
0.0004 
-0.01011 (1.19830) 
-0.01724 (0.09212) 
0.59 (0.7065) 
0.0021 
• Continuous measure of medication availability (CMA) 
Abbreviations: SE =standard error 
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Table 1A-1 . Bivariate correlation of CMA* and all 6 predictive variables 
CMA* Age Gender Health Concomitant No. of SU 
Correlation coefficient 
p value 
1.000 0.03709 
0.2441 
-0.00792 
0.8036 
* Continuous measure of medication availability (CMA) 
plan medication pills/day 
-0.03141 -0.01528 -0.01499 
0.3240 0.6314 0.6379 
Abbreviations: CMA= continuous multiple-interval measure of medication availability; SU = sulfonylurea. 
w 
"' 
Table 1 A-2. Collinearity diagnostics* 
Proportion of variation 
Variable Condition Index Intercept Age Gender Health Plan 
Intercept 1.00000 0.00143 0.00154 0.01587 0.01611 
Age 2.71477 0.00002771 0.00004427 0.60022 0.30821 
Gender 3.07310 0.00074987 0.00052353 0.13499 0.48962 
Health plan 3.49445 0.00044223 0.00142 0.19083 0.11254 
No. of ConMed 4.37622 0.03170 0.04052 0.04945 0.07293 
No. of ~ills/day 16.58110 0.96564 0.95594 0.00864 0.00057832 
* Dependent variable was a continuous measure of medication availability (CMA) 
No. of ConMed No. of 
pills/day 
0.01396 0.01443 
0.00199 0.01919 
0.00000232 0.39949 
0.57139 0.24819 
0.40926 0.27847 
0.00340 0.04022 
FIGURES 
Figure 1-1 . Eligibility criteria of study population 
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Figure 1 A-1 . Frequency distribution of the measurement: CMA 
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Figure 1 A-2. Frequency distribution of the measurement: CMG 
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Figure 1A-3. Frequency distribution of the measurement: CMOS 
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Figure 1 A-4. Two-dimensional plot of residuals against the dependent variable, CMA 
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Figure 1A-5. Two-dimensional plot of studentized residuals against the dependent 
variable, CMA 
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Figure 1A-6. Two-dimensional plot of studentized residuals against age 
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Figure 1A-7. Two-dimensional plot of studentized residuals against number of 
concomitantly prescribed medications 
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Study 2 
Using Prescription Claim Records to Evaluate Adherence with Lipid-lowering 
Medications in Patients with Diabetes Mellitus 
ABSTRACT 
Background: Current American Diabetes Association guidelines recommend 
aggressive treatment of diabetic dyslipidemia that may include pharmacologic therapy 
with lipid-lowering therapy. Adherence with lipid-lowering therapy is essential to 
achieve targeted lipid levels within treatment guidelines. Low adherence with 
lipid-lowering medications has been documented in several patient populations such 
as the elderly and Health Maintenance Organization members. 
Objective: The objective of this study was to evaluate adherence with lipid-lowering 
medications in patients with diabetes mellitus. In addition, the effect of patient- and 
medication-related characteristics on adherence was examined. 
Methods: Using pharmacy claim records, a retrospective cohort study of patients with 
diabetes mellitus identified new users of lipid-lowering therapy. Patients had an initial 
prescription for a lipid-lowering medication between November 1, 1997 and April 30, 
1998 with at least two refills in a nine-month observation period. Adherence was 
measured by the Continuous multiple-interval measure of Medication Availability 
(CMA) using length of therapy as the denominator. Logistic regression models were 
used to assess the effects of patient- and medication-related characteristics on a 
dichotomous measure of adherence using 80% and 90% levels of adherence. 
Results: The study cohort comprised of 90 patients with diabetes (52% males; mean 
age of 60.3 years (range 30-79 years)) . The majority (91 %) of patients were 
prescribed a statin medication. Patients were observed for an average 225 days 
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(range of 59 to 270 days). Overall , mean (±SD) CMA was 82.8% ± 23.4% (range of 
14.3% to 124.8%). Adherence differed by class of lipid-lowering medication 
prescribed at the index date, although not a statistically significant difference. Patients 
prescribed statin and non-statin medications had an average CMA of 84.1 % ± 22.3% 
and 70.0% ± 31 .7%, respectively (p=0.2627). Approximately 66% of patients filled 
enough lipid-lowering medication prescriptions to cover at least 80% or more days 
while only 46% of patients had sufficient medication to cover 90% or more days of 
therapy during a nine-month observation period. In the final logistic regression model, 
adherence was influenced by antidiabetic medication regimen and class of 
lipid-lowering medication prescribed at the index date. Adherent ~80%) patients were 
less likely to be prescribed insulin therapy (OR=0.304, 95% Cl=0.114, 0.815, 
p=0.0180) and more likely to be prescribed statin medications (0R=4.709, 95% 
Cl=0.996, 22.268, p=0.0506) compared with non-adherent patients. No study factor 
(age, gender, health plan, antidiabetic medication, class of index lipid-lowering 
medication, number of concurrent prescription medications) significantly influenced 
adherence using a 90% level of adherence. 
Conclusions: Adherence with lipid-lowering therapy in patients with diabetes mellitus 
was less than optimal. Non-adherence was associated with insulin therapy and 
non-statin medications. This data supports previous investigations that observed an 
effect of class of lipid-lowering medications and insulin therapy on medication 
adherence. Further research is needed to examine the relationship between 
adherence and lipid levels and explore the effect of study factors such as antidiabetic 
medication regimen patient beliefs, prescriber characteristics on medication 
adherence among patients with diabetes mellitus. 
Key Words: lipid-lowering therapy, dyslipidemia, diabetes, adherence 
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INTRODUCTION 
Diabetes mellitus is associated with co-morbid conditions such as 
dyslipidemia 1 which contributes to higher rates of cardiovascular disease. 2.3 
According to the Centers for Disease Control and Prevention (CDC), 97% of adults 
with diabetes have one or more lipid abnormalities although only 32% receive 
treatment with diet, exercise or pharmacotherapy.4 
The American Diabetes Association {ADA) guidelines and the National 
Cholesterol Education Program (NCEP) Adult Treatment Panel {ATP Ill) recommend 
aggressive treatment of diabetic dyslipidemia.5• 6 Current ADA recommendations 
emphasize treatment to lower low-density lipoprotein cholesterol (LDL-C} levels to 
<100 mg/di, even in patients with no history of cardiovascular disease (Table 2-1).7 8 
Based on the Third National Health and Nutrition Examination Survey (NHANES Ill), it 
is estimated that 9.2 million adults with diabetes require treatment for LDL-C levels 
>100 mg/dl.9 
The ATP Ill report for the management of high blood cholesterol in the United 
States recognizes two major approaches to therapy for dyslipidemia: lifestyle 
management and pharmacological therapy.6 Therapeutic lifestyle changes, such as 
weight management and increased physical activity are a major factor in the 
treatment of diabetic dyslipidemia. Current ADA guidelines recommend initiation with 
pharmacological therapy after lifestyle intervention has been implemented.8 
Generally, in patients with diabetes, pharmacological therapy should follow when a 
three- to six-month trial of lifestyle modifications alone fails to adequately lower LDL-C 
levels.10• 11 
Medications available to treat dyslipidemia include HMG-CoA reductase 
inhibitors (statins), bile acid sequestrants, nicotinic acid, and fibrates. Typically the 
lipid-lowering medication selected is largely dependent on the nature of the patient's 
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dyslipidemia.'" 12 Stalins are recommended first-line therapy for reducing LDL-C 
levels in patients with diabetes5 yet statins also increase high-density lipoprotein 
cholesterol (HDL-C) concentrations and recently have been shown to reduce 
triglyceride levels as well. 13 Fibrates have been used as monotherapy to treat diabetic 
dyslipidemia as they effectively reduce triglycerides and increase HDL-C levels 
although they may be used in combination with statin therapy if the patients' LDL-C 
does not reach the target level. 12 Bile acid sequestrants may be used as second-line 
therapy although they may aggravate hypertriglyercidemia and are associated with 
unpleasant gastrointestinal side effects-"· 14' 15 Nicotinic acid can be given to patients 
with diabetes, although it is generally avoided because it may cause worsening 
hyperglycemia. 15• 16 
The relationship between reductions in lipid levels and target treatment goals 
has been demonstrated.11·21 For example, in a comparison with 1998 target values 
defined by the ADA, > 75% of patients with type 2 diabetes mellitus treated with 30 
weeks of atorvastatin reached triglyceride treatment goals and 71 % and 85% of 
patients treated with 10mg and 80mg atorvastatin respectively, reached LDL-C 
treatment goals.18 Stalin medications were more likely to achieve a LDL-C target goal 
of ~100 mg/dl than non-statin therapy in a cohort of patients with diabetes mellitus.21 
Patients with diabetes treated with at least three months of lipid-lowering therapy 
were 36% more likely to achieve NCEP target LDL-C levels than those without 
diabetes (p=0.04).17 
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However, one important factor affecting the pharmacological management of 
dysllp1dem1a 1s adherence. Physicians have been plagued by concerns over patients' 
adherence to medication regimens since Hippocrates.22·2• Adherence has been 
defined as the extent to which a patient freely chooses to follow physicians' orders 
(i.e ., by taking medications or modification of lifestyle changes such as diet and 
exercise) with medical advice.25 Adherence consists of the initial acquisition of 
medication, the consumption of the medication in the prescribed method, and 
acquisition of refills . 
Few studies have demonstrated a connection between medication adherence 
and lipid levels in patients with dyslipidemia. The Helsinki Heart Study, a coronary 
primary prevention trial using gemfibrozil , found that serum lipid levels varied linearly 
with the level of medication adherence.26 The mean change in LDL-C was -10.1 % 
among patients who consumed ~90% of the scheduled dosage of gemfibrozil in 
contrast with a mean change of +2.6% when adherence with mean daily capsule 
count was <50%.26 In addition, data from the five-year Heart Protection Study 
examined adherence and reduction of lipid levels in patients with diabetes. After 
making allowances for compliance (82% of patients were compliant defined as >80% 
of the scheduled mediation taken) actual use of 40mg simvastatin daily would lower 
LDL-C by about 58 mg/dl.27 These results highlight an important factor: adherence 
affects the pharmacological management of dyslipidemia and consequently a 
patient's ability to achieve target lipid levels. 
Adherence with lipid-lowering therapy has been documented in patient 
populations such as the elderly, patients with a history of myocardial infarction (Ml) 
Adherence and compliance are used interchangeably in the literature. Although the 
term compliance has negative connotations, it is still in use and will be referred to in 
this study if utilized in the cited published material. 
57 
and members of Health Maintenance Organizations (HMOs). Regardless of the 
patient population, these studies provide evidence that adherence with lipid-lowering 
medications is varied and often sub-optimal. While these studies document rates of 
adherence with lipid-lowering medications in clinical practice, several studies 
examined diabetes as a covariate in their analyses with inconsistent results . Among 
elderly patients, diabetes was associated with better adherence with lipid-lowering 
therapy.20·30 In contrast, diabetes was associated with non-compliance with 
fluvastatin31 while Mansur and colleagues did not find a relationship between 
adherence with statin therapy and diabetes. 32 
While many studies have documented the frequent utilization of lipid-lowering 
medications among patients with diabetes.33• 34 and reviewed the topic of diabetic 
dyslipidemia,1'- 16• 35• 36 few studies have specifically examined adherence with 
lipid-lowering therapy in patients with diabetes. Thus, the aim of this study was to 
evaluate adherence with lipid-lowering medications in patients with diabetes mellitus 
using prescription claims data. The present study was designed to 1) estimate 
adherence in patients identified as new users of lipid-lowering medications and 2) 
identify factors that might influence adherence with lipid-lowering medications among 
patients with diabetes mellitus. 
METHODS 
Study Design 
This was a retrospective cohort study of patients with diabetes using 
pharmacy claim prescription records. 
Dataset 
Data examined in the analysis were obtained from 198 Consumer Value 
Stores (CVS) pharmacies located in Pennsylvania that provided prescription 
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medications for 4503 patients with diabetes identified by specific therapeutic classes 
(insulins, oral antidiabetic agents-sulfonylureas and other oral antidiabetic agents) 
between April 27, 1997 and May 16, 1999. Patients were either enrolled in a 
nurse-based diabetes management plan or acquired their prescription through a 
local/state/federal program or paid with cash payments. The data represents patients' 
utilization of lipid-lowering medications, though some patients may have filled 
prescriptions elsewhere. 
This prescription claims data extract includes records of dispensed outpatient 
pharmacy prescription records for all prescriptions. The following information was 
obtained from the CVS dataset for this analysis: patient characteristic variables such 
as birth date, gender, and health plan agency as well as prescription related variables 
including quantity of medication dispensed, days supply of medication dispensed, and 
date the prescription was dispensed. No personally identifying information was 
provided. 
Study Population 
Patients were eligible for inclusion in the study population if they (1) had an 
initial prescription claim for a lipid-lowering medication between November 1, 1997 
and April 30, 1998 with at least two refills during a nine-month observation period 
(n=831); (2) were a new user of lipid-lowering therapy (n=136); (3) had no 
dispensations for combination lipid-lowering medication (defined as a claim for a 
second lipid-lowering medication within 30 days of the index medication) (n=O); and 
(4) continuously used the pharmacy to fill prescriptions (i.e., the patient had a least 
one prescription filled for any medication in the three months prior to the index date 
and in the last three months of the observation period) (n=91 ). Patients who switched 
class of lipid-lowering medication to another class during the observation period were 
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excluded from the analysis as class of lipid-lowering medication was evaluated as the 
primary independent variable (n=1 ). 
The date of the initial lipid-lowering prescription between November 1, 1997 
and April 30, 1998 was classified as the index date. Each patient was observed for 
nine months from the index date: all prescription claims for lipid-lowering medications 
from this time period were retrieved from the dataset. 
Presumed new users were defined as patients having no prescription claim for 
a lipid-lowering medication in the 90 days before the index date. Thus, patients with 
less than 90 days of data prior to the index date were excluded. This classification to 
identify new users of therapy has been previously described. 37• 38 
Lipid-Lowering Medications Available in Dataset 
Data from all patients receiving lipid-lowering prescription fills were extracted 
from the dataset. As shown in Table 2-2, this dataset contains prescription claims on 
the following lipid-lowering medications: (1) Stalins (3-hydroxy-3-methylglutaryl 
coenzyme A (HMG CoA) reductase inhibitors): atorvastatin, fluvastatin , lovastatin, 
pravastatin, simvastatin; (2) Fibrates: fenofibrate and gemfibrozil; (3) Bile acid 
sequestrants: cholestyramine resin and colestipol; and (4) Nicotinic acid: niacin. One 
of the objectives of this study was to document adherence with lipid-lowering 
medications. However, due to the small number of patients prescribed non-statin 
medications, class of index lipid-lowering medication was identified as the primary 
independent variable. This variable was categorized as statin or non-statin (fibric acid 
derivatives, bile acid sequestrants, and nicotinic acid) based on 1) previous reports of 
adherence with lipid-lowering medications28• 39 and 2) statin medications are 
considered first-line therapy for patients with diabetes.' · 38• 40 
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Potential Confounding Variables 
The following potential confounding variables were evaluated in th is analysis: 
age, gender, health plan, antidiabetic medication regimen, and the number of 
concomitantly prescribed medications. These factors were classified as 
patient-related characteristics (age, gender, health plan) or medication-related 
characteristics (antidiabetic medication regimen, number of concurrent medications) 
constructed from the prescription profile of each patient. The primary independent 
variable, class of lipid-lowering medication, was based on the prescription filled on the 
index date. 
Age was based on the transaction date for the index lipid-lowering prescription 
fill and was treated as a continuous variable in the univariate data analyses and a 
categorical variable in the multivariate analyses. The patients' health plan, used to 
acquire the index lipid-lowering medication, was dichotomized as either a 
nurse-based diabetes management plan or other (e.g., local/state/federal programs 
or cash payments). 
Based on the prescribed antidiabetic regimen during the observation period, 
antidiabetic medication regimen was classified as oral medication for patients 
dispensed only oral antidiabetic medications or insulin therapy for patients dispensed 
either insulin monotherapy or insulin in combination with oral antidiabetic 
medications. The number of concurrent medications consisted of a count of all 
medications, excluding lipid-lowering medications and diabetic supplies such as blood 
glucose test strips or tuberculin syringes, dispensed during the observation period. 
This variable was treated as a continuous variable in the univariate data analyses and 
a categorical variable in the multivariate analyses. 
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Data Analysis 
Prescription claims for all patients who satisfied the inclusion/exclusion cri teria 
were examined for a nine-month observation period. 
Dataset Preparation 
Prior to analysis, the dataset was checked for outliers for the following 
variables: days supply and posted transaction date of the prescription claim . One 
patient had a days supply recorded as three; this patient's days supply was imputed 
to 30 to coincide with the days supply recorded for other fills and the quantity 
dispensed. Patients with incomplete records (i.e., missing transaction dates) for 
lipid-lowering medications were excluded from the analysis (n=173). 
Calculation of Adherence Measures 
Adherence was measured by the Continuous multiple-interval measure of 
Medication Availability (CMA) using length of therapy as the denominator as 
described by Steiner and colleagues.41 • 42 This measure provided a continuous 
assessment of medication availability during the observation period and is based on 
the assumption that patients cannot be adherent with medication therapy if they have 
not obtained sufficient quantities of medication. 
CMA was calculated for each patient using the following formula: sum of the 
days supply between the first and last prescription fill of lipid-lowering medication 
divided by the number of days of therapy between the first and last prescription 
during the observation period. Adherence was expressed as a percentage and 
indicated the percentage of time between the first and last dispensation that a patient 
had medication available during the observation period. 
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The following example illustrates the calculation of CMA for this study: 
Transaction Date of Lipid-lowering Medication 
July 26, 1998 
August 26, 1998 
September 28, 1998 
October 27, 1998 
November 30, 1998 
Davs Supply 
30 
30 
30 
30 
30 
Total days supply between July 26, 1998 and November 30, 1998: 
30 + 30 + 30 + 30 = 120 days 
Total number of days between July 26, 1998 and November 30, 1998: 
127 days 
Thus, this patient's CMA was: 
120 I 127 X 100% = 94.5% 
The convention has been to define adequate adherence as carrying out 80% 
of the recommended behaviors.43• 44 In this study, adherence was categorized using a 
level of 80% medication coverage (i.e., patients who were dispensed enough 
lipid-lowering medication to cover 80% of days in the observation period). Patients 
were classified as adherent ~80%) or non-adherent (<80%) based on this level. This 
level of adherence is commonly used in adherence studies.45""" 
Although 80% has been justified as a standard since it is used conventionally 
in clinical trials for safety and efficacy assessments that support new drug 
registrations49"51 and there is evidence that this level of adherence is sufficient to 
reduce LDL-C levels in patients with diabetes mellitus,27 we also chose to evaluate a 
higher level of adherence with lipid-lowering therapy that might be needed to lower 
the risk of cardiovascular mortality in patients with diabetes. A sensitivity analysis will 
assess a 90% level of adherence that was utilized in the Helsinki Heart Study.26 
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Univariate Analysis 
Descriptive statistics, mean ± SD for continuous variables and frequencies 
(percentage) for categorical variables, were used to present patient- and 
medication-related characteristics. Chi-square (X2) tests and I-tests were performed 
to determine significant differences for the categorical and continuous variables, 
respectively. X2 and I-tests were used to analyze the proportions of study factors 
between patients who were adherent ~80% or ?.90%) or non-adherent (<80 or 
<90%) with lipid-lowering therapy. 
The Shapiro-Wilk test of normality was used to assess the frequency 
distribution of the continuous variables: age, CMA and number of concurrent 
prescription medications. Age was normally distributed (W statistic= 0.9785; 
p=0.1495). CMA and number of concurrent prescription medications were not 
normally distributed as demonstrated by statistically significant Shapiro-Wilk tests 
(p<0.0001 ); non-parametric rank tests were used to determine significant differences 
for these two variables. The frequency distribution of the 80% and 90% levels of 
adherence measurements are presented in Figures 2A-1 and 2A-2, respectively. 
Multivariate Analysis 
Logistic regression was used to model the effects of study factors on 
adherence with lipid-lowering therapy, using two different levels of adherence as a 
categorical dependent variable (<80%, ?.80% and <90%, ?.90%) and the primary 
variable of interest, class of lipid-lowering medication prescribed at the index date. 
The logistic regression model was built with significant predictive variables and 
interaction terms as described by Hosmer and Lemeshow.52 Assessments of the 
factors that might influence adherence with lipid-lowering therapy included parametric 
assessment of continuous variables, an assessment of potential confounding 
variables, collinearity among the independent variables, and an assessment of 
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multiplicative interaction between the independent variables. All assessments were 
conducted using both the 80% and 90% levels of adherence. 
Parametric Analysis of Continuous Variables 
Parametric assessment of two continuous variables, age and number of 
concomitantly prescribed medications, was based on the methodology described by 
Hosmer and Lemeshow.52 These variables were categorized based on the quartiles 
of the frequency distribution, using the first quartile as the reference group. After 
modeling the dependent variable, adherence, with the quartile-based variable, a plot 
of the odds ratio for the quartiles was visually examined for linearity. If linearity was 
observed, the variable remained continuous. Conversely, if linearity was not 
supported, the variables required categorizations based on cut-points observed in the 
plot. 
The quartile-based parametric analysis suggested that categorization was 
needed for inclusion of the continuous variables, age and number of concomitant 
medications, in the logistic regression model. Based on visual examination of the 
plots of odds ratio, age was categorized in three levels (30-55, 56-65, >65} and 
number of concomitant medications was dichotomized (1-5, >5) (Tables 2A-1 a and 
2A-1b}. 
Assessment of Co/linearity 
Since logistic regression model fitting is sensitive to collinearity among the 
independent variables, the presence of collinearity between the independent 
variables was examined.52• 53 Independent variables with a condition index greater 
than 30 (moderate to severe collinearity) and proportion of variations greater than 0.5 
were further examined for collinearity with other independent variables If there was 
collinearity between the two variables, the variable showing the strongest association 
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with adherence with lipid-lowering therapy was kept in the model. None of the six 
study variables exhibited signs of collinearity {Table 2A-2). 
Assessment of Multiplicative Interactions 
Multiplicative interaction between the independent variables was assessed 
using the -2 Log Likelihood (LL) difference between the models (i.e., the Chunk test) 
as described by Kleinbaum.54 A logistic regression model of factors that might 
influence medication adherence was conducted for the full model {all independent 
variables, two- and three-way interaction terms) and reduced models: all independent 
variables plus two-way interaction terms and a model containing only the independent 
variables. The -2 LL difference in the model versus the model with reduced terms was 
tested for significance using X2 test values. Interaction was not present if the -2 LL 
difference was less than the X2 statistic. 
Several interaction terms, including all of the three-way interaction terms, had 
an odds ratio (OR) >999.999 and the validity of the model was questionable 
suggesting that these terms needed to be removed from the model. Upon further 
examination, the proportion of patients in the categorizations of 50% of the three-way 
interaction terms was .s: 20%. Separate logistic regression models of adherence 
tested these interaction terms; none of the terms significantly influenced adherence 
with lipid-lowering therapy. Examining the -2 LL difference between the models, the 
reduced model of independent variables was not statistically significant from the 
model that included two-way interaction terms {Tables 2A-3a and 2A-3b). 
Assessment of Confounding Variables 
Based on the technique of Hosmer and Lemeshow,52 an assessment of potential 
confounding variables (age, gender, health plan, antidiabetic medication regimen and 
number of concomitant medications) was conducted on the no-interaction model. X2 
tests were conducted to test the effect of the potential confounding variables on the 
66 
dependent variable (dichotomous level of adherence) and primary independent 
variable (class of index lipid-lowering medication). A confounding variable would be 
identified if an association (i.e., the X2 test statistic showed statistical significance, 
p<0.05) were present with both the dependent and primary independent variables. No 
study factors were identified as a confounding variable (Tables 2A-4a and 2A-4b). 
Final Logistic Regression Model 
Significant study factors from the bivariate and multivariate logistic regression 
models along with the primary independent variable were incorporated into the final 
model of adherence with lipid-lowering therapy; a stepwise procedure of model 
selection (entry criteria=0.10) confirmed this choice. 
Analyses were conducted utilizing adherence categorizations with adherence 
defined as ~80% . A sensitivity analysis was conducted using ~90% adherence. All 
statistical tests were two-tailed and the a priori alpha test of significance was set at 
p<0.05. All data analyses were conducted using SAS release 8.02.55 
RESULTS 
Description of the Study Population 
Of the 1276 patients prescribed lipid-lowering medication, 857 had a 
prescription claim from November 1, 1997 and April 30, 1998. Of these patients, 695 
were current users of lipid-lowering therapy; 26 patients were excluded because they 
did not have at least two prescription refills for a lipid-lowering medication during a 
nine-month observation period; 45 did not have continuous prescription dispensations 
from the pharmacy (i.e. , a prescription claim for any medication in the 90 days prior to 
the index date and in the last three months of the observation period}; and one 
patient switched to another class of lipid-lowering medication (Figure 2-1 ). 
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A total of 90 patients were included in the study analyses: 47 (52%) males and 
43 (48%) females with an average age of 60.3 ± 9.9 years (range, 30-79 years). 
Patient- and medication-related characteristics of the study population are shown in 
Table 2-3. Approximately half of the patients were enrolled in a nurse-based diabetes 
management plan at the time of the index lipid-lowering medication prescription. 
Almost three-quarters of the patients (72%) were prescribed only oral antidiabetic 
medications during the observation period; either insulin monotherapy or insulin in 
combination with oral hypoglycemic agents was prescribed for 28% of patients. The 
mean (± SD) number of concomitantly prescribed medications was 8 ± 5 (range of 1 
to 27); 80% of patients were prescribed 1-1 O concomitant medications. 
While the majority of patients (91 %) were prescribed a statin medication as 
their index lipid-lowering medication, eight patients were prescribed a non-statin 
medication: seven patients prescribed fibrates and one patient was a prescribed bile 
acid sequestrant. 
The average number of days of observation was 225 days (range of 59 to 270 
days). Half of the patients received more than seven dispensations of lipid-lowering 
medication during the nine-month observation period (Table 2-4). 
Adherence with Lipid-lowering Therapy 
Overall , mean (±SD) CMA was 82.8% ± 23.4% (range, 14.3%-124.8%). 
Adherence significantly differed by class of lipid-lowering medication prescribed at the 
index date: patients prescribed statin and non-statin medications had a mean (± SD) 
CMA of 84.1 % ± 22.3% and 70.0% ± 31 .7%, respectively (p=0.2627) (Table 2-5). Of 
those patients in the statin group, patients prescribed atorvastatin had the highest 
mean CMA of 87.8%, followed by patients prescribed pravastatin (85.9%), 
simvastatin (82.8%) and fluvastatin (79.3%). One patient prescribed lovastatin had a 
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CMA of 68.4%. Mean CMA for patients prescribed gemfibrozil and cholestyramine are 
71 .5% and 59.0%, respectively. 
Two-thirds of the patients (66%) had sufficient lipid-lowering medication to 
cover 80% or more days in a nine-month observation period; these patients were 
classified as adherent. Patient- and medication-related characteristics were similar 
between patients classified as adherent and non-adherent except for antidiabetic 
medication regimen and class of lipid-lowering medication prescribed at the index 
date (Table 2-6). Adherent patients were less frequently prescribed insulin therapy 
than non-adherent patients (p=0.0297). Additionally, adherent patients were more 
frequently prescribed a statin medication than a non-statin although this proportion 
was not statistically significant (p=0.0802). 
Logistic Regression Model of Adherence (2:.80%) 
In the bivariate logistic regression model of adherence (?_80%), only 
antidiabetic medication regimen had a statistically significant effect on adherence: 
patients prescribed insulin therapy (i .e. , either insulin monotherapy or insulin in 
combination with oral antidiabetic medications) were less likely to adhere with 
lipid-lowering therapy than patients prescribed only oral antidiabetic medications 
(Table 2-7). 
Table 2-8 presents results from the multivariate logistic regression model of 
adherence (?_80%). Controlling for all study factors, antidiabetic medication regimen 
significantly influenced adherence with lipid-lowering medications. Patients prescribed 
insulin therapy were less likely to have sufficient lipid-lowering medication to cover at 
least 80% or more days in a nine-month observation period than patients prescribed 
only oral antidiabetic medications (OR=0.172; 95% Cl=0.053,0.554; p=0.0032). All 
other study factors did not significantly affect adherence with lipid-lowering 
medication (p.2:_0.1048). In a stepwise logistic regression model, which added one 
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study factor at a time, antidiabetic medication regression and class of lipid-lowering 
medication met the entry criteria of p ~0.10 . 
Thus, the resulting final model of adherence ~80%) incorporated the 
significant covariates from the multivariate regression model (Table 2-9). The 
likelihood of patients achieving adherence with lipid-lowering medication was lower 
for patients prescribed insulin therapy (OR= 0.304, 95% Cl=0.114, 0.815, p=0.0180} 
compared with patients prescribed only oral antidiabetic medications. Compared with 
patients prescribed non-statin medications, patients prescribed a statin medication 
were four-fold more likely to be adherent with treatment (0R=4.709, 95% Cl=0.996, 
22.268, p=0.0506); this parameter was close to statistical significance in the final 
model. 
Sensitivity Analysis 
A sensitivity analyses was conducted using adherence defined as having 
adequate lipid-lowering medication to cover at least 90% or more days in a 
nine-month observation period. Results of the univariate analyses were similar to 
those observed with the 80% level of adherence. In summary, only 46% of patients 
were adherent with lipid-lowering therapy. Patient- and medication-related 
characteristics were similar for adherent ~90%) and non-adherent patients 
(p~0 . 1956) (Table 2-10). In bivariate logistic regression models, no study factor 
significantly influenced adherence (Table 2-11). Similarly, no study factors 
significantly affected adherence in the multivariate regression model controlling for all 
study factors (Table 2-12). Since no study variable significantly influenced adherence, 
there were no significant predictors to include in a final regression model using a 90% 
level of adherence. 
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DISCUSSION 
The value of treating dyslipidemia is well established: lipid-lowering 
pharmacotherapy reduces lipid levels and consequently the risk of cardiovascular 
complications. Yet, dyslipidemia is a chronic, asymptomatic condition that may 
require daily pharmacotherapy. Thus, adherence with lipid-lowering therapy is an 
important component in the treatment of dyslipidemia. This study provided an 
opportunity to evaluate adherence with lipid-lowering therapy in patients with 
diabetes. 
We observed a mean CMA with lipid-lowering therapy of 82.8 ± 23.4%. Our 
results are higher than rates reported for Medicaid and managed care 
populations28·56•58 which may reflect a selection bias due to the patient population 
selected for the dataset: patients prescribed oral antidiabetic medications or insulin 
therapy for treatment of hyperglycemia. These patients with diabetes may be more 
adherent with medication regimens than patients whose hyperglycemia is treated with 
diet modification and/or exercise. Thus, our sample of patients may not reflect the 
general population of patients with diabetes. Further study is needed to assess 
adherence with lipid-lowering therapy in patients with diabetes. 
The results of this study support the findings of previous investigations that 
demonstrate better adherence with statin than non-statin medications.28• 39 In general , 
rates of adherence with statins are consistency higher than with non-statin 
medications, especially bile acid sequestrants and niacin. For example, in patients 
aged 65 years or older, the highest rate of adherence was observed with statin 
medications (64% ± 30% of days covered in one-year) while the lowest was with 
cholestyramine (37% ± 29% of days covered) .28 
Since the reason for discontinuation of therapy is not captured in pharmacy 
claims data, we could not determine why more patients adhered with statin therapy 
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than non-statin treatment. These findings may reflect greater convenience of dosing 
regimens for statins.28• 59 Poor palatability and multiple dosing frequency of some of 
the non-statin medications (e.g. , bile acid sequestrants) are related to poor 
adherence.60 Therapeutic ineffectiveness, patient's perception of need for therapy 
and adverse events have been reported as a contributing factors for discontinuation 
of lipid-lowering therapy.37• 59• 61 
Stalins are recommended as first-line pharmacotherapy in the majority of 
hyperlipidemic patients, including patients with diabetes mellitus in part because of 
their potency, convenient dosing and tolerability 1 • 36• 40 Bile acid sequestrants are not 
appropriate therapy in patients with diabetes as they tend to worsen 
hypertriglyceridemia, and nicotinic acid worsens glycemic control. 14• 15• 62 Both statins 
and fibrates are better lipid-lowering therapy choices for patients with diabetes. Thus, 
it was not unexpected that the majority of patients in our cohort were prescribed a 
statin or fibrate medication. 
An interesting finding was the overall percentage of patients prescribed 
lipid-lowering medications in this population. Of the 4503 patients with diabetes in the 
dataset, 28% were prescribed lipid-lowering medications. According to the CDC, 32% 
of adults with diabetes and lipid abnormalities receive treatment with diet, exercise or 
pharmacotherapy.4 Harris reported that 53% of patients with type 2 diabetes 
diagnosed with dyslipidemia were treated with diet or medication.63 While we did not 
have data on diet and exercise therapy in our cohort, we observed that over a quarter 
of the patients in this study population were being treated for lipid abnormalities. This 
proportion of patients prescribed pharmacotherapy may be related to the health plan 
the patient was enrolled in; approximately half were enrolled in a nurse-based 
diabetes management plan at the index date. Several investigations demonstrate that 
implementation of follow-up, patient-mediated interventions, and patient education by 
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nurses resulted in better care of patients with diabetes and better control of metabolic 
parameters.64-<;6 
Studies have shown that several factors such as prescriber characteristics, 
physician-patient relationship, patient beliefs, and characteristics of medication 
complexity play a role in adherence with prescribed lipid-lowering medications.22• 67-69 
Although the use of pharmacy claims data did not allow an assessment of patient 
beliefs or prescriber characteristics, we evaluated the relationship between 
adherence with lipid-lowering therapy and several patient- and medication-related 
characteristics. 
In this study, patients prescribed insulin therapy (i.e., either insulin 
monotherapy or insulin in combination with oral antidiabetic medications) were more 
likely to be non-adherent (<80% of days covered with sufficient quantity of 
medication) with lipid-lowering treatment than patients prescribed only oral 
medications. Larsen and colleagues observed that patients who received insulin 
therapy were at a 38% higher risk for discontinuation with statin therapy than patients 
treated with oral antidiabetic agents.70 Similarly, oral antidiabetic medication use was 
associated with a 28% increase in adherence with antidiabetic therapy compared with 
patients not using oral antidiabetic medications.71 It is known that insulin therapy is 
complex: the need to mix and inject insulin preparations and taking multiple injections 
combined with the fear of injections may result in poor adherence with this treatment 
regimen.72-75 Further study is needed to examine antidiabetic medication regimen as 
a covariate on medication adherence among patients with diabetes mellitus 
As previously described, patients prescribed statin medications were more 
adherent with lipid-lowering therapy than patients prescribed non-statin medications. 
Using an 80% level of adherence, we observed an effect of class of lipid-lowering 
medication prescribed at the index date on adherence. This effect was absent in the 
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regression model of ?.90% adherence. Sung and colleagues58 also observed no class 
effect on compliance with lipid-lowering therapy in a logistic regression model of 
?.90% adherence; no explanation was given by the authors. This finding may be due 
to the fact that 16% of our patients had a CMA between 80-90%; this change in the 
proportion of patients classified as adherent may be sufficient to weaken the class 
effect of lipid-lowering medications. As this level of medication adherence has 
resulted in reductions of lipid parameters,76 this finding needs to be further explored. 
There are inconsistent reports of factors that predict adherence with 
medications such as medication complexity (i.e., number of daily doses, number of 
medications) and occurrence and severity of adverse effects; while factors generally 
not significantly associated with adherence include age and gender.49• 51 • 68• 77 
Problems with medication adherence occur more frequently when patients are 
older;30.47• 67 receive more medications;58· 67· 78 have to take their medications 
regularl~· 79• 80 and over a long period of time.81 For example, younger patients were 
less adherent with lipid-lowering therapy than older patients.30• 47• 67 Sung and 
colleagues report factors with an inverse relationship with compliance include female 
gender and chronic illnesses.58 In addition, the strongest correlate of poor medication 
compliance was complexity of medication regimens, namely an increased frequency 
of dosing, resulted in decreased compliance with lipid-lowering therapy.58The number 
of prescribed medications was inversely correlated to compliance.67• 78 Our data did 
not exhibit a significant effect of age, gender or number of concomitantly prescribed 
medications on adherence with lipid-lowering therapy. 
Limitations 
Our cohort was comprised of patients identified as new users of lipid-lowering 
therapy. Studies have shown that newly treated patients were less adherent with 
lipid-lowering medications than patients taking the same medications for longer 
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( periods of time.
28
•
30
•
47 Our definition of a new user (patients without prescriptions for a 
lip id-lowering medication for a three-month pre-index time period) has been 
previously described in other investigations37· 38 while other investigations use a six-
month or one-year pre-index assessment period to classify new users of 
therapy.28•47·57• 58• 8" 84 Since we used a time period of three months and additionally 
could not determine whether patients received medication samples in a doctor's 
office, we may have misclassified some patients as new users of lipid-lowering 
therapy. 
There are inherent limitations of using pharmacy claims data to assess 
adherence. One limitation is the inability to assess whether the patient is actually 
taking the medication and/or taking the medication as prescribed. Documentation of a 
prescription fill does not always correlate with patient adherence with therapy. This 
could potentially overestimate medication adherence. However, it is reasonable to 
assume that regularly purchased medications are being consumed.85 
Another limitation is the assumption that patients fill all their medications at the 
same pharmacy. Some patients may fill prescribed medications at another pharmacy 
leading to an underestimation of the patient's medication supply. Since we excluded 
patients without continuous use of the pharmacy for prescription dispensations were 
excluded from our study population, this would not likely have affected our results. 
The accuracy of the data in the reported pharmacy claims was not verifiable. It 
was not possible to confirm the prescription fill information with other data sources 
such as medical records, pill counts, or medication diaries. In addition, pharmacy 
claims lack clinical information that may have an influence on patients' medication 
adherence, such co-morbid conditions and medication adverse effects experienced 
by the patient. Without this information, we could not correlate our estimates to 
reasons for non-adherence in this study. Thus, modeling the factors that might affect 
75 
adherence with lipid-lowering therapy may be biased due to incompleteness of the 
model. 
Notwithstanding these limitations, pharmacy claims data can be a useful 
source of data in population-based studies when direct measurements are not 
feasible. Several studies have shown significant associations between refill 
adherence and other measures of adherence.42• 86-s9 Numerous investigations have 
used prescription claims databases to determine the rate or degree of adherence with 
prescribed therapy.23· 42• 45· 49• 61 • 78• 84• 90•97 Thus, utilizing a pharmacy claims database 
may represent the best means to capture utilization data of medication in a patient 
population. 
Since the database included patients with diabetes who were dispensed 
lipid-lowering medications through CVS pharmacies in Pennsylvania and patients 
prescribed pharmacotherapy, the findings from this study may not be generalizable to 
the wider population of patients with diabetes. 
CONCLUSION 
The observations of this study indicate that adherence with lipid-lowering therapy in 
patients with diabetes mellitus was less than optimal. Patients prescribed a statin 
medication as their initial lipid-lowering medication exhibited greater adherence 
compared with patients prescribed non-statin medications. Non-adherence was 
associated with insulin therapy and non-statin medications. This data supports 
previous investigations that observed an effect of class of lipid-lowering medications 
and insulin therapy on medication adherence. 
The ATP Ill report stresses that adherence issues need to be addressed to 
attain the highest possible levels of coronary heart disease risk reduction.6 
Interventions to improve adherence include factors that focus on the patient such as 
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( simplifying medication regimens, reinforcing and rewarding adherence, and 
encouraging the support of family and friends as well as factors that focus on the 
physician and medical office and health delivery system. 
Ideally, future studies should assess the relationship between adherence and 
lipid levels and explore the effect of study factors such as antidiabetic medication 
regimen, patient beliefs, and prescriber characteristics on medication adherence. 
Identifying these factors would help design optimal lipid-lowering therapy regimens for 
patients with diabetes and develop appropriate and effective interventions to modify 
factors that improve patient adherence with lipid-lowering therapy. 
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TABLES 
Table 2-1 . Pharmacological management of lipid abnormalities in adult patients 
with diabetes 
Lipid 
Abnormal ity 
Elevated LDL-C 
Low HDL-C 
Elevated 
triglycerides 
Combined 
hyperlipidemia 
Target Patients 
<100 mg/dl 
>45 mg/dl (men) 
>55 mg/dl (women) 
<200 mg/dl 
As above 
Pharmacological 
Options 
First choice: statin 
therapy 
Second choice: bile 
acid sequestrant 
resins or fenofibrate 
Glycemic control 
Nicotinic acid or 
fib rates 
Improved glycemic 
control 
Fibric acid derivative 
High-dose statin, if 
LDL-C is also 
elevated 
First choice: 
improved glycemic 
control plus high-
dose statin 
Second choice: 
hypoglycemic 
therapy plus high-
dose statin plus 
fibric acid derivative 
Third choice: 
hypoglycemic 
control plus statin 
plus nicotinic acid 
Comments 
Reducing LDL-C 
is the first priority 
Nicotinic acid is 
relatively 
contraindicated* 
Combination 
therapy with a 
statin and 
nicotinic acid* or 
with gemfibrozil 
or fenofibrate 
may increase 
risk of myositis 
• Nicotinic acid should be restricted to ~2 g/day- short-acting nicotinic acid is 
preferred in patients with diabetes. 
Abbreviations: HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density 
lipoprotein cholesterol 
Source: Henry, RR. Clinical Diabetes. 2001; 19(3): 113-120 adapted from American 
Diabetes Association. Diabetes Care. 2003;26(suppl 1):S82-S85. 
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Table 2-2. Lipid-lowering medications 
Class 
Generic (brand) name 
HMG CoA reductase 
inhibitors (Stalin) 
atorvastatin (Lipitor®) 
fluvastatin (Lescol®) 
lovastatin (Mevacor®) 
pravastatin (Pravachol®) 
simvastatin (Zocor®) 
Bile acid sequestrants 
cholestyramine resin (Questran®) 
colestipol (Colestid®) 
Nicotinic acid 
niacin (Niaspan®) 
Fibrates 
fenofibrate (Tricor®) 
gemfibrozil (Lopid®) 
Abbreviations: HMG CoA= 3-hydroxy-3-methylglutaryl coenzyme A 
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Table 2-3. Characteristics of the study population 
Characteristic 
Patient-related 
Age (years) 
Gender 
Male 
Female 
Health Plan* 
Nurse-based diabetes management plan 
Other health plan 
Medication-related 
Antidiabetic Medication Regiment 
Oral medication 
Insulin therapy 
Number of Concomitant Medications* 
N = 90 
60.3 ± 9.9 (30-79) 
47 (52.2) 
43 (47.8) 
49 (54.4) 
41 (45.6) 
65 (72.2) 
25 (27.8) 
8 ± 5 (1-27) 
Class of Lipid-lowering Medication, by Index Prescription 
HMG-CoA reductase inhibitor 82 (91.1) 
Fibrates 7 ( 7.8) 
Bile acid seguestrants 1 ( 1.1) 
Values expressed as number(%) or mean± standard deviation (SD) (range). 
• Health plan used to acquire the index lipid-lowering medication. Other health 
flans include local/state/federal programs or cash payments. 
Antidiabetic medication regimen prescribed during the observation period. 
Insulin therapy includes insulin monotherapy or in combination with oral medication. 
* Number of concomitant medications prescribed during the observation period. 
Abbreviations: HMG CoA= 3-hydroxy-3-methylglutaryl coenzyme A 
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Table 2-4. Frequency of lipid-lowering prescription claims during a 
nine-month observation period 
Number of Lipid-lowering Number(%) of Patients 
Medication Prescription Claims 
3 10(11 .1%) 
4 12 (13.3%) 
5 8 ( 8.9%) 
6 8 ( 8.9%) 
7 7( 7.8%) 
8 17(18.9%) 
9 18 (20.0%) 
10 7 ( 7.8%) 
11 2( 2.2%) 
12 1( 1.1%) 
Total 90 
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Table 2-5. Mean CMA (%)by lipid-lowering medication prescribed 
at the index date 
Index Lipid-lowering 
Medication 
Statin 
Number 
of Patients 
HMG CoA reductase inhibitors 
atorvastatin 27 
4 fluvastatin 
lovastatin 
pravastatin 
simvastatin 
Non-Statin 
Fibrates 
gemfibrozil 
Bile acid sequestrants 
cholestyramine resin 
Total 
2 
48 
7 
90 
CMA 
Mean (SD) 
84.1 (22.3) 
87.8 (21.9) 
79.3 (23.0) 
68.4 
85.9 ( 4.2) 
82.8 (23.3) 
70.0 (31.7} 
71.5 (33.9) 
59.0 
82.8 (23.4) 
Abbreviations: CMA = Continuous multiple-interval measure of Medication 
Availability; HMG CoA= 3-hydroxy-3-methylglutaryl coenzyme A; 
SD = 1 standard deviation 
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Table 2-6. General characteristics of adherent and non-adherent patients* 
Non-Adherent Adherent 
(<80%) ~80%) 
Characteristic N = 31 N = 59 p-value 
Patient-related 
Age (years) 59.1±11.1 60.9 ± 9.2 0.4332 
(36-78) (30-79) 
Gender 0.4212 
Male 18 (58.1) 29 (49.1) 
Female 13 (41.9) 30 (50.9) 
Health Plant 0.3445 
Nurse-based diabetes 19 (61.3) 30 (50.9) 
management plan 
Other health plan 12 (38.7) 29 (49.1) 
Medication-related 
Antidiabetic Medication Regimen* 0.0297 
Oral medication 18 (58.1) 47 (80.0) 
Insulin therapy 13 (41.9) 12 (20.0) 
Number of Concomitant Medications§ 
7 ±4 (2-20) 8 ±5 (1-27) 0.3660 
Class of Index Lipid-lowering Medication 
Sta tin 26 (83.9) 56 (94.9) 0.0802 
Non-Stalin 5(16.1) 3 ( 5.1) 
Values expressed as number (%) or mean ±standard deviation (SD) (range). 
Percentages may not equal 100% due to rounding. 
* Adherence is defined as 80% or more of the prescription dispensed. 
t Health plan used to acquire the index lipid-lowering medication. Other health 
plans include local/state/federal programs or cash payments. 
* Antidiabetic medication regimen prescribed during the observation period. 
Insulin therapy includes insulin monotherapy or in combination with oral medication. 
§ Number of concomitant medications prescribed during the observation period. 
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Table 2-7. Bivariate logistic regression models for adherence* 
Independent Variable (IV) Odds 95% CloR Pr>X2 
Ratio 
Age (years) 
30-55 1.000 
56-65 1.320 0.441 , 3.953 0.6198 
>65 1.907 0.656, 5.538 0.2356 
Gender 
Males 1.000 
Females 1.432 0.596, 3.443 0.4221 
Health Plant 
Nurse-based diabetes 
management plan 1.000 
Other health plan 1.531 0.632, 3.708 0.3458 
Antidiabetic Medication Regimen* 
Oral medications 1 .000 
Insulin therapy 0.354 0.136, 0.918 0.0327 
Number of Concomitant Medications§ 
1-5 1.000 
> 5 0.589 0.244, 1.426 0.2409 
Class of Index Lipid-lowering Medication 
Non-Stalin 1.000 
Statin 3.590 0.797, 16.169 0.0960 
* Adherence is defined as 80% or more of the prescription dispensed. For 
descending logistic regression model, coded as 0 = .::.80%; 1 = <80%. 
t Health plan used to acquire the index lipid-lowering medication. Other 
health plans includes local/state/federal programs or cash payments. 
* Antidiabetic medication regimen prescribed during the observation period. 
Insulin therapy includes insulin monotherapy or in combination with oral medication. 
§ Number of concomitant medications prescribed during the observation period. 
Abbreviations: Cl= confidence interval; OR = Odds Ratio 
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Table 2-8. Multivariate logistic regression models for adherence• 
Independent Variable (IV) Odds Ratio 95% Clo" Pr>X2 
Age (years) 
30-55 1.000 
56-65 0.983 0.288, 3.360 0.9785 
>65 1.690 0.518, 5.520 0.3848 
Gender 
Males 1.000 
Females 2.241 0.778, 6.455 0.1351 
Health Plan 1 
Nurse-based diabetes 
management plan 1.000 
Other health plan 2.111 0.724, 6.160 0.1714 
Antidiabetic Medication Regimen* 
Oral medications 1.000 
Insulin therapy 0.172 0.053, 0.554 0.0032 
Number of Concomitant Medications§ 
1-5 1.000 
> 5 2.263 0.817, 6.264 0.1161 
Class of Index Lipid-lowering Medication 
Non-Stalin 1 .000 
Stalin 3.925 0.752, 20.484 0.1048 
• Adherence is defined as 80% or more of the prescription dispensed. For 
descending logistic regression model, coded as 0 = _:::80%; 1 = <80%. 
t Health plan used to acquire the index lipid-lowering medication. Other health 
plans include local/state/federal programs or cash payments. 
* Antidiabetic medication regimen prescribed during the observation period. 
Insulin therapy includes insulin monotherapy or in combination with oral medication. 
§ Number of concomitant medications prescribed during the observation period. 
Abbreviations: Cl= confidence interval; OR = Odds Ratio 
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Table 2-9. Final logistic regression model of adherence• 
Independent Variable (IV) Odds Ratio 95% Clo" 
Antidiabetic Medication Regiment 
Oral medications 1.000 
Insulin therapy 0.304 0.1 14, 0.815 0.0180 
Class of Index Lipid-lowering Medication 
Non-Stalin 1 .000 
Stalin 4.709 0.996, 22.268 0.0506 
• Adherence is defined as 80% or more of the prescription dispensed. For 
descending logistic regression model, coded as O = ?.80%; 1 = <80%. 
t Antidiabetic medication regimen prescribed during the observation period. 
Insulin therapy includes insulin monotherapy or in combination with oral medication. 
Abbreviations: Cl = confidence interval; OR = Odds Ratio 
86 
Table 2-10. General characteristics of adherent and non-adherent patients* 
Non-Adherent Adherent 
(<90%) ~90%) 
Characteristic N = 49 N = 41 p-value 
Patient-related 
Age (years) 60.3± 10.7 60.3 + 8.9 0.9989 
(36-79) (30-76) 
Gender 0.8030 
Male 25 (51 .0) 22 (53.7) 
Female 24 (49.0) 19 (46.3) 
Health Plant 0.8911 
Nurse-based diabetes 27 (55.1) 22 (53.7) 
management plan 
Other health plan 22 (44.9) 19 (46.3) 
Medication-related 
Antidiabetic Medication Regimen* 0.5116 
Oral medication 34 (69.4) 31 (75.6) 
Insulin therapy 15 (30.6) 10 (24.4) 
Number of Concomitant Medications§ 
7 ±4 (1-20) 8± 6 (2-27) 0.1956 
Class of Index Lipid-lowering Medication 
Stat in 44 (89.8) 38 (92.7) 0.6317 
Non-Stalin 5 (10.2) 3( 7.3) 
Values expressed as number(%) or mean± standard deviation (SD) (range). 
* Adherence is defined as 90% or more of the prescription dispensed. 
t Health plan used to acquire the index lipid-lowering medication. Other health 
plans include local/state/federal programs or cash payments. 
Antidiabetic medication regimen prescribed during the observation period. 
Insulin therapy includes insulin monotherapy or in combination with oral medication. 
§ Number of concomitant medications prescribed during the observation period. 
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Table 2-11. Bivariate logistic regression models for adherence• 
Independent Variable (IV) Odds Ratio 95% Clo" 
Age (years) 
30-55 1.000 
56-65 0.889 
>65 2.240 
Gender 
Males 1.000 
Females 0.900 
Health Plant 
Nurse-based diabetes 
management plan 1.000 
Other health plan 1.060 
Antidiabetic Medication Regimen* 
Oral medications 1.000 
Insulin therapy 0. 731 
Number of Concomitant Medications§ 
1-5 1.000 
>5 0.928 
Class of Index Lipid-lowering Medication 
Non-Slatin 1 .000 
Stalin 1 .439 
0.294, 2.685 
0.799, 6.282 
0.392, 2.065 
0.461 , 2.438 
0.8346 
0.1253 
0.8031 
0.8911 
0.287, 1.865 0.5123 
0.398, 2.166 0.8629 
0.323, 6.423 0.6332 
• Adherence is defined as 90% or more of the prescription dispensed. For 
descending logistic regression model, coded as O = ?.90%; 1 = <90%. 
t Health plan used to acquire the index lipid-lowering medication. Other health 
plans include local/state/federal programs or cash payments. 
Antidiabetic medication regimen prescribed during the observation period. 
Insulin therapy includes insulin monotherapy or in combination with oral medication . 
§ Number of concomitant medications prescribed during the observation period. 
Abbreviations: Cl =confidence interval; OR = Odds Ratio 
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Table 2-12. Multivariate logistic regression models for adherence• 
Independent Variable Odds 95% CloR Pr>X2 
(IV) Ratio 
Age (years) 
30-55 1.000 
56-65 0.870 0.277, 2.729 0.8109 
>65 2.264 0.774, 6.621 0.1357 
Gender 
Males 1.000 
Females 0.973 0.395, 2.397 0.9529 
Health Plant 
Nurse-based diabetes 
management plan 1.000 
Other health plan 1.032 0.413, 2.577 0.9468 
Antidiabetic Medication Regimen* 
Oral medications 1.000 
Insulin therapy 0.673 0.245, 1.847 0.4424 
Number of Concomitant Medications§ 
1-5 1.000 
> 5 1.302 0.522, 3.249 0.5714 
Class of Index Lipid-lowering Medication 
Non-Stalin 1 .000 
Stalin 1.152 0.240, 5.531 0.8595 
• Adherence is defined as 90% or more of the prescription dispensed. For 
descending logistic regression model, coded as 0 = ::::_90%; 1 = <90%. 
t Health plan used to acquire the index lipid-lowering medication. Other health 
rlans includes local/state/federal programs or cash payments. 
Antidiabetic medication regimen prescribed during the observation period. 
Insulin therapy includes insulin monotherapy or in combination with oral medication. 
§ Number of concomitant medications prescribed during the observation period. 
Abbreviations: Cl = confidence interval; OR = Odds Ratio 
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Table 2A-1a. 
Parametric form analysis for continuous independent variables 
Independent Dependent Variable: 
Variable N Coding Adherence* 
Age (years) 
30-54 
55-61 
62-67 
> 67 
22 age (referent) 
23 age1 
25 age2 
20 age3 
Number of Concomitant Medicationst 
0-3 17 conmed (referent) 
4-5 23 conmed1 
6-8 26 conmed2 
> 8 24 conmed3 
Odds Ratio 
1.0 
1.961 
1.038 
1.615 
1.0 
2.032 
2.000 
1.778 
* Adherence is defined as 80% or more of the prescription dispensed. For 
descending logistic regression model, coded as 0 = ?.80%; 1 = <80%. 
t Number of concomitant medications prescribed during the observation period. 
Table 2A-1b. 
Parametric form analysis for continuous independent variables 
Independent Dependent Variable: 
Variable N Coding Adherence* 
Age (years) 
0-54 
55-61 
62-67 
> 67 
22 age (referent) 
23 age1 
25 age2 
20 age3 
Number of Concomitant Medicationst 
0-3 17 conmed (referent) 
4-5 23 conmed1 
6-8 26 conmed2 
> 8 24 conmed3 
Odds Ratio 
1.0 
2.722 
1.375 
1.167 
1.0 
1.310 
0.893 
0.688 
* Adherence is defined as 90% or more of the prescription dispensed. For 
descending logistic regression model, coded as 0 = ?.90%; 1 = <90%. 
t Number of concomitant medications prescribed during the observation period. 
90 
Table 2A-2. Collinearity diagnostics 
ProEorlion of variation 
Variable Condition Intercept Age_re1 Age_re2 Gender AD reg Lipid· Health Conmed_re 
Index class elan 
Intercept 1.00000 0.00269 0.00699 0.00676 0.01143 0.01197 0.00315 0.01163 0.01108 
Age_re1 2.18303 0.000106 0.22205 0.18218 0.00573 0.00002 0.00052 0.00059 0.00270 
Age_re2 2.74354 0.00376 0.02964 0.02332 0.00232 0.86124 0.00378 0.00023 0.00006 
Gender 2.80216 0.000048 0.01311 0.00024 0.36219 0.00104 0.00002 0.38553 0.00249 
AD reg 3.70544 0.000105 0.09404 0.05045 0.1 3163 0.02761 0.00007 0.04744 0.76032 
Lipidclass 4.05600 0.01067 0.1 9784 0.08278 0.46242 0.09254 0.02028 0.55419 0.02195 
Health plan 5.21337 0.06460 0.41841 0.65017 0.00327 0.00216 0.13191 0.00007 0.18745 
Conmed re 10.6426 0.91803 0.01793 0.00410 0.02101 0.00342 0.84027 0.00047 0.01395 
S' 
Table 2A-3a. 
Log Likelihood (LL} ratio test: logistic regression model of adherence• 
Model -2 LL Df LL X2dt Significance 
Difference 
12 Fu ll Model 
Reduced Model 
94.846 
100.110 5t 5.264 11.07 NS 
*Adherence is defined as 80% or more of the prescription dispensed. For 
descending logistic regression model, coded as O = ;::80%; 1 = <80%. 
t Df of full model minus reduced model 
Full Model includes all univariate variables and two-way interaction terms 
Reduced Model includes all univariate variables 
Abbreviations: -2LL = -2 Log Likelihood; Df = degrees of freedom; 
NS = not significant 
Table 2A-3b. 
Lo Likelihood LL ratio test: lo istic re ression model of adherence• 
Model -2 LL Df LL x df Significance 
Difference 
Full Model 111.691 12 
Reduced Model 119.208 5t 7.517 11.07 NS 
• Adherence is defined as 90% or more of the prescription dispensed. For 
descending logistic regression model, coded as 0 = ;::90%; 1 = <90%. 
t Df of full model minus reduced model 
Full Model includes all univariate variables and two-way interaction terms 
Reduced Model includes all univariate variables 
Abbreviations: -2LL = -2 Log Likelihood; Df = degrees of freedom; 
NS = not significant 
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Table 2A-4a. Test for confounding variables in the logistic regression 
modeling of adherence• 
Potential Confounding 
Independent Variables 
Class of Index Lipid-
lowering Medication Adherence 
Age 
30-55 years (referent) 
56-65 years 
>65 years 
Gender 
Male (referent) 
Female 
Health Insurance Plant 
Nurse-based diabetes 
management plan (referent) 
Other Health Plans 
Antidiabetic Medication Regimen* 
Oral Medications (referent) 
Insulin Therapy 
Number of Concomitant Medications§ 
1.0 
0.1672 (0.6826) 
2.7668 (0.0962) 
1.0 
0.0174 (0.8951) 
1.0 
1.4958 (0.2213) 
1.0 
1.0216 (0.3121) 
1-5 (referent) 1 .0 
>5 0.3659 (0.5453) 
X2 (p-value) 
1.0 
0.0290 (0.8647) 
1.1810 (0.2772) 
1.0 
0.6469 (0.4212) 
1.0 
0.8935 (0.3445) 
1.0 
4.7246 (0.0297) 
1.0 
1.3860 (0.2391) 
• Adherence is defined as 80% or more of the prescription dispensed. For 
descending logistic regression model, coded as O = ;::80%; 1 = <80%. 
t Health plan used to acquire the index lipid-lowering medication. Other health plans 
includes local/state/federal programs or cash payments. 
* Antidiabetic medication regimen prescribed during the observation period. 
Insulin therapy includes insulin monotherapy or in combination with oral medication. 
§ Number of concomitant medications prescribed during the observation period. 
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Table 2A-4b. Test for confounding variables in the logistic regression 
modeling of adherence* 
Potential Confounding 
Independent Variables 
Age 
30-55 years (referent) 
56-65 years 
>65 years 
Gender 
Male (referent) 
Female 
Health Insurance Plant 
Nurse-based diabetes 
management plan (referent) 
Other Health Plans 
Antidiabetic Medication Regimen* 
Oral Medications (referent) 
Insulin Therapy 
Number of Concomitant Medications§ 
1-5 (referent) 
>5 
Class of Index Lipid-
lowering Medication 
Adherence 
X2 Ip-value) 
1.0 1.0 
0.1672 (0.6826) 1.5871 (0.2077) 
2.7668 (0.0962} 3.9497 (0.0469) 
1.0 1.0 
0.0174 (0.8951) 0.0623 (0.8030} 
1.0 1.0 
1.4958 (0.2213) 0.0188 (0.8911) 
1.0 1.0 
1.0216 (0.3121) 0.4308 (0.5116) 
1.0 1.0 
0.3659 (0.5453} 0.0299 (0.8629) 
* Adherence is defined as 90% or more of the prescription dispensed. For 
descending logistic regression model, coded as 0 = ~90%; 1 = <90%. 
t Health plan used to acquire the index lipid-lowering medication. Other health plans 
includes local/state/federal programs or cash payments. 
* Antidiabetic medication regimen prescribed during the observation period. 
Insulin therapy includes insulin monotherapy or in combination with oral medication. 
§ Number of concomitant medications prescribed during the observation period. 
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FIGURES 
Figure 2-1. Eligibility criteria of study population 
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Figure 2A-1. Frequency distribution of the measurement: adherence (80%) 
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Figure 2A-2. Frequency distribution of the measurement: adherence (90%) 
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Study 3 
Using Prescription Claim Records to Evaluate Persistence with Lipid-lowering 
Medications in Patients with Diabetes Mellitus 
ABSTRACT 
Background: Dyslipidemia, a risk factor for cardiovascular disease, is modifiable in 
patients with diabetes mellitus. However, treatment of diabetic dyslipidemia may 
require long-term lipid-lowering pharmacotherapy. Studies have shown low rates of 
persistence with lipid-lowering medications especially in the first year of treatment; 
however, few studies have specifically examined persistence with lipid-lowering 
therapy in patients with diabetes. 
Objective: The objective of this study was to assess persistence with lipid-lowering 
medications and evaluate patient- and medication-related characteristics that may 
influence discontinuation of lipid-lowering treatment in patients with diabetes mellitus. 
Methods: A retrospective study of pharmacy claim records of patients with diabetes 
mellitus identified new users of lipid-lowering therapy. Patients with an initial 
prescription dispensing for a lipid-lowering medication between November 1 , 1997 
and October 31, 1998 were observed for up to 18 months. Patients were classified as 
persistent with lipid-lowering therapy if the last prescription filled during the 
observation period provided a quantity of medication to cover the period until the end 
of follow-up (i.e., April 30, 1999). Discontinuation was flagged by identifying patients 
who (1) had more than three times the days supplied elapsed between the last 
prescription fill for lipid-lowering medication and the next fill or the end of the follow-up 
period; (2) switched to a medication in a class different than the index medication; or 
(3) had no refills for the lipid-lowering medication during the follow-up period. 
Switching of index lipid-lowering medication and re-initiation of lipid-lowering therapy 
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during the observation period were evaluated as separate endpoints. Kaplan-Meier 
methods and Cox regression models estimated the rate of discontinuation and 
identified factors associated with discontinuation of lipid-lowering therapy, 
respectively . 
Results: A total of 190 patients with diabetes (53% males; mean age, 59.3 ± 10.4 
years) had at least one prescription claim for a lipid-lowering medication during the 
observation period; the majority (87%) of patients were prescribed a statin 
medication. Overall , 58% of patients persisted with lipid-lowering therapy during the 
observation period. Persistency differed according to the class of lipid-lowering 
medication dispensed at the index date: patients prescribed statins were more 
persistent compared to patients prescribed non-statin medications (Log-rank X2= 
7.9101 ; p=0.0049). Of the 165 patients prescribed statin medications, 74% persisted 
with treatment over six months, 59% over 12 months, and 46% over 18 months of 
observation. At 6 months, 60% of patients persisted with non-statin treatment; only 
26% of patients were persistent over 12 and 18 months of observation. Approximately 
26% of patients who discontinued treatment did so after the initial dispensing. One in 
10 patients switched to another lipid-lowering medication: the majority of switches 
were to another medication within the same class. Compared with patients prescribed 
statins, patients prescribed non-statin medications were more than twice as likely to 
discontinue treatment (HR=2.240; 95% Cl= 1.260, 3.982; p=0.0060). Age, gender, 
type of health plan, number of concomitantly prescribed medications and antidiabetic 
medication regimen, were not found to be a significant influence on discontinuation of 
lipid-lowering therapy. 
Conclusions: Persistence with lipid-lowering therapy in patients with diabetes 
mellitus was sub-optimal. Patients prescribed statins were significantly more likely to 
persist with lipid-lowering therapy than patients prescribed non-statin medications. 
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More research is needed to elucidate factors that may influence persistence with 
lipid-lowering therapy in this patient population. These findings highlight the need for 
health care providers to work together with patients to improve persistence with 
lipid-lowering medications to reduce the risk of major cardiovascular events in 
patients with diabetes mellitus. 
Key Words: lipid-lowering therapy, dyslipidemia, diabetes, persistence, 
discontinuation, switching 
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INTRODUCTION 
Serum triglycerides, total cholesterol and low density lipoprotein-cholesterol 
(LDL-C) levels tend to be elevated in patients with type 2 diabetes even in patients 
with good glycemic control ' · 2 whereas a similar pattern of dyslipidemia is observed in 
type 1 diabetes usually when glycemic control is poor.3· 4 This characteristic pattern is 
termed diabetic dyslipidemia.5 
Along with hypertension and smoking, diabetes and dyslipidemia are well 
known risk factors for cardiovascular disease. The National Cholesterol Education 
Program (NCEP) Adult Treatment Panel (ATP) Ill considers diabetes a coronary heart 
disease (CHD) risk equivalent because it confers a high risk of new CHD within 10 
years in part because of its association with multiple risk factors.6 
The United Kingdom Prospective Diabetes Study (UKPDS) observed an 
association of coronary disease risk with LDL-C among approximately 3000 patients 
with type 2 diabetes.7 Coronary artery disease was significantly associated with 
increased concentrations of LDL-C and triglycerides and decreased concentrations of 
high density lipoprotein cholesterol (HDL-C).7 Results from the Strong Heart Study 
demonstrated that every 10 mg/dl increase in LDL-C (starting with a low of 70 mg/dl) 
was associated with a 12% increase in risk of cardiovascular disease among patients 
with type 2 diabetes. 8 
Primary and secondary intervention trials have demonstrated that single 
medication lipid-lowering therapy can reduce cardiovascular morbidity and 
mortality.•·13 Although these trials included few patients with diabetes, post-hoc 
subgroup analyses of the Helsinki Heart Study, the Scandinavian Simvastatin 
Survival Study (4S} and the Cholesterol and Recurrent Events Study (CARE) trial 
indicate that lipid-lowering intervention in diabetes is likely to reduce the 
cardiovascular event rate.9• ,._,, The Heart Protection Study provided evidence that a 
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reduction in LDL-C would significantly reduce the risk of major vascular events such 
as first non-fatal myocardial infarction , coronary death, or stroke in patients with 
diabetes. ' In addition, several trials are underway to determine the efficacy of 
lipid-lowering therapy for the primary and secondary prevention of CHO in patients 
with diabetes. 1•·21 Nonetheless, these studies suggest that dyslipidemia, a major risk 
factor for cardiovascular disease, is modifiable in patients with diabetes mellitus. 
In the Diabetes Atorvastatin Lipid Intervention {DALI) trial of 217 patients with 
type 2 diabetes mellitus, 30-weeks of 10mg and 80mg (i.e., the lowest and highest 
doses) atorvastatin produced significant reductions in plasma triglyceride and LDL-C 
levels compared with placebo-treated patients.22 In a comparison with 1998 target 
values defined by the American Diabetes Association (ADA), >75% of patients in both 
treatment groups reached triglyceride treatment goals and 71 % and 85% of patients 
treated with 10mg and 80mg atorvastatin respectively, reached LDL-C treatment 
goals.22 
While the efficacy of lipid-lowering medications has been proven during 
clinical trials, the effectiveness of lipid-lowering pharmacotherapy is partly dependent 
upon patient persistence with prescribed medications. Discontinuation of these 
medications may lead to failure to achieve lipid level goals potentially placing the 
patient with diabetes at risk for serious cardiovascular events such as coronary heart 
disease, myocardial infarction or stroke. 
Several studies have shown that persistence with lipid-lowering therapy at 
one-year is often sub-optima1.23•33 For example, 32% of patients receiving lipid-
lowering medication discontinued therapy within one year of initiation, with rates of 
discontinuation for lovastatin, gemfibrozil, bile acid sequestrants, and niacin reported 
as 13%, 28%, 34%, and 45%, respectively.23 Using the United Kingdom General 
Practice Research Database (UK GPRD) for 22,408 patients who initiated lipid-
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lowering therapy, only 69.8% of patients with a statin, 56.4% of patients with a fibrate, 
and 38.4% of patients prescribed a non-statin, non-fibrate medication still used the 
initial mediation at the end of one-year.24 Similarly, at 12 months, 60% of patients 
discontinued lipid-lowering therapy in a prospective study of 61 O adults prescribed 
simvastatin, pravastatin or gemfibrozil ; half of the discontinuations occurred within the 
first 3 months.25 In this study, the predominant reasons for discontinuation included 
poor efficacy (32%) and the patient's uncertainty about the need for treatment (32%) 
while 7% discontinued due to adverse events.25 
Studies of longer-term usage of lipid-lowering medications report similar 
findings. In 970 patients enrolled in a lipid clinic, four-year cumulative discontinuation 
rates for niacin and bile acid sequestrants were 71 % and 83%, respectively, in 
comparison with 28% for statin medications.33 Similarly, five-year post study 
continuation rates were higher for statin users (64.3%) than for patients taking other 
lipid-lowering medications (36.6%).26 A cohort study of 983 new users of statin 
medications demonstrated that statin use declined sharply as 80% of patients 
remained on therapy 45 days alter initiation and only 33% and 13% of patients 
persisted with therapy at one and five years, respectively.27 Of 3623 new users of 
statin therapy, 50% persisted with lipid-lowering therapy continuously for more than 
three years.28 
These studies demonstrate similar findings despite utilizing different 
methodologies to assess persistence with lipid-lowering therapy in various patient 
populations: patients' chronic use of lipid-lowering medication is poor with many 
patients discontinuing treatment as early as three months. 
Few studies examined an association with diabetes and persistency with 
lipid-lowering medications. In a study of patients ?.65 years of age, diabetes was 
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associated with high persistence.26 Treatment continuation with lipid-lowering 
medications was more frequent in patients with diabetes in the UK GPRD.24 
Non-persistence (i.e., discontinuation) of the recommended medication 
regimen poses a major barrier to achieving NCEP ATP 111 · 6 recommended target 
goals for cholesterol management. Long-term pharmacotherapy is needed to treat 
dyslipidemia in patients who do not benefit from lifestyle modifications.6 Providing 
there has not been a lifestyle modification to compensate, patients with established 
dyslipidemia can no longer benefit from a reduction in lipid levels if they discontinue 
lipid-lowering therapy. 
For most patients who persist with pharmacotherapy the benefits outweigh the 
risks. It has been shown that patients with dyslipidemia taking statin medication 
regularly had significant improvement in serum lipid levels in contrast with 
non-adherent patients. Results from the Helsinki Heart Study, a five-year study of 
2046 middle-aged men with hypercholesterolemia, demonstrated that mean changes 
in lipid parameters varied with compliance with prescribed medication (Table 3-1).34 In 
summary, over a five-year period, patients with ?.90% compliance showed a greater 
mean change in lipid parameters than patients compliant with <50% of prescribed 
gemfibrozil medication. After making allowances for non-compliance (18% of patients 
were non-compliant defined as <80% of the scheduled mediation taken) in the Heart 
Protection Study, actual use of 40mg simvastatin daily would lower LDL-C by about 
58 mg/dl and reduce the rates of heart attacks, strokes and revascularization by 
ATP I, published in 1988, identified LDL-C as the primary target of therapy and 
emphasized clinical management of patients with higher levels of LDL-C. ATP II , 
published in 1993, set a lower LDL-C goal, specifically a level equal to or less than 
100 mg/dl in patients who already have CHD. ATP Ill adds a focus on prevention of 
CHD in persons with multiple risk factors. In the 2001 ATP Ill report, LDL-C remains 
the primary target of therapy. A key feature of ATP Ill is the definition of cut points for 
LDL-C goals and for initiation of LDL-lowering therapy. 
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( about one-third.
1 Thus, in patients with a chronic disease such as diabetes mellitus, 
reductions in LDL-C levels and major vascular events are beneficial and continuous 
use of lipid-lowering therapy has an essential role. 1 
These studies have documented a major role of lipid-lowering therapy in 
reducing the risks of major cardiovascular events and the importance of persistence 
with lipid-lowering medications. Many studies demonstrate low persistence rates with 
lipid-lowering therapy in specific patient populations. Thus, the aim of this study was 
to evaluate persistence with lipid-lowering medications in patients with diabetes 
mellitus using prescription claims data. The present study was designed to 1) 
estimate persistence in patients identified as new users of lipid-lowering medications; 
2) evaluate switching of index lipid-lowering therapy; and 3) identify patient- and 
medication-related characteristics that may influence non-persistence with 
lipid-lowering therapy in patients with diabetes mellitus. 
METHODS 
Study Design 
This was a retrospective cohort study of patients with diabetes using 
pharmacy claim prescription records. 
Dataset 
Data examined in the analysis were obtained from 198 Consumer Value 
Stores (CVS) pharmacies located in Pennsylvania that provided prescription 
medications for 4503 patients with diabetes identified by specific therapeutic classes 
(insulins, oral antidiabetic agents-sulfonylureas and other oral antidiabetic agents) 
between April 27, 1997 and May 16, 1999. Patients were either enrolled in a 
nurse-based diabetes management plan or acquired their prescription through a 
local/state/federal program or cash payments. 
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This prescription claims data extract includes records of dispensed outpatient 
pharmacy prescription records for all prescriptions. The following information was 
obtained from the CVS dataset for this analysis: patient characteristic variables such 
as birth date, gender, and health plan agency as well as prescription related variables 
including quantity of medication dispensed, days supply of medication dispensed, and 
date the prescription was dispensed. No personally identifying information was 
provided. 
Study Population 
Patients were eligible for inclusion in the study population if they (1) had a 
prescription claim for at least one lipid-lowering medication (see Table 3-2) between 
November 1, 1997 and October 31 , 1998 (n=865); (2) were a new user of 
lipid-lowering therapy (n=728}; (3) had no dispensations for combination lipid-lowering 
medication (defined as a claim for a second lipid-lowering medication filled within 30 
days of the index medication) (n=727}; and (4) filled a prescription for any medication 
from the CVS pharmacy in the six months prior to the index date and in the last three 
months of the observation period (i.e ., a patient had at least one prescription 
dispensed for any medication during these time points) (n=190}. 
Presumed new users were defined as patients having no prescription claim for 
a lipid-lowering medication in the six months before the index date. Thus, patients 
with less than six months of data prior to the index date were excluded. This time 
period to identify new users of therapy has been previously described.35• 36 
The date of the first lipid-lowering prescription claim between November 1, 
1997 and October 31 , 1998 was classified as the index date. Each patient was 
observed for up to 18 months, through April 30, 1999. Person-time of observation 
was calculated as the amount of time from the index date (i.e., date of entry into the 
cohort) until the date of discontinuation or the end of the follow-up period. 
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Potential Factors of Association with Persistence 
Baseline study factors, such as age, gender, health plan, antidiabetic 
medication regimen and number of concurrent medications, that may influence 
persistence were examined. These factors were classified as patient-related 
characteristics (age, gender, health plan) or medication-related characteristics 
(antidiabetic medication regimen, number of concurrent medications) constructed 
from the prescription profile of each patient. The primary independent variable, class 
of lipid-lowering medication, was based on the prescription filled on the index date. 
Age was based on the transaction date for the index lipid-lowering medication 
prescription fill and was treated as a continuous variable in the analyses. The 
patients' health plan, used to acquire the index lipid-lowering medication, was 
dichotomized as either a nurse-based diabetes management plan or other (e.g., 
local/state/federal programs or cash payments). 
Based on the antidiabetic regimen prescribed within 90 days of the index date, 
antidiabetic medication regimen was classified as oral medication for patients 
dispensed only oral antidiabetic medications or Insulin Therapy for patients dispensed 
either insulin monotherapy or insulin in combination with oral antidiabetic 
medications. The number of concurrent medications dispensed in the three months 
prior to the index date consisted of a count of all medications, excluding lipid-lowering 
medications and diabetic supplies such as blood glucose test strips or tuberculin 
syringes; this variable was treated as a continuous variable for analysis. This 
categorization of baseline (i.e., three months of pre-index data) has been previously 
described. 24 
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Data Analysis 
Prescription claims for all patients who satisfied the inclusion/exclusion criteria 
were examined for an 18-month follow-up period. 
Dataset Preparation 
Prior to analysis, the dataset was checked for outliers for the following 
variables: days supply and posted transaction date of the prescription claim. Potential 
outliers were further examined; no data corrections were necessary in this data set. 
Patients with incomplete records (i.e. , missing transaction dates) for lipid-lowering 
medications were excluded from the analysis (n=173). 
Measures of Persistence, Discontinuation, and Switching 
Patients were classified as persistent with lipid-lowering therapy if the last 
prescription filled during the observation period provided sufficient medication (i.e., 
three times the days supply) to cover the period until the end of follow-up (i.e. , April 
30, 1999). Patients were observed until the first occurrence of one of the following 
events: discontinuation of lipid-lowering therapy or end of the follow-up period (right 
censored). 
Discontinuation of lipid-lowering therapy was identified if a patient (1) had 
more than three times the days supplied elapsed between the last prescription fill for 
lipid-lowering medication and the nex1 fill or the end of the follow-up period; (2) 
switched to a medication in a class different than the index medication; or (3) had no 
refills for the lipid-lowering medication. Since the majority (90%) of patients were 
dispensed a 30 day supply, we utilized three times the elapsed days supply (which 
corresponds to approximately three months) beyond last fill as part of the definition 
for discontinuation. These time frames have been previously described in analyses of 
persistence with antihypertensive medications37-a9 and lipid-lowering medications24• 29 
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( A medication switch was identified if the patient filled a prescription for a 
lipid-lowering medication other than the index medication during the observation 
period. As the exact date of discontinuation was unknown, the date of the last 
prescription fill prior to the switch was assigned as the date of discontinuation. 
Patients were allowed to switch from one medication to another as long as it 
remained in the same class as the index medication since class of lipid-lowering 
medication was evaluated as the primary independent variable. 
Univariate Analysis 
Descriptive statistics, mean ± SD (range) for continuous variables and 
frequencies (percentage) for categorical variables, were used to present patient- and 
medication-related characteristics. Chi-square (X2) tests and I-tests were performed 
to determine significant differences for the categorical and continuous variables, 
respectively. X2 and I-tests were used to analyze the proportions of study factors 
between patients who were persisted or discontinued with lipid-lowering treatment 
and by class of index lipid-lowering medication. 
The Shapiro-Wilk test of normality was used to assess the frequency 
distribution of the continuous variables: age and number of concurrent prescription 
medications. Age was normally distributed 0N statistic= 0.9867; p=0.0697) while the 
number of concurrent prescription medications was not normally distributed as 
demonstrated by a statistically significant Shapiro-Wilk test 0N statistic= 0.9017; 
p<0.0001 ); non-parametric rank tests were used to determine significant differences 
for the later variable. The frequency distribution of the measurement for time to 
discontinuation is shown in Figure 3A-1. 
Multivariate Analysis 
Time-to-event (survival) analysis methodology was used to evaluate 
discontinuation with lipid-lowering therapy. Data was censored for patients persisting 
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with lipid-lowering medication on the last day of the follow-up period or if three times 
the days supply plus the transaction date of the last refill met or exceeded the last 
day of the follow-up period. Because the inclusion criteria required all patients in the 
cohort to continuously use the pharmacy for dispensations of prescription 
medications during the observation period, no patient was censored due to loss to 
follow-up . 
Kaplan-Meier curves illustrated the time course of discontinuation with lipid-
lowering therapy by class of index lipid-lowering medication (statin or non-statin). 
Statistical differences between time-to-event curves were determined by the log-rank 
test. 
The Cox proportional hazards regression model generates hazard ratios (HR) 
and 95% confidence intervals (Cl), which estimate the relative rates of persistency 
(i.e., discontinuation) with lipid-lowering therapy for baseline patient- and 
medication-related characteristics compared to a reference group. 
Testing the Proportional Hazards Assumption 
Before creating the Cox regression model, the proportional hazards 
assumption for each categorical variable was tested (i.e., ensuring that the HR 
remained constant over the follow-up period) by visual inspection of log(-log) curves 
of the time-to-discontinuation for the respective subgroups.40-42 For non-proportional 
variables that significantly influences non-persistency with lipid-lowering therapy in 
the multivariate and bivariate Cox models, a modified Cox model would include 
stratification by the predictive variable. No study factor had an obvious violation of the 
proportional hazards assumption (Figures 3A-2 to 3A-5). 
Assessment of Co/linearity 
The presence of collinearity between the independent variables was 
examined.41 • 43 Independent variables with a condition index greater than 30 
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( (moderate to severe collinearity) and proportion of variations greater than 0.5 were 
further examined for collinearity with other independent variables. If collinearity were 
detected between two variables, the variable showing the strongest association with 
discontinuation of lipid-lowering therapy would remain in the model. None of the six 
study variables exhibited signs of collinearity (Table 3A-1). 
Assessment of Potential Confounding Variables 
Based on the technique of Kleinbaum,41 the effect of potential confounding 
variables (age, gender, health plan, antidiabetic medication regimen and number of 
concomitant medications) was examined. The model containing only the primary 
independent variable, class of index lipid-lowering medication (model A) was 
compared with models containing each potential confounding variable along with the 
primary independent variable (adjusted model). The estimated HR from model A was 
compared with the estimated HR from the adjusted models. If the two estimates were 
meaningfully different, then confounding due to the variable in the adjusted model 
was identified. In addition, the -2 Log-Likelihood (LL) difference in model A versus 
the adjusted models was tested for significance using X2 test values. Confounding 
was not present if the -2LL difference was less than the X2 statistic. No study factor 
was identified as a potential confounding variable (Table 3A-2). 
Assessment of Multiplicative Interactions 
Fitting models that included two- and three-way interaction terms with the 
independent variables tested the presence of an interaction between the independent 
variables was assessed using the -2 LL difference between the models (i.e. , the 
Chunk test) as described by Kleinbaum.41 The -2 LL difference in the model versus 
the model with reduced terms was tested for significance using X2 test values (Table 
3A-3). Interaction was not present if the -2 LL difference was less than the X2 
statistic. Significant interaction terms were tested in the models of independent 
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predictors using backward elimination as described by Kleinbaum.41 No significant 
two- or three-way interaction terms were identified using this methodology 
(p>0.1402). 
Cox Regression Model: Time to Discontinuation with Lipid-lowering Therapy 
The Cox regression model used non-persistency or time to discontinuation, in 
days, as the dependent variable. The procedure applied to select the most 
parsimonious (i.e., best) model from all possible model (bivariate and multivariate) 
combinations was based on the methodology described by Parmar and Machin.40 The 
values of the LR statistic for each model were compared with a X2 distribution (p<.05), 
using the appropriate degrees of freedom (Table 3A-4). The model with the smallest 
associated p-value was selected as the final model that predicted time to 
discontinuation of lipid-lowering therapy; a stepwise procedure of model selection 
(entry criteria=0.10) confirmed this choice. 
Residuals were examined to investigate the lack of fit of the final model to a 
given patient such as a patient who discontinues very early or very late with respect 
to other patients with similar characteristics. Residuals from the final Cox regression 
model were plotted against the value of the linear predictor as described in Marubini 
and Valsecchi.42 For the model to have an overall good fit , it was expected that the 
dots would scatter around zero without showing any particular structure. Upon visual 
examination of the plots, there was no indication of a lack of fit of the model to the 
individual observations (Figures 3A-6 and 3A-7). 
The a priori alpha level of significance was set at p<0.05. All data analyses were 
conducted using SAS release 8.2.44 
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RESULTS 
Description of the Study Population 
Lipid-lowering medication prescription claims were available for 1276 patients. 
Of these patients, 411 were excluded because they did not have at least one 
prescription claim for a lipid-lowering medication between November 1, 1997 and 
October 31 , 1998 and incomplete transaction dates for all lipid-lowering prescription 
claims during the observation period; 137 were current users of lipid-lowering 
therapy; 537 did not continuously use the pharmacy during the observation period 
(i.e., a prescription claim for any medication in the six months prior to the index date 
and in the last three months of the observation period); and one patient was 
prescribed combination lipid-lowering therapy (Figure 3-1). A total of 190 patients 
were included in the study analyses: 100 (53%) males and 90 (47%) females with an 
average age of 59.3 ± 10.4 years (range, 32-80 years). These patients were followed 
for a total of 47,372 person-days, a mean of 248 person-days. 
Characteristics of the study population are shown in Table 3-3. Half (50%) of 
the patients were enrolled in the health plan that provided a nurse-based diabetes 
management plan. A majority (75%) of patients did not receive a prescription for 
insulin therapy within 90 days of the index date. At baseline (i.e., three months prior 
to the index date), patients were prescribed an average of 5 ± 3 concurrent 
medications other than lipid-lowering medications and diabetic supplies. 
Stalins were the most frequently (87%) prescribed lipid-lowering medication at 
the index date; 15 patients were prescribed fibrates, nine patients were prescribed a 
bile acid sequestrant and one patient was prescribed nicotinic acid. Patient- and 
medication-related characteristics were similar between patients prescribed a statin 
and non-statin medication; no statistically significant differences were observed 
(P?.0.1340) (Table 3-4). 
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Patterns of Persistence and Discontinuation with Lipid-lowering Medication 
In general, persistence with lipid-lowering therapy was low. Overall, 58% of 
patients persisted with lipid-lowering medication. Patient- and medication-related 
characteristics stratified according to persistence or discontinuation are shown in 
Table 3-5. Class of index lipid-lowering medication was statistically significant 
(p=0.0176): patients prescribed statins were more likely to be persistent than patients 
prescribed non-statin medications. Proportions for all other study factors were similar 
among patients who persisted with lipid-lowering therapy and those patients who 
discontinued treatment. 
Of the 165 patients prescribed statin medications, 74% persisted with 
treatment over six months, 59% over 12 months, and 46% over 18 months of 
observation. At six months, 60% of patients in the non-statin group persisted with 
treatment; only 26% of patients were persistent over 12 and 18 months of 
observation. Kaplan-Meier curves of non-persistency statistically differed for patients 
prescribed statin and non-statin therapy (Log-rank X2 = 7.9101; p = 0.0049) (Figure 
3-2). It should be noted that for both classes of lipid-lowering medications there was a 
steep drop in patients persisting with therapy around 90 days; a sensitivity analysis 
was conducted and is discussed below. 
Among patients who discontinued treatment, 23 (26%) patients interrupted 
treatment after a single prescription. When the data for patients who discontinued 
after a single prescription fill were excluded from analysis, substantial non-
persistence remained: only 47% and 68% of patients prescribed non-statin and statin 
therapy, respectively, persisted with lipid-lowering therapy at 18 months although the 
statistical difference between the classes was no longer observed (Log-rank 
X2=3.5037; p=0.0612) (Figure 3-3). In contrast to Figure 3-2, the steep drop in the two 
curves disappears. This may be due to classification of the time to discontinuation 
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variable (i.e., three times the days supply). In this patient population, the majority of 
patients were dispensed a 30 day supply of medication. Thus, using this 
classification, time of discontinuation would equal (3X30} or 90 days for patients who 
discontinued after first fill. Since in actuality patients may fill a prescription only once, 
these patients were included in subsequent analyses. 
Of the 87 patients who discontinued lipid-lowering therapy, 28 (32%) restarted 
lipid-lowering medication during the observation period; the median time to 
re-initiation was 63 days (range 2-316 days) . The majority of patients (22, 79%) 
remained with the same medication as prescribed at the index date with four patients 
prescribed a higher dosage whi le six patients restarted with another medication in the 
same class as the index lipid-lowering medication (Table 3-6). Almost half (43%) 
restarted therapy after the initial lipid-lowering medication prescription was not refilled. 
Switching of Lipid-lowering Medications 
Patients were classified as switching medication if they filled a prescription for 
a lipid-lowering medication other than the index medication during the observation 
period. Overall , 19 (10%) of patients switched to another lipid-lowering medication . 
The majority (84%} of the patients who switched medication changed to another 
medication in the same class as the index lipid-lowering medication (Table 3-7). 
Fifteen patients prescribed a statin medication switched to a different statin 
medication while two patients switched to a non-statin medication. Of these patients, 
one patient switched back to the index statin medication. Of the 25 patients initially 
prescribed a non-statin medication, one patient each switched to another non-statin 
and statin medication during the observation period. 
Predictors of Time to Discontinuation 
Hazard ratios (HR) and 95% Cl for all study factors that potentially influence 
discontinuation with lipid-lowering therapy are shown in Table 3-8. Controlling for all 
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study factors, class of index lipid-lowering medication was a significant predictor of 
discontinuation of treatment (p=0.0051 ). Patients prescribed insulin therapy were 
50% more likely to discontinue lipid-lowering therapy than patients prescribed oral 
antidiabetic medications only, although this study factor did not significantly influence 
discontinuation (p=0.1706). All other variables, age, gender, health plan and number 
of concomitantly prescribed medications had little to no effect on discontinuation with 
lipid-lowering therapy in this patient population (p?,0.4720). 
The final Cox regression model showed that discontinuation with lipid-lowering 
therapy was related to class of index lipid-lowering medication (Table 3-9). Compared 
with patients prescribed statin medications, patients prescribed non-statin 
medications were more than twice as likely to discontinue lipid-lowering therapy 
(HR=2.240; 95% Cl= 1.260, 3.982; p=0.0060). Inclusion of other study factors or 
interaction terms into the Cox regression model did not significantly influence non-
persistency with lipid-lowering therapy. 
DISCUSSION 
Our findings provide evidence of low persistence with lipid-lowering 
medications in patients with diabetes. While few studies have demonstrated that 
diabetes was related to higher persistence with lipid-lowering therapy'"· 26 30 this study 
provided an opportunity to evaluate persistence with lipid-lowering therapy among 
patients with diabetes. Our findings extend the information previously published in 
other patient populations.23'25• 28 32 
Our data supports the findings of other investigations23'25 in that patients 
prescribed statin medications are more likely to persist with lipid-lowering therapy 
than patients prescribed non-statin medications. Since the reason for discontinuation 
or change in therapy (i.e., switches or dosage changes) is not captured in pharmacy 
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claims data, we could not determine why more patients continued with statin therapy 
than non-statin treatment at the end of six, 12, and 18 months of observation. These 
findings may reflect greater convenience of dosing regimens for statins or differing 
adverse event profiles of these medications.26• 45 Therapeutic ineffectiveness, 
patient's perception of need for therapy and adverse events have been reported as a 
contributing factors for discontinuation of lipid-lowering therapy.23•25 
Although bile acid sequestrants, fibrates and nicotinic acid are prescribed to 
treat dyslipidemia, statins are recommended as first-line pharmacotherapy in the 
majority of hyperlipidemic patients, including patients with diabetes mellitus in part 
because of their potency, convenient dosing and tolerability.46·48 Stalins, first 
introduced in the United States in 1987, reduce LDL-C levels, raise HDL-C levels and 
recently have been shown to reduce triglyceride levels as well.49 Major statin trials 
have established the value of lowering LDL-C and triglyceride levels in reducing the 
rate of major cardiovascular events.•·13 Subgroup analyses of some of these 
landmark trials suggest that statins have beneficial effects across the lipid profile and 
reduce major cardiovascular events in patients with type 2 diabetes. It was not 
unexpected that the majority of patients in our cohort were prescribed statin 
medications. 
An interesting finding was that the majority of patients who switched 
medication replaced their initial medication with another medication from the same 
class. Similar to our results, Yang and colleagues reported that 13% of patients 
switched to another lipid-lowering medication: almost half of these patients remained 
within the same class of medication as the initial medication.24 Compared with 
patients who continued lipid-lowering treatment, patients who switched therapy 
frequently received non-statin medications as the initial therapy.24 These findings may 
reflect greater convenience of dosing regimens for statins.26• 45 Poor palatability and 
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multiple dosing frequency of some of the non-statin medications (e.g., bile acid 
sequestrants) are related to poor adherence.50 Therapeutic ineffectiveness, patient's 
perception of need for therapy and adverse events have been reported as a 
contributing factors for discontinuation of lipid-lowering therapy.23.25. 45 
In an analysis of the influence of patient- and medication-related 
characteristics on discontinuation of lipid-lowering therapy, we found that patients 
prescribed insulin therapy (i.e. , either insulin monotherapy or insulin in combination 
with oral antidiabetic medications) were more likely to discontinue lipid-lowering 
treatment than patients prescribed oral medications only. These findings are 
consistent with those of Larsen and colleagues who observed that patients who 
received insulin therapy were at a 38% higher risk for discontinuation with statin 
therapy than patients treated with oral antidiabetic agents.28 It is known that insulin 
therapy is complex: the need to mix and inject insulin preparations and taking multiple 
injections combined with the fear of injections may result in poor adherence with this 
treatment regimen51•54 which may lead to poor persistency with other medications. 
Further study is needed to examine antidiabetic medication regimen as a covariate on 
persistence with lipid-lowering medications among patients with diabetes mellitus. 
The relationship between other predictive study factors and persistence with 
lipid-lowering medications has been studied although with inconsistent results. For 
example, older age was associated with higher persistence.24• 25• 28 The use of 
concurrent cardiovascular medications was associated with a higher rate of treatment 
continuation24• 25 while the number of non-cardiovascular medications was inversely 
associated with higher continuation rates.24• 26 Yang and colleagues found that 
females were more likely to discontinue lipid-lowering therapy24 while Larsen and 
colleagues did not observe an association with gender and treatment continuation.28 
Our findings did not indicate an effect of age, gender or number of concomitantly 
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prescribed medications on discontinuation with lipid-lowering therapy in our patient 
population. 
Limitations 
Even though it is an imperfect measure of the patients' lifetime prescription 
history, the first date of a prescription fill is commonly used as the time the patient 
enters the cohort . Many researchers use a one-year pre-index time frame to assess 
classification of new and long-term users24• 28· 37• 38• 55-57 while others use shorter 
periods of six to ten months.35• 58 Our objective was to estimate persistence over 18 
months of follow-up and two years of prescription claims were available in this 
database thus only six months of data was available for pre-index assessments of 
new users of therapy. Although reports on methodology of measuring persistence 
with medications state that at least six months is sufficient to identify patient as 
incident users of therapy59 • 60 this shorter time period may have led to misclassification 
of new users of lipid-lowering therapy that could affect our study results, especially 
since we were not able to determine whether patients received medication samples in 
a doctor's office. 
Since the database included patients with diabetes who were dispensed 
lipid-lowering medications through CVS pharmacies in Pennsylvania, the results from 
this study may not be generalizable to the wider population of patients with diabetes. 
While claims data provide some advantage related to the availability to 
perform pharmacoepidemiological analyses, they also have a number of limitations 
that could affect the validity of study results. One limitation is the assumption that 
patients fill all their medications at the same pharmacy. Some patients may fill 
prescribed medications at another pharmacy leading to an underestimation of the 
patient's medication supply. Since a total of 529 patients without continuous use in 
127 
the CVS pharmacy system were excluded from our study population , this would not 
likely have affected our results. 
Pharmacy claims data does not allow direct observation of discontinuation of 
therapy. Thus, discontinuation and time-to-discontinuation is assumed to have 
occurred when no refill claim is entered into the database. A component of our 
definition of discontinuation (i.e ., elapsed fill intervals greater than three times the 
days supply) was based on previous investigations24• 25• 37•39 that utilized similar 
criteria for defining discontinuation of treatment to allow for sufficient time to refill 
prescriptions. Other investigators used varying lengths of time to define 
discontinuation ranging from 30 to 60 days28• 31 • 32• 55• 57 to four to six months of 
elapsed time since last fill.23• 35• 36• 61 • 62 Our findings were consistent with previous 
studies of discontinuation rates with lipid-lowering therapy. Nonetheless, our definition 
of discontinuation may have affected our estimates of discontinuation in this patient 
population as evidenced by the range of time to re-initiation of treatment after 
discontinuation (i.e., 2-316 days) 
We included patients with only one lipid-lowering prescription claim in this 
study in order to replicate real life situations. Our sensitivity analysis, which excluded 
these patients, still demonstrated an increased risk of discontinuation for patients 
prescribed non-statin medications compared with patients prescribed statins, 
although the statistical significance disappeared. Thus, although we may have 
overestimated the risk of non-persistency with lipid-lowering therapy in this patient 
population, we don't feel that including these patients in subsequent analyses 
compromised our results. 
Pharmacy claims lack clinical information that may influence patients' use of 
medication, such as co-morbid conditions, serum lipid levels, and adverse effects 
experienced by the patient. Stalin medications are generally well tolerated; Andrade 
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and colleagues reported that 7% of patients prescribed lovastatin and 26% of patients 
prescribed niacin discontinued treatment due to adverse events.23 Hiatt and 
colleagues report that cumulative discontinuation rates for niacin and bile acid 
sequestrants at one year were 48% and 59%, respectively, in comparison with 10% 
for statin medications.33 In this study, the primary reason for discontinuation of niacin 
and bile acid sequestrants was adverse events.33 Without information such as rates of 
adverse events, we could not correlate our estimates to reasons for discontinuation or 
switching of medications in this study. Thus, modeling the factors that might affect 
persistence with lipid-lowering therapy may be biased due to incompleteness of the 
model. 
The accuracy of the data in the reported pharmacy claims was not verifiable. It 
was not possible to confirm prescription claim information with other data sources 
such as medical records, pill counts, or medication diaries. 
Notwithstanding these limitations, pharmacy claims data can be a useful 
source of data in population-based studies when direct measurements are not 
feasible. Utilizing a pharmacy claims database may represent the best means to 
capture utilization data of medication in a patient population as clinical trials are 
limited predictors of treatment discontinuation in actual medical practice. The 
one-year probability of discontinuation for lipid-lowering therapy was substantially 
higher in Health Maintenance Organizations than in randomized clinical trials.23 
CONCLUSION 
The observations of this study indicate that persistence with lipid-lowering 
therapy in patients with diabetes mellitus was sub-optimal. Patients prescribed a 
statin medication as their initial lipid-lowering medication exhibited greater persistency 
compared with those patients prescribed non-statin medications. Further research is 
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needed to uncover reasons for low persistence with lipid-lowering therapy in patients 
with diabetes. These findings highlight the need for health care providers to manage 
persistence with lipid-lowering medications that may reduce the risk of major 
cardiovascular events in patients with diabetes mellitus. 
Our results have important implications for persistency with pharmacotherapy 
for dyslipidemia in patients with diabetes. First, since statins are the recommended 
first line of therapy for this patient population, it is essential to document persistence 
with lipid-lowering therapy in a "real-world" setting. Secondly, it is known that statins 
are generally well tolerated and have been reported to reduce LDL-C levels, 
significantly decreasing the risk of cardiovascular events and total mortality. In an 
effort to optimize the choice of therapeutic regimens and improve patients' continuous 
use of lipid-lowering therapy, clinical practice guidelines, patient education, and 
quality of care assessments should emphasize factors that predispose patients to 
non-persistency with lipid-lowering therapy. 
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TABLES 
Table 3-1 . Relationship between lipid parameter changes and compliance in the 
Helsinki Heart Study (n = 1963 males treated with 600mg gemfibrozil BID) 
Compliance* 
Lipid Parameter < 50% ~90% 
Total cholesterol 
LDL cholesterol 
HDL cholesterol 
Triglycerides 
-0.02% 
+2.6% 
+2.7% 
-6.2% 
-11 .4% 
-10.1% 
+13.3% 
-40.0% 
• Compliance was defined as mean daily capsule count and reported as a 
percentage of scheduled daily dose 
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Table 3-2. Lipid-lowering medications 
Class 
Generic (brand) name 
HMG CoA reductase 
inhibitors (Stalin) 
atorvastatin (Lipitor®) 
fluvastatin (Lescol®) 
lovastatin (Mevacor®) 
pravastatin (Pravachol®) 
simvastatin (Zocor®) 
Bile acid sequestrants 
cholestyramine resin (Questran®) 
colestipol (Colestid®) 
Nicotinic acid 
niacin (Niaspan®) 
Fibrates 
fenofibrate (Tricor®) 
gemfibrozil (lopid®} 
Abbreviations: HMG CoA= 3-hydroxy-3-methylglutaryl coenzyme A 
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Table 3-3. Characteristics of the study population 
Characteristic 
Patient-related 
Age (years) 
Gender 
Male 
Female 
Health Plan* 
Nurse-based diabetes management plan 
Other health plans 
Medication-related 
Antidiabetic Medication Regiment 
Oral medication 
Insulin therapy 
Number of Prescription Medications* 
N = 190 
59.3 ± 10.4 (32-80) 
100 (52.6) 
90 (47.4) 
95 (50.0) 
95 (50.0) 
143 (75.3) 
47 (24.7) 
5 ± 3 (0-17) 
Class of Lipid-lowering Medication, by Index Prescription 
HMG-CoA reductase inhibitor (statins) 165 (86.8) 
Fibrates 15 ( 7.9) 
Bile acid sequestrants 9 ( 4.7) 
Nicotinic acid 1 ( 0.5) 
Values expressed as number (%) or mean ± standard deviation (SD) (range). 
Percentages may not equal 100% due to rounding 
* Health plan used to acquire the index lipid-lowering medication. Other health 
rlans includes local/state/federal programs or cash payments. 
Antidiabetic medication regimen dispensed within 90 days of the index date. 
Insulin therapy includes insulin monotherapy or in combination with oral medication. 
* Number of prescription medications in the three months prior to index lipid-lowering 
medication. 
Abbreviations: HMG CoA= 3-hydroxy-3-methylglutaryl coenzyme A 
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Table 3-4. Characteristics of the study population by class of index 
lipid-lowering medication 
Stalin Non-Stalin 
Characteristic N = 165 N =25 
Patient-related 
Age (years) 59.3 ± 10.2 58.9±12.0 
(32-80) (39-80) 
Gender 
Male 89 (53.9) 11 (44.0) 
Female 76 (46.1) 14 (56.0) 
Health Plan* 
Nurse-based diabetes 79 (47.9) 16 (65.2) 
management plan 
Other health plans 86 (52.1) 9 (64.0) 
Medication-related 
Antidiabetic Medication Regiment 
Oral medication 122 (73.9) 21 (84.0) 
Insulin therapy 43 (26.1) 4(16.0) 
Number of Prescription Medications; 
5 ±3 (0-17) 5±4 (1-17) 
p-value 
0.8554 
0.3549 
0.1340 
0.2786 
0.4134 
Values expressed as number (%) or mean ±standard deviation (SD) (range). 
* Health plan used to acquire the index lipid-lowering medication. Other health 
plans includes local/state/federal programs or cash payments. 
Antidiabetic medication regimen dispensed within 90 days of the index date. 
Insulin therapy includes insulin monotherapy or in combination with oral medication. 
; Number of prescription medications in the three months prior to index lipid-lowering 
medication. 
134 
Table 3-5. Characteristics of the study population by the pattern of persistence 
with lipid-lowering therapy 
Persisters* Discontinuers* 
Characteristic N = 110 N =80 ~-value 
Patient-related 
Age (years) 59.4 ± 9.9 59.1±11.2 0.8689 
(35-79) (32-80) 
Gender 0.2282 
Male 62 (56.4) 38 (47.5) 
Female 48 (43.6) 42 (52.5) 
Health Plant 0.7694 
Nurse-based diabetes 54 (49.1) 41 (51 .3) 
management plan 
Other health plans 56 (50.9) 39 (48.7) 
Medication-related 
Antidiabetic Medication Regimen* 0.1527 
Oral medication 87 (79.1) 56 (70.0) 
Insulin therapy 23 (20.9) 24 (30.0) 
Number of Prescription Medications§ 
5 ± 3 (0-17) 5±4(1-17) 0.9059 
Class of Lipid-lowering Medication, by Index Prescription 0.0176 
Stalins 101 (91.8) 64 (80.0) 
Non-Stalins 9 ( 8.2) 16 (20.0) 
Values are number (%) or mean ±standard deviation (SD) (range) 
*Persisters are defined as patients who persisted with lipid-lowering medication 
using the class dispensed at the index date; Patients who did not persist with 
lipid-lowering therapy were defined as Discontinuers. 
t Health plan used to acquire the index lipid-lowering medication. Other health 
plans includes local/state/federal programs or cash payments. 
Antidiabetic medication regimen dispensed within 90 days of the index date. 
Insulin therapy includes insulin monotherapy or in combination with oral medication. 
§Number of prescription medications in the three months prior to index lipid-lowering 
medication. 
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Table 3-6. Frequency of re-initiation• of lipid-lowering therapy during the 18-month follow-up period (N = 28) 
Lipid-lowering medication prescription at re-initiation 
Stalins Non-Stalins 
Index lipid-lowering 
medication .. atorvastatin fluvastatin lovastatin pravastatin simvastatin cholestryamine gemfibrozil 
Statins 
atorvastatin 
fluvastatin 
lovastatin 
pravastatin 
simvastatin 
Non-Statins 
cholestyramine 
gemfibrozil 
2t 
2 14t 
2 
• A patient re-initiated lipid-lowering therapy after meeting the criteria for discontinuation (i.e., patient (a) had more 
1 
2 
than three times the days supplied elapsed between the last prescription fill for lipid-lowering medication and the next fill or 
the end of the follow-up period; (b) switched to a medication in a class different than the index medication; or (c) had no 
refills for the lipid-lowering medication during the observation period} 
t One patient had a dosage increase 
t Three patients had a dosage increase 
w 
...., 
Table 3-7. Frequency of switching* of lipid-lowering therapy during the 18-month follow-up perioq (N = 19) 
Index 
lipid-lowerin9 
medication t 
Statins 
atorvastatin 
fluvastatin 
pravastatin 
simvastatin 
Non-Statins 
cholestyramine 
gemfibrozil 
Lipid-lowering medication prescription at switch 
St tin Non-Stalins I I 
atorvastatin fluvastatin lovastatin pravastatin simvastatin gemfibrozil fenofibrate 
2 2 
31 4 
1 
2 
• A medication switch was identified if the patient filled a prescription for a lipid-lowering medication other than the index 
medication during the observation period 
t One patient switched back to atorvastatin 
-... 
( Table 3-8. Cox regression model: time to discontinuation with lipid-lowering th era in atients with diabetes 
Unad"usted Ad·usted* 
Study Factor Hazard Ratio p-value Hazard Ratio p-value 
95% CI 95%CI 
Patient-related 
Age 0.993 0.5800 0.994 0.6196 
(0.971 , 1.017) (0.972, 1.017) 
Gender 
Male 1.0 1.0 
Female 1.325 0.2209 1.188 0.4720 
(0.844, 2.081) (0.742, 1.903) 
Health Plant 
Nurse-based 
diabetes 1.0 1.0 
management plan 
Other health 0.917 0.7061 0.919 0.7317 
plans (0.584, 1.439) (0.567, 1.490) 
Medication-related 
Antidiabetic Medication Regimen* 
Oral medication 1.0 1.0 
Insulin therapy 1.378 0.2035 1.457 0.1706 
(0.841 , 2.257) (0.850, 2.498) 
Number of Prescription Medications§ 
1.005 0.8987 1.000 0.9953 
(0.937, 1.076) (0.929, 1.076) 
Class of Lipid-lowering Medication, by Index 
Prescription 
Stat in 1.0 1.0 
Non-Stalin 2.240 0.0060 2.308 0.0051 
(1 .260, 3.982) (1 .285, 4.1 47) 
* adjusted for all study factors in the table 
t Health plan used to acquire the index lipid-lowering medication. Other health 
plans includes local/state/federal programs or cash payments. 
Antidiabetic medication regimen dispensed with in 90 days of the index date. 
Insulin therapy includes insul in monotherapy or in combination with oral medication. 
§Number of prescription medications in the three months prior to index date. 
Abbreviations: Cl = confidence intervals 
138 
Table 3-9. Final Cox regression model: time to discontinuation with lipid-lowering 
therapy in patients with diabetes 
Factor 
Regression 
Coefficient Hazard Ratio* (95% Cl) 
Class of Lipid-lowering Medication, by Index Prescription 
Slatin 1.0 
Non-Stalin 0.80650 2.240 (1 .260, 3.982) 
Global X = 6.5434 (p = .0105) 
Abbreviations: Cl = confidence intervals 
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p-value 
0.0060 
Table 3A-1 . Collinearity diagnostics 
Pro~ortion of variation 
Variable Condition Intercept Lipidclass Age Gender AD regimen Health Con med 
Index Ian 
Intercept 1.00000 0.00133 0.00753 0.00138 0.01521 0.01416 0.01457 0.01107 
Lipid class 2.17328 0.0000105 0.73534 0.0000100 0.00348 0.10630 0.02370 0.00133 
Age 2.60887 0.00127 0.06756 0.00173 0.04200 0.72132 0.10170 0.00929 
Gender 2.82434 0.0002495 0.15894 0.0002969 0.50295 0.12588 0.20088 4.311104E-7 
ADregimen 3.74263 0.00462 0.01299 0.00600 0.37869 0.00567 0.63565 0.17806 
Health plan 4.81068 0.02738 0.01443 0.03072 0.05262 0.01841 0.02138 0.80012 
Con med 17.2459 0.96514 0.00320 0.95987 0.00504 0.00825 0.00213 0.00012424 
:;;: 
0 
~ 
Table 3A-2. Test for confounding variables 
LR 
Variable Name B11o1dclass HR11o1dclass Pr> X'* -2LL statistic p-valuet Significance 
Model A: lipidclass 
Lipidclass + age 
Lipidclass + gender 
Lipidclass + healthplan 
Lipidclass + ADregimen 
Lipidclass + conmed 
0.67362 1.961 0.0161 785.470 
0.67104 1.956 0.0166 785.345 
0.65003 1.916 0.0205 783.977 
0.67129 1.957 0.0167 785.448 
0.71144 2.037 0.0114 782.659 
0.68068 1.975 0.0157 785.178 
• p-value associated with X2 test of overall model 
0.125 
1.493 
0.022 
2.811 
0.292 
t p-value associated with X2 distribution with appropriate degrees of freedom 
3.84 
3.84 
3.84 
3.84 
3.84 
NS 
NS 
NS 
NS 
NS 
Abbreviations: HR= Hazard Ratio; -2LL = -2 Log Likelihood; LR= Likelihood Ratio; NS= non significant at p=0.05 level 
Table 3A-3. Likelihood Ratio (LR) statistic: modeling of time to discontinuation 
LR 
Model 
Full Model 
Reduced Model 1 
Reduced Model 2 
-2 LL 
575.268 
604.818 
607.661 
DI* Statistic 
20 
9 29.550 
5 2.843 
p-valuet 
16.92 
11.07 
* Df of fuller model minus reduced model with less variable terms 
Significance 
SIG 
NS 
t p-value associated with X2 distribution for appropriate degrees of freedom 
Full Model includes all univariate variables, two-way and three-way interaction terms 
Reduced Model 1 includes all univariate variables and two-way interaction terms 
Reduced Model 2 includes all univariate variables 
Abbreviations: -2LL = -2 Log Likelihood; Df = degrees of freedom; NS = not 
significant; SIG = statistically significant at p=0.05 level 
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Table 3A-4. Likelihood Ratio (LR) statistics for choosing the best model of time to 
discontinuation with lipid-lowering therapy 
Model LR p- Signif-
Model -2LL di p-value* Statistic valuet icance 
Null (no covariates) 617.530 
Full model : all IVs 607.661 6 0.0870 11 .044 12.59 NS 
Age 617.225 1 0.5807 0.305 3.84 NS 
Gender 616.030 1 0.2206 1.500 3.84 NS 
Lipidclass 610.987 1 0.0105 6.543 3.84 SIG 
Health plan 617.388 1 0.7061 0.142 3.84 NS 
ADregimen 615.978 1 0.2128 1.552 3.84 NS 
Con med 617.514 1 0.8997 O.D16 3.84 NS 
Age+ Gender 615.740 2 0.4084 1.790 5.99 NS 
Age + lipidclass 610.738 2 0.0335 6.792 5.99 NS 
Age + Healthplan 617.099 2 0.8059 0.431 5.99 NS 
Age + ADregimen 615.678 2 0.3960 1.852 5.99 NS 
Age+ Conmed 617.196 2 0.8460 0.334 5.99 NS 
Gender + lipidclass 609.827 2 0.0212 7.703 5.99 NS 
Gender + Healthplan 615.982 2 0.4611 1.548 5.99 NS 
Gender+ ADregimen 614.953 2 0.2756 2.577 5.99 NS 
Gender + Conmed 616.025 2 0.4712 1.505 5.99 NS 
Lipidclass + 610.945 2 0.0371 6.585 5.99 NS 
Healthplan 
Lipidclass + 608.668 2 0.0119 8.862 5.99 SIG 
AD regimen 
Lipidclass + Conmed 610.916 2 0.0366 6.614 5.99 NS 
Healthplan + 615.611 2 0.3830 1.919 5.99 NS 
ADregimen 
Healthplan + Conmed 617.339 2 0.9087 0.191 5.99 NS 
ADregimen + 615.927 2 0.4486 1.603 5.99 NS 
Con med 
Lipidclass + gender + 608.042 3 0.0235 9.488 7.81 SIG 
ADregimen 
lipidclass + age + 610.370 3 0.0670 7.160 7.81 NS 
Ii page 
Lipidclass + age + 609.490 4 0.0901 8.040 9.49 NS 
gender + lipagegen 
lipidclass + age + 609.040 5 0.1312 8.490 11.07 NS 
gender + lipage + 
lipagegen 
Lipidclass + gender + 608.904 4 0.0712 8.626 9.49 NS 
conmed + lipgencon 
Lipidclass + age + 607.584 6 0.1 269 9.946 12.59 NS 
gender + conmed + 
lipage + lipagegen + 
lipgencon 
All IVs+ lipage + 604.659 9 0.1685 12.871 16.92 NS 
lipagegen + lipgencon 
• p-value associated with x2 test of overall model 
t p-value associated with X2 distribution with appropriate degrees of freedom 
Abbreviations: -2LL = -2 Log Likelihood; IV = independent variables; LR = likelihood ratio 
statistic; NS= non significant at p=0.05 level ; SIG =statistically significant at p=0.05 level 
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FIGURES 
Figure 3-1. Eligibility criteria of study population 
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( Figure 3-2. Kaplan-Meier time-to-event curves of persistence with lipid-lowering medications in patients with diabetes, stratified by class of index lipid-lowering 
medication 
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( Figure 3-3. Kaplan-Meier time-to-event curves of persistence with lipid-lowering medications in patients with diabetes (excluding patients with one lipid-lowering 
medication prescription) , stratified by class of index lipid-lowering medication 
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Figure 3A-1. Frequency distribution of the measurement: time to discontinuation 
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Figure 3A-2. Test of Proportional Hazard Assumption: Gender 
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Figure 3A-3. 
Test of Proportional Hazard Assumption: Class of Index Lipid-Lowering Medication 
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Figure 3A-4. Test of Proportional Hazard Assumption: Healthplan 
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Figure 3A-5. Test of Proportional Hazard Assumption: Antidiabetic Medication 
Regimen 
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Figure 3A-6. Martingale residual plot of final Cox regression model 
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Figure 3A-7. Deviance residual plot of final Cox regression model 
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APPENDIX A 
Background and Review of the Problem 
Since Hippocrates, physicians have been plagued by concerns over patients' 
adherence to medication regimens.1•2 The terms compliance, adherence, and 
concordance have been used in the literature to describe the manner in which a 
patient manages a prescribed medication regimen . Compliance has been defined as 
the extent to which the patients' history of medication administration corresponds to 
the actual prescribed regimen3 whereas the term adherence captures the increasing 
complexity of medical care by characterizing patients taking a more active and 
voluntary role in defining and pursuing goals for their own medical treatment• while 
concordance focuses on the patients' agreement with treatment and harmony in the 
physician-patient relationship. Adherence will be the preferred term used in this 
research. 
Three phases are used to describe a patient's dosing history: 
Acceptance of the medication treatment and regimen during the initial 
patient/physician consultation leading to actual dispensation of the 
prescription; 
Adherence with the dosing regimen; 
Persistence with therapy once it's initiated.5 
There are several methods for measuring medication adherence although 
none is considered a gold standard. Indirect measures include patient interviews or 
questionnaires, pill counts, review of prescription records and claims, and electronic 
monitoring devices, while direct measures of adherence include pharmacologic 
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markers and direct observation of the patient taking the medication.6.a The selection 
of the measurement depends on the type of intervention being evaluated, resources 
of the organization, and patient confidentiality (e.g., contacting patients whether by 
mail or in person). 
While no single measure of adherence is appropriate for all settings or 
outcomes, database records of dispensed prescriptions may represent one of the 
most accurate methods of assessing medication utilization in a patient population.•· 10 
Prescription records allow the assessment of patients with multiple medication 
regimens based on refill patterns. Because this method of assessment is unobtrusive 
and does not influence adherence behavior (e.g., the Hawthorne effect) , pharmacy 
databases are suitable for long-term monitoring of medication use in population 
studies. 11 Although prescription refill data does not verify administration of the therapy 
regimen, it does signify availability of medication. This method of assessing 
adherence is based on the assumption that if the medication is not available for use, 
patients clearly cannot adhere with the medication regimen. 
Although pharmacy claims databases contain all the data necessary to 
determine medication adherence, various measures of adherence have been utilized. 
For instance, continuous measures of medication availability such as Medication 
Possession Ratios (MPR) or Continuous, multiple-interval measures of Medication 
Availability (CMA) are commonly used while some researchers evaluate gaps in 
therapy and medication oversupply. A review by Fairman and Motheral12 illustrates 
the process of selecting the right tool to measure medication adherence. For 
example, an analysis of gaps in refills can be used to determine whether a medication 
adherence program successfully reduced the number of medication holidays whereas 
if a program were aimed at encouraging patients to use their chronic medication on a 
regular basis, a continuous measure of medication availability (i.e., CMA or MPR) 
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would be an appropriate measurement tool. However, a study determining the nature 
and extent of adherence should use all the measures described allowing for an 
evaluation of the problem prior to developing a targeted solution . 
Research suggests that predictors of medication adherence vary according to 
the population or disease state under evaluation. In general, the scope of adherence 
ranges across all age groups and medical disciplines and can be influenced by many 
factors including tolerability of the medication, complexity of the medication regimen, 
cost and convenience of the therapy, and characteristics of the patient, medical 
system and physician. Although some associations have been reported between 
adherence and demographic characteristics (e.g., age, sex, marital status, social 
class) and disease factors, the direction of these associations was inconsistent 
between studies.' · 13' 16 In addition, there are inconsistent reports of factors that predict 
adherence with medications such as medication complexity (e.g., class of medication, 
number of daily doses, number of medications) and occurrence of adverse 
effects.13•14•17 The most significant influences on compliance are patient's beliefs 
about medications and about medicine in general18 however, few investigations 
evaluate patients' own beliefs and their perspective on health and illness in research 
on compliance with medications.19 
Failure to follow prescribed medication regimens jeopardizes a patients' health 
and well-being, interferes with a physician 's therapeutic efforts and poses a 
considerable financial burden upon health care systems.5• 13• 20 Estimates of rates of 
noncompliance with prescribed therapeutic regimens typically range from 30% to 
60%. 21 Because of its potentially negative consequences, medication adherence may 
be one of the greatest therapeutic challenges facing healthcare professionals.22·2• 
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Medication adherence is especially important for patients with chronic diseases who 
must often obtain prescription refills throughout their lives.25 
Patients with diabetes mellitus are at particular risk for non-adherence to 
antidiabetic treatment regimens.26 Once diagnosed, patients with diabetes are 
confronted with the need for lifestyle modifications including nutrition and exercise 
therapy and treatment with an antidiabetic medication is often unavoidable. The 
importance of glycemic control in preventing and minimizing diabetes-related 
complications is well recognized.21-29 However, diabetes is no longer a disease of 
sugar alone.30 Attention to other cardiovascular risk factors is also an important 
aspect of diabetes management. Cardiovascular disease is up to four times more 
common in patients with diabetes than those without and 50% of patients with 
diabetes have evidence of cardiovascular disease at the time of diagnosis.31 
Reductions in blood pressure and blood lipid levels may be needed to reduce 
diabetes-related complications. All of this requires a substantial degree of treatment 
adherence from patients. A major barrier to management of diabetes mellitus and co-
morbidity is the extent to which individuals adhere to their prescribed treatment 
regimens.32 
This research focused on adherence and persistence with prescribed 
medications in patients with diabetes mellitus. The aim of the first study was to 
evaluate adherence with sulfonylurea medications using continuous and dichotomous 
measurements such as medication availability, gaps in therapy and surplus 
medication. The effect of the length of observation and the relationship between 
these adherence measurements were investigated along with the influence of patient-
and medication-related characteristics on adherence with sulfonylureas. This study 
should provide insight into the variety of measures currently used for investigations of 
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adherence, as there is no standard method to evaluate and report rates of adherence 
with medication . The findings of this study may also increase knowledge on the 
extent of medication adherence with sulfonylureas. 
The aim of the second study was to evaluate adherence with lipid-lowering 
therapy among patients with diabetes. Since persistence with medication regimens is 
an integral part of diabetes management, the aim of the third study was to examine 
persistence with lipid-lowering therapy. Patient- and medication-related 
characteristics that may influence adherence and persistence were also evaluated. 
The findings from these two studies should expand current knowledge on adherence 
and persistence with lipid-lowering therapy among patients with diabetes mellitus. 
The observations from these three studies may guide the health care provider 
to integrate patient-education and other intervention programs into diabetes 
management as a means to improve medication adherence. Enhancing adherence 
and persistence with prescribed medications should have a profound impact on 
health outcomes of patients with diabetes. 
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APPENDIX B 
Details of Methodology 
The data for this research project was provided by Consumer Value Stores 
(CVS) pharmacies to the University of Rhode Island Applied Pharmaceutical 
Sciences department. The data was derived from 198 CVS pharmacies located in 
Pennsylvania and includes records of dispensed outpatient pharmacy prescription 
records of patients with diabetes mellitus. Patients were enrolled either in a 
nurse-based diabetes management plan or acquired their prescription through a 
federal , state, or local program or paid with cash. The data represents patients' 
utilization of lipid-lowering medications, although some patients may have filled 
prescriptions elsewhere. 
This prescription claims data extract contains dispensation data from complete 
prescription records (all medications) for patients with diabetes who were identified by 
specific therapeutic classes (insulins, oral antidiabetic agents-sulfonylureas and other 
oral antidiabetic agents). The data includes all pharmacy records between April 27, 
1997 and May 16, 1999 (288, 171 observations) for 4503 patients with diabetes. The 
dataset contains information on patient characteristic variables such as birth date, 
gender, and health insurance plan as well as prescription-related variables including 
quantity of medication dispensed, days supply of medication dispensed, and date the 
prescription was dispensed (Table B-1 ). 
Re-labeling of Medication Names 
Using a Physician's Desk Reference, sulfonylurea and lipid-lowering 
medications were identified using the medication name (LABELNM). The medications 
were then categorized by class- first, second, or third generation for sulfonylurea 
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medications or statin and non-statin for lipid-lowering medications. In order to code 
the study variable, antidiabetic regimen, all hypoglycemic agents were coded as oral 
(i.e ., oral antidiabetic agents) or insulin (e.g., Humalog®, Novopen®, etc.). Diabetic 
supplies such as blood glucose monitoring test strips and syringes were coded as 
supply; this categorization was used to exclude prescription claims for these items 
from counting the number of concomitantly prescribed medications. 
The variables, LABELNM, DAYSSUPP, QTY, and POSTXNDT, were 
transposed to create one record per patient. With the dataset in this format, 
calculations of measurements of adherence and persistence and categorization of 
study variables were performed as described in Tables B-2- to B-4. 
All variable coding and statistical analyses were conducted using PC SAS 
release 8.02. SAS procedures used for descriptive statistics and univariate and 
multivariate analyses are listed in Table B-5. 
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Table B-1. Variables available in the CVS pharmacy dataset 
Variable Label Description 
ID 
BDATE 
GENDER 
LABELNM 
NOC 
POSTXNDT 
DAYSSUPP 
QTY 
FILL_NBR 
AVAILFIL 
RX_NBR 
AWPPRICE 
AGENCYNM 
AGENCYID 
DEA 
STORENO 
Identification Number Unique patient identifier 
Date of Birth Patient date of birth 
Gender M=male; F=female 
Label Name Name of medication dispensed-
includes strength and formulation 
National Drug Code 
Posted transaction 
date 
Days Supply 
Quantity 
Fill Number 
Available Refills 
RX Number 
AWP Price 
Agency Name 
Agency Identification 
Number 
Drug Enforcement 
Number 
Store Number 
Unique identifier of medication 
dispensed 
Date the medication was dispensed 
Days supply of medication dispensed 
Quantity of medication dispensed 
The number of the fill 
Number of refills remaining on the 
prescription 
Number assigned by the pharmacy 
for each prescription fill 
The average wholesale price of the 
prescription medication 
Name of the health insurance plan 
used to acquire prescriptions 
Unique identification number of the 
health insurance plan used to 
purchase prescriptions 
Unique identification number 
assigned to the prescribing physician 
Unique number of the pharmacy 
dispensing the medication 
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Table B-2. Variable specifications for Study 1 
Variable Description Coding in Dataset Coding for 
Analyses 
CMA continuous multiple- Sum of the days Continuous 
interval measure of supply between first variable 
medication and last fill for 
availability sulfonylurea divided 
by the number of 
days from first to 
last fill 
CSA continuous, single- Days supply Continuous 
interval measure of obtained during an variable 
medication interval divided by 
availability the total number of 
days in that interval 
CSG continuous, single- Number of days Continuous 
interval measure of that medication was variable 
medication gaps unavailable for use 
in an interval 
divided by the total 
number of days in 
that interval 
CMG continuous, Total number of Continuous 
multiple-interval days in treatment variable 
measure of gaps divided by the 
medication gaps total number of 
days from first to 
last fill 
csos continuous, single- Number of days Continuous 
interval measure of that surplus variable 
medication medication was 
oversupply available for use in 
an interval divided 
by the total number 
of days in that 
interval 
CMOS continuous multiple- Total number of Continuous 
interval measure of days in treatment variable 
over-supply surplus divided by 
the total number of 
days from first to 
last fill 
Medication categorization of CMA dichotomized ADHERENCE_80 
Availability CMA on ?,80% (?.90%) <80%; ?,80% 
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Gaps in 
therapy 
Surplus 
Medication 
Sulfonylurea 
medication 
categorization of 
CMG 
categorization of 
CMOS 
Brand and generic 
(where applicable) 
used to code 
sulfonylurea 
medication and 
class of sulfonylurea 
medication 
adherence with 
treatment regimen 
CMG dichotomized 
on ~10% ~20%) 
gaps in therapy 
CMOS 
dichotomized on 
~10% ~20%) 
surplus medication 
Coded based on 
label name 
(LABELNM) 
Acetohexamide: 
acetohexamide 
250mg tablet, 
Dymelor 250mg 
tablet, Dymelor 
SOOmg tablet 
Chlorpropamide: 
chlorpropamide 
1 OOmg tablet, 
chlorpropamide 
250mg tablet, 
Diabinese 1 OOmg 
tablet, Diabinese 
250mg tablet 
Glimepiride: 
Amaryl 1 mg tablet, 
Amaryl 2mg tablet, 
Amaryl 4mg tablet 
Glipizide: 
glipizide Smg 
tablet, glipizide 
1 Omg tablet, 
Glucotrol Smg 
tablet, Glucotrol 
1 Omg tablet, 
Glucotrol XL Smg 
tablet SA, Glucotrol 
XL 1 Omg tablet SA 
Glyburide: 
glyburide 1.25mg 
tablet, glyburide 
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ADHERENCE_90 
<90%; ~90% 
CMG_10 
<10%; ~10% 
CMG_20 
<20%; ~20% 
CMOS_10 
<10%; >10% 
CMOS_2o 
<20%; ~20% 
INDEXCLASS_RE 
O = 2nd generation 
SU· glipizide, 
glyburide 
1 = 1st generation 
SU· 
acetohexamide, 
chlorpropamide, 
tolazamide, 
tolbutamide 
2 = 3"' generation 
SU- glimepiride 
Age 
Gender 
Health plan 
Age 
Gender 
Health plan used for 
sulfonylurea 
2.5mg tablet, 
glyburide 5mg 
tablet, glyburide 
MICRO 1.5mg 
TAB, glyburide 
MICRO 3mg tablet, 
glyburide MICRO 
6mg tablet, DiaBeta 
1 .25mg tablet, 
DiaBeta 2.5mg 
tablet, DiaBeta 5mg 
tablet, Glynase 
1.5mg PRESTAB 
Glynase3mg 
PREST AB, 
Glynase 6mg 
PREST AB, 
Micronase 1.25mg 
tablet, Micronase 
2.5mg tablet, 
Micronase 5mg 
tablet 
Tolazamide: 
tolazamide 1 OOmg 
tablet, tolazamide 
250mg tablet, 
tolazamide 500mg 
tablet, Tolinase 
1 OOmg tablet, 
Tolinase 250mg 
tablet 
Tolbutamide: 
tolbutamide 500mg 
tablet, Orinase 
500mg tablet 
Transaction date of Continuous 
sulfonylurea variable 
medication during 
index window 
minus date of birth 
(BDATE) 
M=male GENDER_RE 
F=female 0 = Male 
1 =Female 
Health plan used to HEAL THPLAN 
fill sulfonylurea 0 = nurse-based 
173 
medication medication during diabetes 
index window management plan 
1 =other 
(including local 
and state 
programs, cash 
payments) 
Number of Number of Medications other Continuous 
Medications prescribed than antidiabetic variable 
medications during medications and 
study period supplies were 
counted. 
Use of Use of insulin during Was patient INSUSE 
Insulin study period prescribed insulin O =no 
during study 1 =yes 
period? 
Number of Number of Days supply of DOSE 
pills per day sulfonylurea pills sulfonylurea O = 1 per day 
prescribed per day prescription fill 1 = >1 per day 
divided by quantity 
of medication 
dis ensed 
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Table B-3. Variable specifications for Study 2 
Variable 
CMA 
Adherence 
Lipid-
lowering 
medication 
Descri lion 
continuous 
multiple-
interval 
measure of 
medication 
availability 
access to at 
least 80% 
(90%)of 
lipid-
lowering 
medication 
based on 
calculated 
CMA 
Brand and 
generic 
(where 
applicable) 
used to 
code lipid-
lowering 
medication 
and class of 
lipid-
lowering 
medication 
Cod in in Dataset 
Calculated from 
days supply (sum of 
the days supply 
between first and 
last claim for lipid-
lowering medication 
and days of therapy 
(number of days of 
therapy between the 
first and last 
prescription fill of 
lipid-lowering 
medication); 
continuous variable 
Coded based on 
CMA; categorized 
using 80% and 90% 
levels 
Coded based on 
label name 
(LABELNM) 
Cholesltyamine: 
Cholestryamine light 
packet; 
Cholestyramine light 
powder; 
Cholestyramine 
powder; Questran 
light packet; 
Questran light 
powder; Questran 
packet; Questran 
powder 
Colestid: Colestid 
1 gm tablet; Colestid 
flavored granules; 
Colestid granules; 
Colestid granules 
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Coding for Logistic 
Re ression Anal sis 
n/a 
ADHERENCE_80 
0=~80 
1 =<80 
ADHERENCE_90 
0 =~90 
1 =<90 
LIPIDCLASS 
0 = Non-Stalin 
(cholestyramine resin , 
colestipol, fenofibrate, 
gemfibrozil , niacin) 
1 = Stalin (atorvastatin, 
fluvastatin, lovastatin, 
pravastatin, simvastatin) 
packet 
Lopid: Gemfibrozil 
600mg tablet; Lopid 
600mg tablet 
Lesol : Lescol 20mg 
capsule; Lescol 
40mg 
capsule 
Lipitor: Lipitor 1 Omg 
tablet; Lipitor 20mg 
tablet; Lipitor 40mg 
tablet 
Mevacor: Mevacor 
1 Omg tablet; 
Mevacor 20mg 
tablet; Mevacor 
40mg tablet 
Niacin: Niacin 
1 OOmg tablet; Niacin 
250mg capsule SA; 
Niacin 500mg tablet; 
Niaspan 500mg 
tablet SA; Niaspan 
750mg tablet SA 
Pravachol: 
Pravachol 1 Omg 
tablet; Pravachol 
20mg tablet; 
Pravachol 40mg 
tablet 
Tricor: Tricor 67mg 
capsule 
Zocor: Zocor 1 Omg 
tablet; Zocor 20mg 
tablet; Zocor 40mg 
tablet; Zocor 5mg 
tablet; Zocor BOmg 
tablet 
Age Age Calculated as first AGE_RE 
transaction date 0, O = <55 years 
minus year of birth 0, 1 = 56-65 years 
(YR BORN) 1 , O = >65 years 
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Gender Gender Coded as GENDER_RE 
M=males O =Males 
F=females 1 =Females 
Health Plan Health plan Categorized as HEALTHPLAN 
used to nurse-based O = nurse-based diabetes 
acquire diabetes management plan 
lipid- management plan or 1 =other 
lowering other including 
medication local/state programs 
prescribed and cash payments 
at index 
date 
Number of Number of Medications other CONMED_CNT 
Concomitant concomitant than lipid-lowering 0, 0= 1-5 
Medications medications medication were 0, 1 =6-10 
prescribed counted as 1, 0=>10 
during study concomitant 
period medication 
Antidiabetic Antidiabetic Categorized as AD REG 
Medication medication Insulin therapy 0 = oral medications only 
Regimen dispensed (patients dispensed 1 = insulin therapy 
during study either insulin 
period monotherapy or 
insulin in 
combination with 
oral agents) or 
Oral (patients 
dispensed oral 
antidiabetic 
medications 
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Table B-4. Variable specifications for Study 3 
Variable Descri tion Codin in Dataset Codin for Anal ses 
Discontinuation N/A 
Censor 
Lipid-lowering 
medication 
N/A 
Brand and 
generic 
(where 
applicable) 
used to code 
lipid-lowering 
medication 
and class of 
lipid-lowering 
medication 
A discontinuation of 
lipid-lowering 
medication was 
identified if a patient (1) 
had more than three 
times the days supplied 
elapsed between the 
last prescription fill for 
the index lipid-lowering 
medication and the 
next fill or the end of 
the follow-up period; or 
(2) switched lipid-
lowering medication to 
another class; or (3) 
had no refills for the 
index medication 
during the observation 
period. 
Patients with 
continuous coverage of 
lipid-lowering 
medication were 
censored throughout 
observation period 
Coded based on label 
name (LABELNM) 
Baycol: Baycol 0.2mg 
tablet; 
Baycol 0.3mg tablet 
Cholestrvamine: 
Cholestryamine light 
packet; Cholestyramine 
light powder; 
Cholestyramine 
powder; Questran light 
packet; Questran light 
powder; Questran 
packet; Questran 
powder 
Colestid: Colestid 1 gm 
tablet; Colestid flavored 
granules; Colestid 
granules; Colestid 
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TIMETODC 
Continuous 
variable 
CENSOR 
O =failure 
(discontinuation) 
1 =censored 
LIPIDCLASS 
0 = Non-Stalin 
bile acid 
sequestrant resins-
cholestyramine, 
colestipol ; fibrates-
femfibrozil, 
fenofibrate; 
nicotinic acid-
niacin 
1=Slatin 
atorvastatin, 
fluvastatin , 
lovastatin, 
pravastatin, 
simvastatin 
Age Age 
Gender Gender 
granules packet 
Lapid: Gemfibrozil 
600mg tablet; Lapid 
600mg tablet 
Lesol : Lesco! 20mg 
capsule; Lesco! 40mg 
capsule 
Lipitor: Lipitor 1 Omg 
tablet; Lipitor 20mg 
tablet; Lipitor 40mg 
tablet 
Mevacor: Mevacor 
1 Omg tablet; Mevacor 
20mg tablet; Mevacor 
40mg tablet 
Niacin: Niacin 100mg 
tablet; Niacin 250mg 
capsule SA; Niacin 
500mg tablet; Niaspan 
500mg tablet SA; 
Niaspan 750mg tablet 
SA 
Pravachol: Pravachol 
1 Omg tablet; Pravachol 
20mg tablet; Pravachol 
40mg tablet 
Tricor: Tricor 67mg 
capsule 
Zocor: Zocor 1 Omg 
tablet; Zocor 20mg 
tablet; Zocor 40mg 
tablet; Zocor 5mg 
tablet; Zocor 80mg 
tablet 
Calculated as first 
transaction date 
minus date of birth 
(BDATE) 
Coded as 
M=male 
F=female 
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Continuous variable 
GENDER_RE 
O = Male 
1 =Female 
Health plan Health plan Categorized as HEALTHPLAN 
used to nurse-based O = nurse-based 
acquire index diabetes diabetes management 
lipid-lowering management plan plan 
medication or other including 1 =other 
local/state/federal 
programs or cash 
payments 
Number of Number of Medications other Continuous variable 
Prescription prescription than lipid-lowering 
Medications medications medication and 
within three antidiabetic 
months prior supplies were 
to index date counted as 
concomitant 
medication 
Antidiabetic Antidiabetic Categorized as oral ADREG 
Medication medication (patients dispensed O = oral medications 
Regimen dispensed oral antidiabetic 1 = insulin therapy 
within 90 medications) or 
days of index insulin therapy 
date (patients dispensed 
either insulin 
monotherapy or 
insulin in 
combination with 
oral antidiabetic 
medications 
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Table B-5. SAS procedures and their respective analy!ical measure 
SAS Procedure Analytical Measure 
PROC FREQ 
PROC FREQ with CHISQ option 
PROC GLM 
PROC LIFETEST 
PROC LOGISTIC 
PROC MEANS 
PROC NPAR1WAY 
PROC PHREG 
PROC REG 
PROC TRANSPOSE 
PROCTTEST 
PROC UNIVARIATE 
Frequency distribution of study variables 
Statistical comparison of categorical 
variables 
Multiple Regression Modeling 
Nonparametric estimates of the survivor 
function either by the product-limit 
method (also called the Kaplan-Meier 
method). 
Logistic Regression Modeling 
Descriptive statistics for variables across 
all observations and within groups of 
observations. 
Statistical comparison for non-parametric 
variables 
Performs regression analysis of survival 
data based on the Cox proportional 
hazards model. 
Multiple Regression Modeling, assess 
collinearity of variables 
Creates an output data set by 
restructuring the values in a SAS data 
set, transposing selected variables into 
observations. 
t-test for comparison of means 
Performs test for normality 
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APPENDIXC 
Confidentiality of Data 
Data has been provided by CVS Pharmacies at no cost, through agreement 
and arrangement with the University of Rhode Island College of Pharmacy. All 
information will be held confidential , and results will not include any reference 
allowing for the identification of individuals in the data set. Patient name, address, 
telephone and social security number are not included in the data. Dates of birth 
included in the data set are not linked to any other identifying information. Thus, there 
is no identifying information that could link a patient's identity to the prescription claim. 
The Institutional Review Board at the University of Rhode Island granted approval for 
this research project on November 20, 2002. 
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APPENDIX D 
Overview of Major Findings 
Since there is no standard measurement of medication adherence, the 
objective of the first study was to measure adherence with sulfonylureas based on 
continuous and dichotomous measures of medication availability, gaps, and surplus 
and evaluate the relationship between these measures. Patient-related and 
medication regimen complexity characteristics that may influence adherence with 
sulfonylureas in patients with diabetes mellitus were also examined. 
A total of 988 patients were prescribed a sulfonylurea medication during the 
study period and included in the study analyses. The most commonly prescribed 
sulfonylureas were the second-generation sulfonylureas: glyburide (57%) and 
glipizide (35%); 7% of patients were prescribed glimepiride and 2% prescribed a 
first-generation sulfonylurea. 
Single-interval measures of medication availability (CSA), gaps (CSG), and 
oversupply (CSOS) provide an accurate representation of adherence with 
sulfonylureas from fill to refill and allow an individual assessment of medication 
adherence and highlights particular times of non-adherence with medication, for 
example, patient-initiated medication holidays or dose reductions. In contrast, 
multiple-interval measures of medication availability (CMA), gaps (CMG), and 
oversupply (CMOS) provide a broad assessment of medication adherence over an 
extended period of time. The focus of the analysis was on the multiple-interval 
measures of adherence since they are more descriptive when evaluating overall 
adherence in patient populations. 
Overall , patients had an average period of observation (i.e., date from first 
sulfonylurea dispensation to last fill in the study period) of 315 days (range, 32 to 364 
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days). Based on CMA, medication was available for an average (± SD) of 89% ± 18% 
of days during the 12-month study period. When CMA was dichotomized, 78% and 
66% of patients had sufficient medication to cover at least 80% and 90% of days in 
the study period, respectively. An analysis of gaps in therapy supports the findings of 
medication availability. That is, patients had an average CMG of 47 days; only nine 
(1 %) patients prescribed sulfonylureas had no gaps in therapy. Almost 1 in 4 patients 
had gaps in therapy for six or more days per month. The majority of patients (85%) 
had surplus sulfonylurea medication during the 12-month observation period: the 
average CMOS was 5% of days (range, 0 to 80%) among patients prescribed 
sulfonylurea medications. Dichotomous measures of adherence demonstrated that 
46% and 15% of patients had ?.10% of days during the study period with gaps or 
excess sulfonylurea medication, respectively. This study demonstrated that patients 
with diabetes obtained less sulfonylurea medication than prescribed over a 12-month 
period of observation. 
Correlations for all continuous and dichotomous measures of adherence were 
statistically significant (p<0.0001 ). Measures of medication availability were 
significantly correlated with measures of gaps in therapy (r = -0.95) and surplus 
medication (r=0.41). Similarly, measures of gaps in therapy were significantly 
correlated with measures of surplus medication (r= -0.20). While the continuous 
measure of medication availability, CMA, was correlated with both dichotomous 
categorizations, the strongest relationship was observed between CMA and 
adherence dichotomized with the 80% level (r=0.82) The continuous measure of gaps 
in therapy was strongly associated with the 20% level of dichotomization (r=0.84) 
while the correlation between dichotomous categorizations and the continuous 
measure of surplus medication (CMOS) were similar (r ~0. 79). 
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To evaluate the effect of observed time on the measures of adherence, 
subsequent analyses examined prescription claims for six and nine months. As the 
length of follow-up time increased, measures of available medication decreased while 
measures of gaps in therapy and oversupplies of medication increased. Based on 
CMA, the average proportion of days with available sulfonylurea medication was 
statistically significant using six, nine, and 12 months of observation; 92%, 90%, and 
89%, respectively (p=0.0137). An average of 13% of days with gaps in therapy was 
observed during six months of observation while 15% of days had gaps when the 
observation time increased to nine and 12 months (p=0.0195). In contrast, CMOS did 
not seem to be affected by the amount of time under observation. These findings 
illustrate that a nine-month examination of prescription claims was adequate to 
assess adherence. 
In a multiple regression model, no study factors significantly influenced 
adherence (i.e., availability of sulfonylurea medication) (F5, 987 = 0.59; p=0.7065). 
Although not a significant predictor of medication availability in this patient population, 
increasing age by one-year increments led to an increase in the rate of adherence of 
approximately 4.1 %. An increase in the number of concomitantly prescribed 
medications had an inverse relationship with CMA. Higher rates of adherence were 
also observed for males, patients enrolled in a nurse-based diabetes management 
plan, and patients prescribed one sulfonylurea pill per day. 
In summary, relying solely on a single measure of medication adherence, 
such as CMA, provides the health care provider one-dimension of information 
regarding appropriate and adequate use of a medication within a population. As 
illustrated in this study, by combining assessments of medication availability with 
analyses of gaps in therapy and surplus medication, the scope of the problems of 
non-adherence with medications is more defined. 
186 
The objective of the second study was to evaluate adherence with 
lipid-lowering medications in patients with diabetes mellitus. In addition, the effect of 
patient- and medication-related characteristics on adherence was examined. 
A total of 90 patients were identified as new users of lipid-lowering therapy 
during a nine-month observation period. The majority of patients (91 %) were 
prescribed a statin medication as their index lipid-lowering medication while eight 
patients were prescribed a non-statin medication. 
The average number of days of observation was 225 days (range, 59 to 270 
days). Overall, mean (±SD) CMA was 82.8% ± 23.4%. Adherence differed by class 
of lipid-lowering medication prescribed at the index date: patients prescribed statin 
and non-statin medications had a mean (± SD) CMA of 84.1 % ± 22.3% and 70.0% ± 
31.7%, respectively (p=0.2627). 
Two-thirds of the patients (66%) had sufficient lipid-lowering medication to 
cover 80% or more days in a nine-month observation period; these patients were 
classified as adherent. Adherent patients were less frequently prescribed insulin 
therapy than non-adherent patients (p=0.0297). Additionally, adherent patients were 
more frequently prescribed a statin medication than a non-statin although this 
proportion was not statistically significant (p=0.0802). 
A logistic regression model of adherence (?_80%) incorporated significant 
covariates from the bivariate and multivariate models. The likelihood of patients 
achieving adherence with lipid-lowering medication was lower for patients prescribed 
insulin therapy (OR= 0.304, 95% Cl=0.114, 0.815, p=0.0180) compared with patients 
prescribed only oral antidiabetic medications. Compared with patients prescribed 
non-statin medications, patients prescribed a statin medication were four times more 
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likely to be adherent with treatment (0R=4.709, 95% Cl=0.996, 22.268, p=0.0506); 
this parameter was close to statistical significance in the final model. 
Results of a sensitivity analyses (adherence defined as having adequate 
lipid-lowering medication to cover at least 90% or more days) found that only 46% of 
patients were adherent with lipid-lowering therapy. No study factors significantly 
influenced adherence in the bivariate or multivariate logistic regression model this 
level of adherence. 
The observations of this study indicate that adherence with lipid-lowering 
therapy in patients with diabetes mellitus was less than optimal. Patients prescribed a 
statin medication as their initial lipid-lowering medication exhibited greater adherence 
compared with patients prescribed non-statin medications. Non-adherence was 
associated with insulin therapy and non-statin medications. 
The objective of the third study was to assess persistence with lipid-lowering 
medications and evaluate patient- and medication-related characteristics that may 
influence discontinuation of lipid-lowering treatment in patients with diabetes mellitus. 
A total of 190 patients were identified as new users of lipid-lowering therapy; 
these patients were followed for a total of 47,372 person-days, an average of 248 
person-days. Stalins were the most frequently (87%) prescribed lipid-lowering 
medication at the index date. 
Overall , 58% of patients persisted with lipid-lowering medication. Patients 
prescribed statins were more likely to be persistent than patients prescribed 
non-statin medications (p=0.0176). Of the 165 patients prescribed statin medications, 
74% persisted with treatment over six months, 59% over 12 months, and 46% over 
18 months of observation. At six months, 60% of patients in the non-statin group 
persisted with treatment while only 26% of patients were persistent over 12 and 18 
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months of observation. Kaplan-Meier curves of non-persistency statistically differed 
for patients prescribed statin and non-statin therapy (Log-rank X2=7.9101 ; p=0.0049). 
Among the 87 patients who discontinued treatment, 23 (26%) patients 
interrupted treatment after a single prescription. Twenty-eight (28, 32%) restarted 
lipid-lowering medication during the observation period with the median time to 
re-initiation of 63 days; 43% of patients restarted therapy after the initial lipid-lowering 
medication prescription was not refilled. 
Overall , 19 (10%) of patients switched to another lipid-lowering medication 
other than the index medication. The majority (84%) of the patients who switched 
medication changed to another medication in the same class as the lipid-lowering 
medication prescribed at the index date. 
A Cox regression model showed that discontinuation with lipid-lowering 
therapy was related to the class of lipid-lowering medication prescribed at the index 
date. Compared with patients prescribed statin medications, patients prescribed non-
statin medications were more than twice as likely to discontinue lipid-lowering therapy 
(HR=2.240; 95% Cl= 1.260, 3.982; p=0.0060). Inclusion of other study factors or 
interaction terms into the Cox regression model did not significantly influence 
non-persistency with lipid-lowering therapy. 
The observations of this study indicate that persistence with lipid-lowering 
therapy in patients with diabetes mellitus was sub-optimal. Patients prescribed a 
statin medication as their initial lipid-lowering medication exhibited greater persistency 
compared with those patients prescribed non-statin medications. These findings 
highlight the need for health care providers to manage persistence with lipid-lowering 
medications that may reduce the risk of major cardiovascular events in patients with 
diabetes mellitus. 
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APPENDIX E 
Interventions to Improve Adherence with Prescribed Medication Regimens 
for Patients with Diabetes Mellitus 
C Everett Koop, former US surgeon general , observed "Drugs don't work in 
patients who don't take them."'· 2 This statement is reinforced by the findings of a 
recent World Health Organization (WHO) report on adherence to long-term therapy 
which concluded that improving adherence required multidisciplinary and multilevel 
interventions that take individual patients' experiences of illness seriously.2 The ability 
of patients to follow treatment plans in an optimal manner is complex and is 
frequently compromised by more than one barrier. Five dimensions have been 
identified as barriers to adherence: social and economic factors; health care system; 
characteristics of the disease; treatment-related factors; and patient-related factors.2 
Solving the problem related to each of these dimensions is necessary if patients' 
adherence and persistence with prescribed medication regimens is to be improved. 
A review of the literature demonstrates that no single intervention strategy will 
assure adherence with prescribed therapy.2.a Rather, adherence and persistence with 
medications require a multifaceted approach, encompassing behavioral , cognitive, 
and social strategies.•· 7 Interventions that target adherence must be tailored to the 
particular illness-related demands experienced by the patient. To accomplish this, 
health care systems and providers need to develop means of accurately assessing 
not only adherence and persistence, but also those factors that influence it. As we 
have shown in this research, adherence and persistence with prescribed medication 
varies across all age groups and disease entities and can be influenced by many 
factors including tolerability of the medication, complexity of the medication regimen, 
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cost and convenience of the therapy, as well as characteristics of the patient, medical 
system and physician. 
Providing access to clear information about health care options is especially 
important in improving patients' adherence to treatment. When patients are 
prescribed medication regimens, they should be able to obtain easily understandable 
information about the expected benefits and potential outcomes, any risks, 
interactions and adverse events associated with the prescribed medication. A 
combination of keeping the medication regimen as simple as possible, negotiating 
priorities with the patient, providing clear verbal and written instructions for the 
patient, family intervention, monitoring adherence with treatments and appointments, 
appointment and prescription refill reminders, and reinforcing the importance of high 
adherence or rewards for improved adherence and treatment response with 
prescribed therapy at each visit will provide practical and effective help for many 
patients with diabetes to follow prescribed regimens.•·10 In addition, counseling and 
continuing support from other health care professionals and patients affected with the 
same disorder are key to improving medication adherence with prescribed therapy 
among patients with diabetes mellitus. 
Interventions directly focused on enhancing patients' participation in diabetes 
care have been proven to be the most powerful in improvement of glycemic control 
and quality of life for patients with diabetes: automated telephone diabetes 
management programs including personal nursing support, patient empowerment 
education, interactive group education/peer support meetings and family-oriented 
disease management therapy.11-1 9 For example, Skaer and colleagues observed that 
patients who received mailed prescription-refill reminders, special medication 
packaging, or a combination of both interventions achieved a significant (ps_0.05) 
increase in adherence with sulfonylurea therapy compared with patients who received 
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standard pharmaceutical care.20 Anderson and colleagues observed that a patient 
empowerment program designed to improve psychosocial self-efficacy and attitudes 
towards diabetes was an effective approach to developing educational interventions 
to address the psychosocial aspects of living with diabetes. 14 This study also 
observed an improvement in glycemic control in patients assigned to the intervention 
group compared with the control group.14 
Beyond interventions focusing on the patient, interventions that target health 
care providers can be used to improve self-management of diabetes and its co-
morbid conditions. Patient-provider communication is essential to support diabetes 
self-care21 • 22 and is associated with patients' glycemic control.23 
Pharmacist-intervention programs have proven beneficial in the management of 
diabetes24" 6 and increased medication compliance and reductions of low-density 
lipoprotein cholesterol (LDL-C) levels in patients with dyslipidemia.27• 26 For example, 
enhanced pharmacist intervention (i.e., educational module including 
recommendations for therapeutic interventions and follow-up telephone calls) 
reduced LDL-C levels about 18 mg/dl during a six-month period with an adherence 
rate of 84% in patients receiving lipid-lowering medication; 31 % of patients achieved 
National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP 111)29 
recommended target levels G:100 mg/dl).26 
Adherence to prescribed medications is one of the many challenges in 
managing diabetes. Thus, it is important for health care providers to be able to 
appreciate the complexity of a diabetics' treatment regimen and understand the 
psychological, physiological, environmental , and regimen-specific factors that affect a 
patient's adherence to treatment regimens. Clearly the solution to the problem of poor 
adherence with diabetes self management, including medication adherence and 
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persistence, must involve a combination of approaches that include intensive efforts 
to modify the behavior of patients with diabetes together with efforts to make changes 
in the health care system and larger environment that shape and modify behaviors.30 
The International Pharmaceutical Federation Statement on Professional Standards31 
has listed the following steps as building blocks for adherence with medication 
regimens: 
Training and supporting health care providers in different styles of consultation; 
Including cultural beliefs, patients' beliefs, lifestyle priorities, and medicine-
taking issues of the patients; 
Sharing information among physicians, pharmacists, nurses and patients; 
Extending the educational role of physicians, pharmacists, and nurses; 
Creating and using all available opportunities to discuss issues relayed to the 
prescribed medication; 
Providing high quality tailored information for patients when medication 
regimen is prescribed. 
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